Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Evaluation of Investigational Daily Disposable Multifocal Contact [CONTACT_288774]-6418Version: 2.0Date: 10 February 2021
Investigational Products: JJVC Investigationa l Multifocal-PG Contact [CONTACT_288775] A C3 
Control: Dailies Total 1
®Multifocal Contact [CONTACT_19542] A material
Keywords: Multifocal, Senofilcon A C3, Delefil con A, Manufacturing, Presby[CONTACT_19555], Daily 
Wear, Daily Disposable, Dispensing, Randomized
Statement of Compliance to protocol, GC P and applicable regulatory guidelines:
This trial will be conducted in compliance with the protocol, ISO [ZIP_CODE],1the International
Council for Harmonization Good Clinical Practice E6(R2) (ICH GCP),2the Declaration of 
Helsinki,3and all applicable regulatory requirements.
Confidentiality Statement:
This document contains confident ial information, which should not be copi[INVESTIGATOR_530], referred to, 
released or published without written approval fr om [COMPANY_012] Vision Care, Inc. The 
information may not be disclosed to others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee a pproval and informed consent, or as required 
by [CONTACT_19543], Federal and State Laws, as a pplicable. Persons to whom this information is 
disclosed must be informed that this informati on is privileged and confidential and that it 
should not be further disclosed without the written permission of [COMPANY_012] Vision 
Care, Inc. Any supplemental information that may be added to this document is also 
confidential and proprieta ry to [COMPANY_012] Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document.
CR-6418, v 2.0  
Page 1 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
TABLE OF CONTENTS
PROTOCOL TITLE, NUMBER, VERSION AND DATE...................................................... [ADDRESS_352063] Articles............................................................................................ 24  
CR-6418, v 2.0  
Page 2 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
6.2. Ancillary Supplies/Products..................................................................................... [ADDRESS_352064] Articles ................................................................................ 26  
7. STUDY EVALUATIONS.............................................................................................. 27  
7.1. Time and Event Schedule......................................................................................... 27  
7.2. Detailed Study Procedures ....................................................................................... 30  
VISIT 1 ........................................................................................................................... 30  
VISIT 2 ........................................................................................................................... 35  
VISIT 3 ........................................................................................................................... 39  
VISIT 4 ........................................................................................................................... 45  
VISIT 5 ........................................................................................................................... 49  
VISIT 6 ........................................................................................................................... 55  
FINAL EVALUATION.................................................................................................. 57  
7.3. Unscheduled Visits................................................................................................... 58  
7.4. Laboratory Procedures ............................................................................................. 59  
8. SUBJECTS COMPLETION/WITHDRAWAL.............................................................. 59  
8.1. Completion Criteria.................................................................................................. 59  
8.2. Withdrawal/Discontinuation from the Study ........................................................... 60  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. [ADDRESS_352065] QUALITY COMPLAINTS.............. 63  
13. ADVERSE EVENTS................................................................................................... 64  
13.1.  Definitions and Classifications............................................................................. 64  
13.2.  Assessing Adverse Events.................................................................................... 66  
13.2.1.  Causality Assessment.................................................................................... 67  
13.2.2.  Severity Assessment...................................................................................... 67  
13.3.  Documentation and Follow-Up of Adverse Events.............................................. 67  
13.4.  Reporting Adverse Events .................................................................................... 69  
13.4.1.  Reporting Adverse Events to Sponsor .......................................................... 69  
CR-6418, v 2.0  
Page 3 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
13.4.2.  Reporting Adverse Events to the Respons ible IEC/IRB and Health Authorities
[ADDRESS_352066] KEEPI[INVESTIGATOR_1645]/ARCHIVING................................ 74  
15.1.  Electronic Case Report Form/Data Collection ..................................................... [ADDRESS_352067]...................................................................................................... 75  
15.3.  Trial Registration on ClinicalTrials.gov............................................................... 75  
16. DATA MANAGEMENT............................................................................................. 76  
16.1.  Access to Source Data/Document ........................................................................ 76  
16.2.  Confidentiality of Information.............................................................................. 76  
16.3.  Data Quality Assurance ........................................................................................ 76  
16.4.  Data Monitoring Committee (DMC).................................................................... [ADDRESS_352068] (IEC/IRB) .......... [ADDRESS_352069] RETENTION................................................................................ 81  
20. FINANCIAL CONSIDERATIONS ............................................................................ 81  
21. PUBLICATION........................................................................................................... 82  
22. REFERENCES ............................................................................................................ 82  
CR-6418, v 2.0  
Page 4 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTC OMES (STUDY QUESTIONNAIRES)
............................................................................................................................... .................. 83  
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) ................................. 111  
APPENDIX E: PRESBY[CONTACT_19544] ............................... 115  
APPENDIX F: OCULAR DOMINANCE ........................................................................ 116  
APPENDIX G: LENS FITTING GUIDE ......................................................................... 117  
APPENDIX H: CONTROL LENS FITTING GUIDE .................................................... 119  
APPENDIX I:  C-QUANT STRAYLIGHT MEASUREMENT ..................................... 152  
APPENDIX J:  VISIONIX CORNEAL TOPOGRAPHY AND WAVEFRONT ......... 159  
APPENDIX K: .............................. 168 
, LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS .............................. [ADDRESS_352070] REPORTED OCULAR SYMPTOMS/PROBLEMS ................ 198 
, DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIVE ERROR ................................ ................................ ................................ .....200 
, BIOMICROSCOPY SCALE ................................ ................................ .......... 206 
, DISTANCE AND NEAR SNELLEN VISUAL ACUITY EVALUATION 212 
, DISTANCE LOGMAR VISUAL ACUITY MEASUREMENT 
PROCEDURE ................................ ................................ ................................ ..................... 217 
, PATIENT REPORTED OUTCOMES ................................ .......................... 221 
, VISUAL ACUITY CHART LUMINANC E AND ROOM ILLUMINATION 
TESTING ................................ ................................ ................................ ............................. 223 
APPENDIX L: VWI-0081, GUIDELINES FOR COVID-19 RISK MITIGATION .... 232  
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_1783] ........................ [ADDRESS_352071] OF TABLESTable 1: Test Articles.............................................................................................................. 24
 
Table 2: Ancillary Supplies .................................................................................................... 25  
Table 3: Time and Events ....................................................................................................... 27 
Table 4: Disallowed systemic medications............................................................................. 61  
Table 5: Examples of major and minor protocol deviations................................................... 62  
Table 6:  Binocular High Luminance High Contrast Visual Performance –1-Week 
Follow-up................................ ................................ ................................ ................................ 71 
CR-6418, v 2.0  
Page 5 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 
LIST OF FIGURES
Figure 1: Study Flowchart ...................................................................................................... 15 
PROTOCOL TITLE, NUMBER, VERSION AND DATE 
Title: Evaluation of Investigational Daily Disposab le Multifocal Contact [CONTACT_288776]: CR-6418Version: 2.0Date: 10 February 2021
SPONSOR NAME [CONTACT_19616] & Johnson Vision Care, Inc. (JJVC)
[ADDRESS_352072] be notified by [CONTACT_93822]/site by e-mail or telephone 
within 24 hours of learning of a Serious Adverse Ev ent. The Medical Monitor may be contact[CONTACT_35479]. G eneral study related questions should be 
directed towards your assigned clinical research associate.
The Medical Monitoring Plan is maintained as a separate document and included in the Trial 
Master File.
 
CR-6418, v 2.0  
Page 6 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
AUTHORIZED SIGNATURES 
The signatures below constitutes the approval of  this protocol and the attachments and provide 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statement s regarding confidentiality, and according to local legal and 
regulatory requirements and applicable U.S. federal regulations,4ISO [ZIP_CODE],1ICH guidelines,2
and the Declaration of Helsinki.3
Author See Electronic Signature [CONTACT_288847]-6418, v 2.0  
Page 7 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 
 Medical Safety 
Officer
See Electronic Signature [CONTACT_288848]-6418, v 2.0  
Page 8 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
CHANGE HISTORY 
Version Originator Description of Change(s) and Section 
Number(s) AffectedDate
1.0 Original Protocol 21 Jan 2021
2.0 Section 7.1-removed corneal 
topography and wavefront procedure 
in time and events.
Section 3.1 -corrected typo referring 
to myopes in population description.
Appendix A- added preference 
questionnaires at visit 5. 10 Feb 2021
CR-6418, v 2.0  
Page 9 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
SYNOPSIS  
Protocol Title Evaluation of Investigational Daily Disposable Multifocal 
Contact [CONTACT_288777], [ADDRESS_352073] Article(s) Investigational Product:  JJVC Investigational Multifocal-PG
Contact [CONTACT_288778] A C3
Control: Dailies Total 1®Multifocal Contact [CONTACT_288779] A material
Wear and Replacement 
SchedulesWear Schedule: The test lenses will be used on a daily 
disposable basis.  
Replacement Schedule: The lenses w ill be replaced after a day 
of wear.
Objectives The objective of this study is to evaluate the visual 
performance (logMAR) and subjective vision responses of the JJVC Inve
stigational Multifocal-PG Contact [CONTACT_288780] A C3 and compare the results to 
Dailies Total 1®Multifocal Contact [CONTACT_288781] A material.
Study Endpoints Primary endpoint: logMAR visual acuity scores
Secondary endpoint: CLUE vision scores
Study Design This is a single-masked, 2×3 crossover, randomized-
controlled, dispensing clinical trial.  A total of approximately 
70 hyperopic eligible subjects will be targeted to complete the study.  The subjects will be ra ndomized and fit (Visit 1) in a 
study lens and wear the lens for 3±1 day then undergo optimization (Visit 2) and wear the optimized pair for approximately 1 week (7±1 day). At the follow
-up visit (Visit 
3) the endpo ints will be measured and subjects will be fit in 
the 2ndstudy lens. The visits will be repeated wearing the 2nd
study lens (Visit 3 Fit/Visit 4 Optimization/Visit 5 Follow up). 
At Visit 5 the subjects will be fit in a new pair of lenses that 
match the sa me type and power they were dispensed at Visit 4, 
and wear the lenses for 1 week (7±1 day). At the follow-up 
visit (Visit 6) the endpoints will be measured and the subject 
will be exited from the study
The primary endpoint will be logMAR visual acuity scores 
and the secondary endpoint will be CLUE vision scores.
See the flow chart at the end of the synopsis table for the 
schematic of the study visits and procedures of main 
observations (Figure 1).
CR-6418, v 2.0  
Page 10 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Sample Size A total of approximately [ADDRESS_352074] lens history recorded, baseline questionnaires completed, and refractive and anterior segment status determined.  For a detail flowchart of procedures below .
CR-6418, v 2.0  
Page 11 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Eligibility Criteria -
InclusionPotential subjects must satisfy all of the following criteria to 
be enrolled in the study
Inclusion Criteria after Screening:
1.The subject must read, understand, and sign the 
STATEMENT OF INFORMED CONSENT and 
receive a fully executed copy of the form.
2. The subject must appear  able and willing to a dhere to 
the instructions set forth in this clinical protocol.
3.The subject must be at lea st [ADDRESS_352075] lens 
wearer in both eyes (i.e. worn lenses a minimum of 2 
days per week for at leas t 6 hours per wear day, for 1 
month or more duration).
6.The subject must either already be wearing a 
presby[CONTACT_288782] (e.g., reading 
spectacles over contact [CONTACT_13276], mult ifocal or 
monovision contact [CONTACT_13276], etc.) or if not respond 
positively to at least one symptom on the “Presby[CONTACT_19552]”.
Inclusion Criteria after Baseline:
7.The subject’s distance spherical equivalent refraction 
must be in the range of + 1.25 D to +3.[ADDRESS_352076]’s refracti ve cylinder must be ≤0.[ADDRESS_352077]’s ADD power must be in the range of 
+0.75 D to +2.[ADDRESS_352078] corrected visual 
acuity of 20/20-3or better in each eye.
CR-6418, v 2.0  
Page 12 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Eligibility Criteria –
ExclusionPotential subjects who meet any of the following criteria will 
be excluded from participating in the study: 
Exclusion Criteria after Screening:
1. Currently pregnant or lactating.
2. Any active or ongoing ocular or systemic allergies that 
may interfere with contact [CONTACT_13279].  
3.Any active or ongoing systemic disease, autoimmune 
disease, or use of medication, which may interfere with contact [CONTACT_13279]. This  may include, but not be 
limited to, diabetes, hyperthyroidism, Sjögren ’s 
syndrome, xerophthalmia, acne ro sacea, Stevens-
Johnson syndrome, and immunosuppressive diseases 
or any infectious diseases (e.g. hepatitis, tuberculosis).
4.Any previous, or planned, ocular or intraocular 
surgery (e.g. radial keratotomy, PRK, LASIK, lid 
procedures, cataract surgery, retinal surgery, etc.).
5.A history of amblyopia, strabismus or binocular vision 
abnormality.
6.Use of any of the following medications within 1 week 
prior to enrollment: oral retinoid, oral tetracyclines, 
anticholinergics, oral phenothiazines, oral/i nhaled 
corticosteroids.  See Table 9.[ADDRESS_352079] 
clinical trial within 30 days prior to study enrollment.
12.Employee or immediate family member of an 
employee of clinical site (e.g., Investigator, 
Coordinator, Technician).
13. Any known hypersensitivity or allergic re action to 
non-preser ved rewetting drop solutions or sodium 
fluorescein.
Exclusion Criteria after Baseline:
14.Clinically significant (Gra de 3 or greater) corneal 
edema, corneal vascularizat ion, corneal staining, tarsal 
abnormalities or bulbar injection, or any other corneal 
orocular abnormalities whic h would contraindicate 
contact [CONTACT_13279].
CR-6418, v 2.0  
Page 13 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
15. Entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], extrusions, chalazia, recurrent 
styes, glaucoma, history of recurrent corneal erosions.
16. Any current ocular infection or inflammation.
17. Any current ocular abnormality t hat may interfere with 
contact [CONTACT_13279].
Disallowed Medications/Interventions Use of any prescription or over-the-counter (OTC) medications that may affect contact [CONTACT_13279]. See section 
9.[ADDRESS_352080] (UADE), or any serious adverse event (SAE) where relationship to study agent cannot be ruled out, will result in stoppi[INVESTIGATOR_71144]. In the event of a UADE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of subject(s) and may discuss this with the Principal Investig ator before any further subjects 
are enrolled.
Ancillary Supplies/ Study-Specific Materials Non-Preserved Rewetting drops, lens cases, glass vials, saline, ETDRS light 
cabinet, 4 M logMAR charts, and Near logMAR 
charts.
Principal Investigator(s) 
and Study 
Institution(s)/Site(s)A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is 
included in the study Trial Master File.
CR-6418, v 2.0  
Page 14 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Figure 1: Study Flowchart
70 Subjects to Complete
Potential Subjects Identified Based On:
x Age: 40-70 yrs. (inclusive)  
x Habitual contact [CONTACT_93833]
x Refraction: Spherical Equivalent +1.25D to +3.75D
x Cylinder: ≤ 0.75D
x Add: +0.75D to +2.50D
x Visual Acuity: Best corrected 20/20-3 or better in each eye 
Informed Consent 
Eligibility Criteria
Baseline Information
x Habitual lens type, modality, and contact [CONTACT_94645]. Wear Time
x Baseline and CLDEQ-8 Questionnaire
x Subjective refraction, Add Determination, Ocular Dominance, Add Refinement
x Biomicroscopy
Modifications
(if necessary)Yes
No
After 10 Minute Settling
x Exit Visual Acuity
x Dispensing Criteria, Subject Instructions
x Schedule Follow-up 3 ± 1 DayYesVisit 1 Treatment 1 / Visit 3 Treatment 2 / Visit 5 Treatment 3 (Optimized 
lens pair and NO Modification)
x Lens Selection
x Lens Insertion and Lens Damage
x Lens Settling, Visual Satisfaction, Visual Acuity, Over-Refraction
x Lens fit assessment
Visit 2 Treatment 1 Follow-up 1 /Visit 4 Treatment 2 Follow-up 1
x Medical History and Concomitant Medication Review
x Wear Time and Compliance
x PRO Questionnaire
x Visual Satisfaction, Entrance,  Visual Acuity, Over-Refraction
Modifications
(if necessary)YesYes
After 10 Minute Settling
x Exit Visual Acuity
x Dispensing Criteria. Subject Instructions
x Biomicroscopy
x Schedule Follow-up 7±1 DayNo
Visit 3 Treatment 1 Follow-up 2 / Visit 5 Treatment 2 Follow-up 2 / 
Visit 6 Treatment 3 Follow-up 1
x Medical History and Concomitant Medication Review
x Wear Time and Compliance
x PRO and CLDEQ-8 Questionnaire
x Visual Satisfaction, Entrance,  Visual Acuity, Binocular Over-Refraction
x logMAR Visual Performance
x Biomicroscopy
Final EvaluationCrossover
The Subject will 
be fit with the 
2nd Test lens at 
Visit [ADDRESS_352081]
optimized study 
lens and wear 
for 7±[ADDRESS_352082] will 
be exited from 
the study
CR-6418, v 2.0  
Page 15 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF 
TERMS 
Add Near addition; the additional power required for near vision correction
ADE Adverse Device EffectADHD Attention Deficit Hyperactivity DisorderAE Adverse Event/Adverse ExperienceAO1DfA ACUVUE OASYS® 1-DAY with Hydra Luxe™ TECHNOLOGY for 
ASTIGMATISM
AOfA ACUVUE OASYS® 2- WEEK for ASTIGMATISM
BSCVA Best Spectacle Corrected Visual Acuity
CFR Code of Federal Regulations
CLUE Contact [CONTACT_288783]
D Diopter
DMC Data Monitoring Committee
eCRF Electronic Case Report Form
EDC Electronic Data Capture
ESD Eyelid Stabilized Design
ETDRS Early Treatment D iabetic Retinopathy Study
FDA Food and Drug Administration
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act
HIV Human Immunodeficiency Virus
IB Investigator’s Brochure
ICH The International Council for Harmonization
IDE Investigational Device Exemption
IEC Independent Ethics Committee
IRB Institutional Review Board
ISO International Organization for Standardization
ITT Intent-to-Treat
JJVC [COMPANY_012] Vision Care, Inc.
LASIK Laser-Assisted in Situ Keratomileusis
LogMAR Logarithm of Minimal Angle of Resolution
OD Right Eye
OS Left Eye
OU Both Eyes
PIG Patient Instruction Guide
PQC Product Quality Complaint
PRK Photorefractive Keratectomy
PRO Patient Reported Outcome
QA Quality Assurance
SAE Serious Adverse Event/Serious Adverse Experience
CR-6418, v 2.0  
Page 16 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
SAP Statistical Analysis Plan
SAS Statistical Analysis System
SD Standard Deviation
UADE Unanticipated Adverse Device Effect
[LOCATION_003]DE Unanticipated Serious Adverse Device Effect
VA Visual Acuity
1. INTRODUCTION AND BACKGROUND 
The purpose of this study is to evaluate the visual performance and subjective responses of the 
JJVC Investigational Multifocal Contact [CONTACT_288784] a different manufacturing lens hydration 
process. The lenses differ from previous prototypes by [CONTACT_2329] a different lens hydration process form previous similar lens prototypes that have been evaluated.  The lens hydration process 
used in this study for the test lenses is used in  some marketed lenses that are manufactured by 
[CONTACT_32473] & Johnson Vision Care, Inc
1.1. Name [CONTACT_288849]: JJVC Investigationa l Multifocal-PG Contact [CONTACT_288775] A C3 
Control: Dailies Total 1
®Multifocal Contact [CONTACT_19542] A material.
1.2. Intended Use of Investigational Products 
All lenses are intended to correct spherical refr active error and presby[CONTACT_19555].  For this study both 
of the lenses will be worn as a daily disposab le lens, with the lenses being discarded after a 
day of wear.  The Lenses will be  fit in a randomized fashion.  After fitting, each subject will 
return for an optimization visit and then a follow- up.  The sequence will then be repeated with 
the other study lens type and then the lens type worn at visit [ADDRESS_352083] s who participate in th is trial.  Refer to 
study lens package insert for additional details f or the control lens and the Investigational 
Brochure (IB) for the Investigational lens.  Both the study multifocal contact [CONTACT_288785]. The 
investigational study contact [CONTACT_288786] d in senofilcon A C3 and the control lens is 
CR-6418, v 2.0  
Page 17 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
manufactured in delefilcon A.  Both of the lense s will be worn in a daily disposable wear 
modality. These lenses are not intended for extended wear in this study.
1.5. Relevant Literature References and Pr ior Clinical Data Relevant to Proposed 
Clinical Study 
The Test lenses have been previous ly tested in clinical studies 
   was discontinued early by [CONTACT_288787] -
[ADDRESS_352084] completed the study.  The investigator co nsidered the event to be not related to study
article/procedure.  
In 41subjects completed the stud y per the protocol.  The lenses displayed good 
clinical vision performance with binocular, high luminance, high contrast logMAR visual 
acuity of -0.104and 0.[ADDRESS_352085] refer to study lens package insert for additional 
details (APPENDIX C: PACKAGE INSE RT (APPROVED PRODUCT) and the 
Investigational Brochure (IB) for the Investigational product.
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES 
2.1. Objectives  
The objective of this study is to evaluate the visual performance (logMAR) and subjective 
vision responses of the JJVC Investigational Mu ltifocal-PG Contact [CONTACT_288788] A C3 and compare the results to Da ilies Total 1® Multifocal Contact [CONTACT_288779] A material.
2.2. Endpoints  
Primary Endpoint:
Visual Performance (logMAR)
Visual Performance will be assessed binocularly at each 1-week follow-up evaluation under 
high luminance high contrast conditions. At dist ance (4 meters), VA is assessed using ETDRS 
Charts; while near (40 cm) and intermediate (64 cm ) assessments will be made using reduced 
CR-6418, v 2.0  
Page 18 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Guillon-Poling charts. See  in Appendix I for details 
regarding the collection of visual acuity (logMAR).
Secondary Endpoint:
Subjective Vision 
Subjective vision will be assessed using the Contact [CONTACT_169754] (C LUE™) 
questionnaire at each 1-Week follow- up evaluation.  CLUE™ is a validated patient -reported 
outcomes questionnaire to assess patient-experience attributes of soft, disposable contact 
[CONTACT_13276] (comfort, vision, handling, and packaging)  in a contact-lens wearing population in the 
US, ages 18- 65.  Derived CLUE™ scores using Item Response Theory (IRT) follow a normal 
distribution with a population average score of 60 (SD 20), where higher scores indicate a more 
favorable/positive response with a range of 0-120.  A 5- point increase in an average CLUE™ 
score translates into 10% shift in the distribut ion of scores for population of soft contact [CONTACT_89626].6
Other Endpoints:
xCLUETMComfort 
xCLUETMHandling 
xLens Optimization Summary 
xMechanical Lens Fit
xSlit Lamp Findings
2.3. Hypotheses 
All primary and secondary hypotheses must be met in order to satisfy the objective of this 
study.Primary Hypotheses
1. After approximately [ADDRESS_352086] lens will be non-inferior 
compared to that of the Control lens. A non-inferiority margin of 0.05 logMAR will 
be used.
CR-6418, v 2.0  
Page 19 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Secondary Hypotheses
1. After approximately [ADDRESS_352087] satisfy all the following criteria to be enrolled in the study: 
Inclusion Criteria after Screening:
1. The subject must read, understand, a nd sign the STATEMENT OF INFORMED 
CONSENT and receive a fully executed copy of the form.
2. The subject must appear able and willing to adhere to the instructions set forth in this 
clinical protocol.
3. The subject must be at least [ADDRESS_352088] be an adapted soft contac t lens wearer in both eyes (i.e. worn lenses 
a minimum of 2 days per week for at leas t 6 hours per wear day, for 1 month or more 
duration).
6. The subject must either already be wear ing a presby[CONTACT_171178] (e.g., 
reading spectacles over contact [CONTACT_13276], mu ltifocal or monovision contact [CONTACT_13276], etc.) 
or,if not respond positively to at least one symptom on the “Presby[CONTACT_19557]” (Appendix E).
Inclusion Criteria after Baseline:
7.The subject’s distance spheri cal equivalent refraction must be in the range of +1.25 D 
to +3.[ADDRESS_352089]’s refractive cylinder must be ≤0.[ADDRESS_352090]’s ADD power must be in the range of +0.7 5 D to +2.[ADDRESS_352091] corrected visual acuity of 20/20-3or better in each 
eye.
3.3. Exclusion Criteria 
Potential subjects who meet any of the following cr iteria will be excluded from participating 
in the study: 
CR-6418, v 2.0  
Page 20 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Exclusion Criteria after Screening:
1. Currently pregnant or lactating.
2. Any active or ongoing ocular or systemic allergies that may interfere with contact 
[CONTACT_13279].  
3. Any active or ongoing systemic disease, autoimmune disease, or use of medication, 
which may interfere with contact [CONTACT_13279]. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren’s s yndrome, xerophthalmia, acne rosacea, 
Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
4. Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, 
LASIK, lid procedures, catarac t surgery, retinal surgery, etc.).
5. A history of amblyopia, strabismus or binocular vision abnormality.
6. Use of any of the following medications w ithin 1 week prior to enrollment: oral 
retinoid, oral tetracyclines, anticholin ergics, oral phenothiazines, oral/inhaled 
corticosteroids.  See Table 9.[ADDRESS_352092] clinical trial within 30 days prior 
to study enrollment.
12. Employee or immediate family member of an employee of clinical site (e.g., 
Investigator, Coordinator, Technician).
13. Any known hypersensitivity or allergic reaction to non-preserved rewetting drop 
solutions or sodium fluorescein.
Exclusion Criteria after Baseline:
14. Clinically significant (Grade 3 or greater)  corneal edema, corneal vascularization, 
corneal staining, tarsal abnormalities or bul bar injection, or any other corneal or 
ocular abnormalities which would contraindicate contact [CONTACT_13279].
15. Entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], extrusions, chalazia, recurrent styes, glaucoma, history of 
recurrent corneal erosions.
16. Any current ocular infection or inflammation.17. Any current ocular abnormality that may interfere with contact [CONTACT_13279].
3.4. Enrollment Strategy 
Study subjects will be recruited from the Institution/clinical si te’s subject database and/or 
utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved 
materials .
CR-6418, v 2.0  
Page 21 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
4. STUDY DESIGN AND RATIONALE 
4.1. Description of Study Design 
This is a 6-visit, subject-masked, multi-site, 2×3 crossover dispensing tr ial. Approximately 80 
subjects will be enrolled with an aim of approximately 70 subjects to complete the study. 
The study begins with an initial visit (Visit 1). If a subject is found to meet all eligibility criteria, 
they will be randomized to one of two len s wear sequences (Test/Control/Control or 
Control/Test/Test) in a bilateral fashion. If the subject is dispensed study lenses at the initial visit, five a dditional visits will be 
conducted. The first follow-up visit (Visit 2) will occur 3±1 days after the initial visit. At 
Visit 2, subjects will undergo lens optimization if  necessary. Subjects will wear the study 
lenses for 7±[ADDRESS_352093] follow-up visit (Visit  4) 3±1 days after Visit 3, for lens optimization. 
Subjects will return for their second follow-up visit 7±[ADDRESS_352094] study lens per th e randomization schedule and wear the lens for 7±1 
days. The final visit will be the follow-up (Visit 6).
4.2. Study Design Rationale 
Crossover designs are a well-established study de sign in which subjects are exposed to multiple 
treatments during different time periods.  A 2×[ADDRESS_352095] Article Allocation  
The study lenses will be worn in a bilateral and random fashion using a 2×3 crossover design. 
A computer-generated randomization scheme will be used to randomly assign subjects, in 
blocks of 4, to one of the two possible len s wear sequences: Test/Control/Control or 
Control/Test/Test. The random scheme will be  generated using the PROC PLAN procedure 
from Statistical Analysis System (SAS) Softwa re Version 9.4 or higher (SAS Institute, Cary, 
NC).[ADDRESS_352096] or assign subjects.  The randomized assignment of 
CR-6418, v 2.0  
Page 22 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
subjects will be performed at the first visit prior to the first fitting.  The following must have 
occurred prior to randomization:
oInformed consent has been obtained
oSubject meets all the inclusion / exclusion criteria
oSubject history and baseline in formation has been collected.
5.2. Masking 
This is a single-masked study with the subj ects being masked.  The term partial masking is 
being used as subjects will not be told a ny information regarding the optical designs of the 
lenses beyond that they are intended to correct for their refractive error and presby[CONTACT_19555], 
however there are slight differences in the tint  of the lenses which is impossible to mask from 
the subject.   
Under normal circumstances, the mask should not be broken until all subjects have completed 
the study and the database is fi nalized. Otherwise, the mask shoul d be broken only if specific 
emergency treatment/course of ac tion would be dictated by [CONTACT_35496]. In such cases, the Investigator may, in an emergency, contact [CONTACT_7195].  In 
the event the mask is broken, the Sponsor must be informed as soon as possible. The date, 
time, and reason for the unmasking must be docum ented in the subject record. The Investigator 
is also advised not to reveal the study trea tment assignment to the clinical site or Sponsor 
personnel. 
Subjects who have had their treatment assignment unmasked are expected to return for all 
remaining scheduled evaluations.  Subjects who are discontinued may be replaced.
5.3. Procedures for Maintaining and Breaking the Masking 
The test articles mask shall not be broken un less information concerning the lens type is 
necessary for the urgent medical treatment of a subject. The Sponsor must be notified before 
the mask is broken.When dispensing test articles, the following steps should be followed to maintain 
randomization codes:
1. Investigator or designee (documented on the Delegation Log) will consult the lens 
fitting schedule/randomization scheme to ob tain the test article assignment for that 
subject prior to dispensing.
2. Investigator or designee will record the subject’s number on the appropriate line of the 
randomization scheme if applicable
Investigator or designee will pull the appropria te test articles from the study supply. All test 
articles that are opened, whether dispensed (placed/fit on eye or dispensed outside the clinical site) or not, must be recor ded on the Test Article Accountability  Log in the “Dispensed” section
CR-6418, v 2.0  
Page 23 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
6. STUDY INTERVENTION 
6.1. Identity of Test Articles  
The following contact [CONTACT_35498]:
Table 1: Test Articles
6.2. Ancillary Supplies/Products 
The following solutions will be used in this study:Test Control
Name [CONTACT_288850] [CONTACT_288789] 1® Multifocal 
Contact  [CONTACT_288790] & Johnson®Vision 
Care, Inc.Alcon
N/A
Lens Material senofilcon A (C3) delefilcon A 
Nominal Base Curve 8.35 mm 8.5 mm
Nominal Diameter 14.3 mm 14.1 mm
Nominal Distance 
Powers (D)+1.00 D to +4.00 D in 0.25 D 
steps+1.00 D to +4.25 D in 0.25 D 
steps
Nominal ADD Powers 
(D)LOW, MID, HI LO, MED, HI
Water Content 38% 33%
Center Thickness 
@ -3.00 D0.07 mm
@ -3.00 D0.09 mm@ -1.00 D
Oxygen Permeability 
(Dk)103 156
@ -3.00 D
Wear Schedule in 
Current Study Daily Wear Daily Wear 
Replacement 
FrequencyDaily Daily
Packaging Form (vial, 
blister, etc.)Blister Blister
CR-6418, v 2.0  
Page 24 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Table 2: Ancillary Supplies
Single-Use Preservative-Free Rewetting Solutions (any one 
of these three rewetting solutions options may be supplied)
Solution Name/DescriptionEye-Cept®
Rewetting DropsScleralFil®
Preservative Free 
Saline SolutionLacriPure Saline 
Solution
Manufacturer Optics Laboratory B&L Menicon
Preservative Non-Preserved Non-preserved Non-preserved
6.3. Administration of Test Articles 
Test articles will be dispensed to subjects mee ting all eligibility requirements, including any 
dispensing requirements set forth in this clin ical protocol. Subjects will be dispensed an 
adequate supply of test articles to complete th e study. Lost or damaged test articles may be 
replaced at the discretion of the investigator and/or the sponsor.
6.4. Packaging and Labeling 
The test articles will be packaged in blisters, as the primary packaging. The test article will be 
over-labeled to mask the subject to the identit y of the lens. The test articles will be in 
investigational cartons sealed with a tamper ev ident seal, commercial cartons, or in plastic bags 
as the secondary packaging form. The sample study label is shown below:
6.5. Storage Conditions 
Test articles will be maintained at ambient temper atures at the clinical site. Test articles must 
be kept under secure conditions.
6.6. Collection and Storage of Samples 
When possible, any lens or test article associ ated with an Adverse Event and/or a Product
Quality Complaint must be retained and stored in a glass vial with moderate solution pending 
directions from the sponsor for potential return to JJVC.
CR-6418, v 2.0  
Page 25 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
6.7. Accountability of Test Articles 
JJVC will provide the Investigator with sufficient  quantities of study articles and supplies to 
complete the investigation. The Investigator is asked to retain all lens shipment documentation 
for the test article accountability records. 
Test articles must be kept in a locked storage  cabinet, accessible only to those assigned by [CONTACT_35500]. The Investigator may delegate this activity to authorized study site personnel listed on the Site Delegation Log. All test articles must be accounted. This includes:
1. What was dispensed for the subject for trial fitting, to wear out of the office, or issued 
for the subject to replace appropriately between visits.
2. What was returned to the Investigator unused, including expi[INVESTIGATOR_93785].
3. The number and reason for unplanned replacements.
The Investigator w ill collect all unused test articles from the subjects at the end of the subject’s 
participation. Subject returned unused test articles must be separated from the clinical study 
inventory of un-dispensed test articles and must be  labeled with the subject number and date 
of return. Following final reconciliation of test articles by [CONTACT_2037], the Investigator or 
monitor will return all unused test articles to JJVC.
If there is a discrepancy between the shipment  documents and the contents, contact [CONTACT_163078] .
          
CR-6418, v 2.0  
Page 26 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
7. STUDY EVALUATIONS  
7.1. Time and Event Schedule 
Table 3: Time and Events
Visit Information Visit 1
Screening, 
Baseline, 
Treatment 
1Visit 2
Treatment 1
Follow -up 1 
Optimization Visit 3
Treatment 1
Follow -up 2 
Treatment 2Visit 4
Treatment 
2
Follow-up
1
Optimizati
onVisit 5
Treatment 
2
Follow-up
2
Treatment 
3Visit 6
Treatment 
3
Follow-up
1
Time Point Day 0 Day 3±1
from V1Day 7±1 
from V2
Day 0Day 3±1
from V3Day 7±1
from V4Day 7±1 
from V5
Estimated Visit 
Duration2.5 hours 1.0 hour 2.0 hour 1.0 hour 2.0 hour 1.5 hour
Statement of 
Informed Consent x
Demographics x
Medical 
History/Concomitant Medications x
Adverse Events 
and Concomitant 
Medications 
Reviewx XX xx
Compliance x X X x x
Habitual Contact 
[CONTACT_288791]/Exclusion Criteria x
CR-6418, v 2.0  
Page 27 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit Information Visit 1
Screening, 
Baseline, 
Treatment 
1Visit 2
Treatment 1
Follow -up 1 
Optimization Visit 3
Treatment 1
Follow -up 2 
Treatment 2Visit 4
Treatment 
2
Follow-up
1
Optimizati
onVisit 5
Treatment 
2
Follow-up
2
Treatment 
3Visit 6
Treatment 
3
Follow-up
1
Time Point Day 0 Day 3±1
from V1Day 7±1 
from V2
Day 0Day 3±1
from V3Day 7±1
from V4Day 7±[ADDRESS_352097] Reported 
Ocular 
Symptomsxx XX xx
Baseline PRO 
(CLUE and MRD) Questionnairex
CLDEQ-8
Questionnairex X xx
Distance and 
Near Entrance Visual Acuity xx XX xx
Lens Removal x x X X x x
Subjective 
Refraction and 
Distance Visual Acuityx
Near ADD
Determinationx
Ocular 
Dominancex
ADD Refinement x
Near Visual 
Acuityx
Biomicroscopy x x X X x x
Baseline 
Inclusion/
Exclusion Criteriax
Continuance X x
Lens Selectionxx (if 
modified)Xx (if 
modified)x
Lens Insertion x x X X x
CR-6418, v 2.0  
Page 28 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit Information Visit 1
Screening, 
Baseline, 
Treatment 
1Visit 2
Treatment 1
Follow -up 1 
Optimization Visit 3
Treatment 1
Follow -up 2 
Treatment 2Visit 4
Treatment 
2
Follow-up
1
Optimizati
onVisit 5
Treatment 
2
Follow-up
2
Treatment 
3Visit 6
Treatment 
3
Follow-up
1
Time Point Day 0 Day 3±1
from V1Day 7±1 
from V2
Day 0Day 3±1
from V3Day 7±1
from V4Day 7±1 
from V5
Estimated Visit 
Duration2.5 hours 1.0 hour 2.0 hour 1.0 hour 2.0 hour 1.5 hour
10-Minute 
Settling xx (if 
modified)x (if 
modified)x
Visual 
Satisfaction /
Subjective 
Acceptancexx XX xx
Study Lens 
Distance and Near Visual Acuity xx XX xx
Distance Over 
Refraction and Visual Acuity xx XX xx
Subjective Lens 
Fit Assessmentxx XX xx
Lens Deposits X x x
Lens Wettability X x x
Binocular Over 
RefractionX xx
Compliance x X X x x
Follow-up PRO 
(CLUE / MRD) 
Questionnairex XX xx
Visual 
PerformanceX xx
Modifications x x X
Distance and 
Near Exit Visual Acuity xx XX x
Dispensing 
Criteriaxx XX x
Instructions x x X X x
CR-6418, v 2.0  
Page 29 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit Information Visit 1
Screening, 
Baseline, 
Treatment 
1Visit 2
Treatment 1
Follow -up 1 
Optimization Visit 3
Treatment 1
Follow -up 2 
Treatment 2Visit 4
Treatment 
2
Follow-up
1
Optimizati
onVisit 5
Treatment 
2
Follow-up
2
Treatment 
3Visit 6
Treatment 
3
Follow-up
1
Time Point Day 0 Day 3±1
from V1Day 7±1 
from V2
Day 0Day 3±1
from V3Day 7±1
from V4Day 7±[ADDRESS_352098] lenses to accurately assess 
baseline PRO (CLUE and MRD) pe rformance.  If the subject is not wearing their lenses they 
must be rescheduled.
Visit 1: Screening
Step Procedure Details
1.[ADDRESS_352099] read, understand, and sign 
the Statement of Informed Consent before being enrolled into the study.  The Principal Investigator [INVESTIGATOR_022]/her designee conducting the informed consent discussion must also sign the
consent form.
NOTE :The subject must be provided a 
signed copy of this document.
1.[ADDRESS_352100]’s age, gender, race and 
ethnicity.
1.[ADDRESS_352101]’s medical 
history and concomitant medications.
1.[ADDRESS_352102]’s habitual 
lens type and parameters.
1.5 Habitual Lens 
Duration of Wear/Days per weekQuestions regarding t he subject’s duration of 
contact [CONTACT_288792].  
CR-6418, v 2.0  
Page 30 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1.[ADDRESS_352103]’s correction type (i.e. 
monovision, multifocal, sphere with readers, 
etc.).
1.[ADDRESS_352104]’s wear time and 
comfortable wear time with their habitual contact [CONTACT_13276].  
1.[ADDRESS_352105] be answered “yes” and all 
responses t o Exclusion Criteria must be 
answered “no” for the subject to be 
considered eligible.
If subject is deemed to be ineligible after 
screening, proceed to Final Evaluation and complete Subject Disposition. Refraction and Biomicroscopy forms are not required.
Visit 1: Baseline
Step Procedure Details
1.9 Baseline PRO 
(CLUE and MRD) and CLDEQ
-[ADDRESS_352106] will evaluate the vision 
characteristics, comfort characteristics, handling characteristics, and visual symptoms of their habitual lenses using the PRO (CLUE and MRD) questions.  
1.[ADDRESS_352107]’s 
habitual contact [CONTACT_93850]. 
For near measures use the ETDRS [ADDRESS_352108] letter.
NOTE :Best distance visual acuity with 
sphero -cylindrical refraction must be at 
least 20/20-3in each eye for the subject to be 
eligible in the study.
CR-6418, v 2.0  
Page 31 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1.14 Near ADD 
DeterminationThe near reading addition will be determined 
using the binocular crossed cylinde r
technique (BCC) at [ADDRESS_352109] using a +1.[ADDRESS_352110] the BCC result in the trial frame and 
refine the near prescription with trial lenses (or flippers) under binocular conditions. 
1.[ADDRESS_352111] be answered “yes” and all responses to Exclusion Crit
eria questions must be 
answered “no” for the subject to be 
considered eligible.If so, proceed to lens fitting.  
If subject is deemed to be ineligible after 
baselin
e, proceed to Final Evaluation and 
complete all forms.
Visit 1: Treatment [ADDRESS_352112] lens parameters (power and 
lot number).  
CR-6418, v 2.0  
Page 32 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1.[ADDRESS_352113]’s vision is 
acceptable with the lenses.  Allow the subject 
to look down a hallway or out of a window 
for distance vision assessments, and for them to read a book, magazine or similar for near vision.  
1.[ADDRESS_352114] the results.
Note: Use the ETDRS [ADDRESS_352115] on near vision under monocular and/or binocular conditions.   
1.[ADDRESS_352116] reports unsatisfactory vision or
isunable to obtain 20/[ADDRESS_352117] reports satisfactory vision with th e
lenses a modification is not required, how ever
atthe Investigato r’s discretion and based
upon their findings on the measured visu al
acuity and/or over- refractio n the investigator 
may make a modification .
Up to two attempts at modification are 
permitted, if necessary, in order to achieve an acceptable di
stance and near binocular 
performance for the subject, and to enable 
them to wear that particular lens type.  
CR-6418, v 2.0  
Page 33 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Follow the fitting guide allowing for at least 
10 minutes of settling time between each lens 
modification attempted.   If modificati
ons are required steps 1.22- 1.27
will be repeated for each modification. 
1.28 Lens Fit Assessment Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push-up test).
1.[ADDRESS_352118] letter OD, OS and 
OU.
NOTE
: The distance v isual acuity must be 
at least 20/[ADDRESS_352119] will be discontinued.
xDistance Snellen acuity equal to or
better than 20/[ADDRESS_352120] the following:
xThe lenses will be worn on a daily wear 
basis. 
xOnly enough lenses will be dispensed to 
the subject to wear for the required number of days until their follow-
up visit. 
No additional lenses will be dispensed.
xA new lens will be opened and worn each 
day.
xInstruct the subject to bring back all 
unworn study lenses.
CR-6418, v 2.0  
Page 34 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xInstruct the subject no cleaning or 
disinfecting solutions will be used for this 
lens type. 
xIf determined necessary by [CONTACT_93851]-preserved 
rewetting drops may be dispensed to be 
used as needed for dryness.
xSubjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every 
day during the study.
xSubjects will be instructed to wear their 
glasses when not wearing the study 
lenses .
xA patient instruction booklet will be 
provided.
NOTE: In the event a lens is lost or damaged, 
the subject will return to the clinical site for 
replacement.  As much as reasonably possible, a damaged lens and packaging should be returned to the clinical site (wet, if possibl
e) an d then returned to the Sponsor.  
If lens damage is present, complete the 
Product Quality Complaint Form.  The lens 
will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor.
1.[ADDRESS_352121] will be scheduled to return for 
their follow -up appointment in 3±1 days.
NOTE : To count the follow- up visit as a day 
of wear the Subject must have worn the 
study lenses for [ADDRESS_352122] six (6) hours prior to the visit.
Visit 2: Treatment 1 Follow-up 1
Step Procedure Details
CR-6418, v 2.0  
Page 35 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
2.[ADDRESS_352123]’s concomitant 
medications and record any changes from the 
previous study visit.Record any adverse events or medical history changes from the previous study visit.
2.[ADDRESS_352124]’s compliance with 
wearing the study lenses.  
NOTE: Subjects must have worn lenses for 
at least [ADDRESS_352125]’s distance and 
near vision with the lenses is acceptable.
2.[ADDRESS_352126] on near 
vision under monocular and/or binocular 
conditions.   
2.[ADDRESS_352127] reports unsatisfactory vision or
isunable to obtain 20/[ADDRESS_352128] reports satisfactory visio n with
the lenses a modification is not required,
however at the Investigato r’s discretion and 
CR-6418, v 2.0  
Page 36 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
based upon their findings on the measured
visual acuity and/or over- refraction the 
investigator may make a modification .
Up to two attempts at modification are 
permitted if necessary, in order to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type.  Follow the fitting guide and steps 1.[ADDRESS_352129] 10 
minutes of settling time between each lens modification.
2.9 Lens Fit Assessment Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push-up test).
xThe subject should not proceed to wear 
the lenses if any of the following is 
observed:
xpresence of limbal exposure (appearance 
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement 
(excessive or insufficient) in all three
movement categories (primary gaze, 
upgaze, and push-up).
NOTE : If lens fit is unacceptable subject 
will be discontinued from the study. Remove 
the lenses, and complete the Final 
Evaluation forms.
2.10 Collection of
unworn lenses (if 
applicable)Collect unworn lenses returned by [CONTACT_288793].
If lens power was not changed allow the
subject to use the unworn lenses dispense d at
Visit [ADDRESS_352130] until their next
visit.
2.11 Lens Removal The study lenses will be removed and 
discarded.
2.12 Biomicroscopy Perform biomicroscopy OD and OS. Slit 
Lamp Classification Scales will be used to grade the findings. 
CR-6418, v 2.0  
Page 37 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
If the clearance of the fluorescein needs to be 
expedited, preservative -free rewetting drops 
may be instilled.  
2.[ADDRESS_352131] letter OD, OS and OU.
NOTE: The distance visual acuity must be 
at least 20/[ADDRESS_352132] will be discontinued.
xDistance Snellen acuity equal to or 
better than 20/[ADDRESS_352133] the following:
xThe lenses will be worn on a daily wear 
basis.
xOnly enough lenses will be dispensed to 
the subject to wear for the required 
number of days until their follow- up visit. 
No additional lenses will be dispensed.
xA new lens will be opened and worn each 
day.
xInstruct the subject to bring back all 
unworn study lenses.
xInstruct the subject no cleaning or 
disinfecting solutions will be used for this 
lens type. 
CR-6418, v 2.0  
Page 38 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xIf determined necessary by [CONTACT_93851]-preserved 
rewetting drops may be dispensed to be 
used as needed for dryness.
xSubjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every 
day during the study.
xSubjects will be instructed to wear their 
glasses when not wearing the study 
lenses .
NOTE : In the event a lens is lost or da maged, 
the subject will return to the clinical site for 
replacement.  As much as reasonably possible, a damaged lens and packaging should be returned to the clinical site (wet, if possible) and then return ed to the Sponsor.  
If lens damage is present, complete the Product Quality Complaint Form.  The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor.
2.[ADDRESS_352134] will be scheduled to return for 
their follow -up appointment in 7±1 days.
NOTE :To count the follow- up visit as a day 
of wear the Subject must have worn the 
study lenses for [ADDRESS_352135] six (6) hours prior to the visit.
CR-6418, v 2.0  
Page 39 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 3: Treatment [ADDRESS_352136]’s concomitant 
medications and record any changes from the previo
us study visit.
Record any adverse events or medical history 
changes from the previous study visit.
3.[ADDRESS_352137]’s compliance with 
wearing the study lenses.  
NOTE: Subjects must have worn lenses for 
at least [ADDRESS_352138] worn the study lenses 
for 6 hours prior to the visit.
3.4 PRO (CLUE and 
MRD) and CLDEQ-[ADDRESS_352139] will evaluate the vision 
characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO (CLUE and MRD) 
and lens preference 
questionnaires.  
3.[ADDRESS_352140]’s distance and 
near vision with the lenses is acceptable.
3.[ADDRESS_352141] letter OD, OS and OU.
3.8 Visual Performance
Distance (4M) 
Intermediate (64 cm)
Near (40 cm)Binocular Visual performance will be
recorded for the following:
Distance, Bright Illuminance
High and Low Contrast ET DRS Charts         
4M-HC#3 and LC#3
Near, Bright Illuminance
Reduced Guillon-Poling Charts Intermediate
(64 cm) High Contrast and Low Contrast
CR-6418, v 2.0  
Page 40 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Near (40 cm) High Contrast and Low
Contrast
Distance, Dim Illuminance (with Distan ce
goggles)
High Contrast ET DRS Charts 4 M-HC#6
Near, Dim Illuminance (with Near goggles)
Reduced Guillon-Poling charts
High Contrast Intermediate (64 cm) and N ear 
(40 cm).
Note:
xThe room illuminance must be
between 7.3 and 7.9 EV (394- 597 
lux).
xDistance, HC-1 Chart luminanc e
Acceptable Range 10.5-10. 7 EV 
(181-208 cd/m2).
xGuillon-Poling, Near Chart
Luminance Acceptable Range 1 0.8-
11.1 EV (223-274 cd/m2).
xDo not use the Mesopic filter for 
Dim luminance (Dim luminance will 
be simulated by [CONTACT_19561])
3.[ADDRESS_352142] the OD and OS results and distance 
visual acuity.  Note: No lens changes are allowed based on the over-refraction.  
3.10 Lens Fit Assessment Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push-up test).
xThe subject should not proceed to wear 
the lenses if any of the following is 
observed:
xpresence of limbal exposure (appearance 
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement 
(excessive or insufficient) in all three
movement categories (primary gaze, upgaze, and push-up).
CR-6418, v 2.0  
Page 41 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
NOTE: If lens fit is unacceptable subject 
will be discontinued from the study. Remove 
the lenses, and complete the Final 
Evaluation forms.
3.11 Collection of
unworn lense s (if 
applicable)Collect unworn lenses returned by [CONTACT_19564].
3.[ADDRESS_352143] remove the study lenses and 
store in saline in a labeled glass vial.NOTE
: Lenses do not need to be stored in a 
refrigerator.
3.[ADDRESS_352144] is eligible to 
continue in the study based on the examination findings.  
Visit 3: Treatment [ADDRESS_352145] the lens pair and power based on the 
randomization scheme, spherical equivalent refraction (measured at Visit 1 baseline) and fitting guide for each eye.  Record the Test lens parameters (power and lot number).  
3.[ADDRESS_352146]’s vision is acceptable 
with the lenses.  Allow the subject to look down a hallway or out of a window for 
distance vision assessments, and for them to 
CR-6418, v 2.0  
Page 42 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
read a book, magazine or similar for near 
vision.  
3.[ADDRESS_352147] on near vision under monocular and/or binocular conditions.   
3.[ADDRESS_352148] reports unsatisfactory vision or
isunable to obtain 20/[ADDRESS_352149]
reports satisfactory vision with the lenses a
modification is not required, however at t he
Investigato r’s discretion and based upon t heir
findings on the measured visual acuity an d/or
over- refractio n the investigator may make a 
modification .
Up to two attempts at modification are 
permitted, if necessary, in order to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type.  Follow the fitting guide allowing for at least
10
minutes of settling time between each lens 
modification attempted.   If modif
ications are required steps 3.19- 3.25
will be repeated for each modification. 
3.26 Lens Fit Assessment Evaluate overall lens fit acceptance 
(acceptable or unacceptable) based on 
centration, movement and other fitting 
characteristics.
3.[ADDRESS_352150]. 
For near measures use the ETDRS 2000 
Series Chart 1 or 2. The acuity will be 
CR-6418, v 2.0  
Page 43 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
recorded to the nearest letter OD, OS and 
OU. 
NOTE : The distance v isual acuity must be at 
least 20/[ADDRESS_352151]
will be discontinued.
xDistance Snellen acuity equal to or 
better than 20/[ADDRESS_352152] the following:
xThe lenses will be worn on a daily wear 
basis. 
xOnly enough lenses will be dispensed to 
the subject to wear for the required number of days until their follow-
up visit. 
No additional lenses will be d ispensed.
xA new lens will be opened and worn e ach 
day.
xInstruct the subject to bring back all unworn study lenses.
xInstruct the subject no cleaning or 
disinfecting solutions will be used for this 
lens type. 
xIf determined necessary by [CONTACT_93851]-preserved 
rewetting drops may be dispensed to be 
used as needed for dryness.
xSubjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every day during the study.
CR-6418, v 2.0  
Page 44 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xSubjects will be instructed to wear their 
glasses when not wearing the study 
lenses .
xA patient instruction booklet will be 
provided.
NOTE: In the event a lens is lost or damaged, 
the subject will return to  the clinical site for 
replacement.  As much as reasonably 
possible, a damaged lens and packaging should be returned to th e clinical site (wet, if 
possible) and then return ed to the Sponsor.  
If lens damage is present, complete the Product Quality Complaint Form.  The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the Sponsor.
3.[ADDRESS_352153] will be scheduled to return for 
their follow -up appointment in 3±1 days.
NOTE :To count the follow- up visit as a day 
of wear the Subject must have worn the 
study lenses for [ADDRESS_352154] six (6) hours prior to the visit.
Visit 4: Treatment [ADDRESS_352155]’s concomitant 
medications and record any changes from the previous study visit.Record any adverse events or medical history 
changes from the previous study visit.
4.[ADDRESS_352156]’s compliance with 
wearing the study lenses.  
CR-6418, v 2.0  
Page 45 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
NOTE: Subjects must have worn lenses for 
at least [ADDRESS_352157]’s distance and 
near vision with the lenses is acceptable.
4.[ADDRESS_352158] on near 
vision under monocular and/or binocular 
conditions.   
4.[ADDRESS_352159] reports unsatisfactory vision or
isunable to obtain 20/[ADDRESS_352160] reports satisfactory visio n with
the lenses a modification is not required,
however at the Investigator’s discretio n and 
based upon their findings on the measure d
visual acuity and/or over- refraction the 
investigator may make a modification .
Up to two attempts at modification are 
permitted, if necessary, in order to achieve an 
acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type.  Follow the fitting guide and steps 3.[ADDRESS_352161] 10 
minutes of settling time between each lens 
modification.
CR-6418, v 2.0  
Page 46 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
4.9 Lens Fit Assessment Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push-up test).
xThe subject should not proceed to wear 
the lenses if any of the following is 
observed:
xpresence of limbal exposure (appearance 
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement 
(excessive or insufficient) in all three
movement categorie s (primary gaze, 
upgaze, and push-up).
NOTE : If lens fit is unacceptable subject 
will be discontinued from the study. Remove 
the lenses, and complete the Final 
Evaluation forms.
4.10 Collection of
unworn lenses (if 
applicable)Collect unworn lenses returned by [CONTACT_19563].
If lens power was not changed allow the
subject to use the unworn lenses dispense d at
Visit [ADDRESS_352162] letter OD, OS and 
OU.
CR-6418, v 2.0  
Page 47 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
NOTE: The distance v isual acuity must be 
at least 20/[ADDRESS_352163] will be discontinued.
xDistance Snellen acuity equal to or 
better than 20/[ADDRESS_352164] the following:
xThe lenses will be worn on a daily wear 
basis. 
xOnly enough lenses will be dispensed to 
the subject to wear for the required number of days until their follow-
up visit. 
No additional lenses will be dispensed.
xA new lens will be opened and worn each 
day.
xInstruct the subject to bring back all unworn study lenses.
xInstruct the subject no cleaning or 
disinfecting solutions will be used for this 
lens type. 
xIf determined necessary by [CONTACT_93851]-preserved 
rewetting drops may be dispe nsed to be
used as needed for dryness.
xSubjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every 
day during the study.
xSubjects will be instructed to wear their 
glasses when not wearing the study 
lenses .
CR-6418, v 2.0  
Page 48 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xSubjects will be instructed to bring their 
habitual contacts or spectacles to the next 
visit.
NOTE: In the event a lens is lost or damaged, 
the subject will return to the clinical site for 
replacement.  As much as reasonably 
possible, a damaged lens and packaging should be 
returned to the cli nical site (wet, if 
possible) and then return ed to the Sponsor.  
If lens damage is present, complete the 
Product Quality Complaint Form.  The lens will be stored in labeled vial with saline, and 
clearly differentiated  from the other worn
lenses that will be shipped back to the 
Sponsor.
4.[ADDRESS_352165] will be scheduled to return for 
their follow -up appointment in 7±1 days.
NOTE : To count the follow- up visit as a day 
of wear the Subject must have worn the 
study lenses for [ADDRESS_352166] six (6) hours prior to the visit.
Visit 5: Treatment [ADDRESS_352167]’s concomitant medications and record any changes from the previous study visit.Record any adverse events or medical history changes from the previous study visit.
5.[ADDRESS_352168]’s compliance with wearing the study lenses.  
CR-6418, v 2.0  
Page 49 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
NOTE: Subjects must have worn lenses for 
at least [ADDRESS_352169] worn the study lenses for 6 hours prior to the visit .
5.4 PRO (CLUE and 
MRD) and CLDEQ-[ADDRESS_352170] will evaluate the vision 
characteristics, comfort characteristics, 
handling characteristics, and visual 
symptoms of the study lenses using the PRO (CLUE and MRD) 
lens preference 
questionnaires.  
5.[ADDRESS_352171]’s distance and 
near vision with the lenses is acceptable.
5.[ADDRESS_352172] letter OD, OS and OU.
5.8 Visual Performance
Distance (4M) 
Intermediate (64 cm)
Near (40 cm)Binocular Visual performance will be
recorded for the following:
Distance, Bright Illuminance
High and Low Contrast ET DRS Charts         
4M- HC#3 and LC#3
Near, Bright Illuminance
Reduced Guillon-Poling Charts Intermediate
(64 cm) High Contrast and Low Contrast
Near (40 cm) High Contrast and Low
Contrast
Distance, Dim Illuminance (with Distan ce
goggles)
High Contrast ET DRS Charts 4 M-HC#6
Near, Dim Illuminance (with Near goggles)
Reduced Guillon-Poling charts
High Contrast Intermediate (64 cm) and N ear 
(40 cm).
Note:
xThe room illuminance must be
between 7.3 and 7.9 EV (394-597 
CR-6418, v 2.0  
Page 50 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
lux).
xDistance, HC-1 Chart luminanc e
Acceptable Range 10.5-10. 7 EV 
(181-208 cd/m2).
xGuillon-Poling, Near Chart
Luminance Acceptable Range 1 0.8-
11.1 EV (223-274 cd/m2).
xDo not use the Mesopic filter for 
Dim lumina nce (Dim luminance will 
be simulated by [CONTACT_19561])
5.[ADDRESS_352173] the OD and OS results and distance visual acuity.  
Note: No lens changes are allowed based on 
the over-refraction.   
5.10 Lens Fit Assessment Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and tightness (push
-up test).
The subject should not proceed to wear the 
lenses if any of the following is observed:
xpresence of limbal exposure (appearance 
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement 
(excessive or insufficient) in all three
movement categories (primary gaze, 
upgaze, and push-up).
NOTE: If lens fit is unacceptable subject 
will be discontinued from the study. Remove the lenses, 
and complete the Final 
Evaluation forms.
5.11 Collection ofun
worn lense s (if 
applicable)Collect unworn lenses returned by [CONTACT_19564].
5.[ADDRESS_352174] remove the study lenses and 
store in saline in a labeled glass vial.
NOTE : Lenses do not need to be stored in a 
refrigerator.
5.13 Biomicroscopy Perform biomicroscopy OD and OS. Slit Lamp Classification Scales will be used to grade the find
ings.
CR-6418, v 2.0  
Page 51 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
If the clearance of the fluorescein needs to be 
expedited, preservative -free rewetting drops 
may be instilled.  
5.[ADDRESS_352175] is eligible to 
continue in the study based on the examination findings.  
Visit 5: Treatment [ADDRESS_352176] lens parameters (power and lot number).  
5.[ADDRESS_352177]’s vision is acceptable 
with the lenses.  Allow the subject to l ook
down a hallway or out of a window for 
distance vision assessments, and for them to read a book, magazine or similar for near vision.  
5.[ADDRESS_352178] 
on near vision un der monocular and/or 
binocular conditions.   
CR-6418, v 2.0  
Page 52 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
5.25 Lens Fit Assessment Evaluate overall lens fit acceptance 
(acceptable or unacceptable) based on 
centration, movement and other fitting characteristics.
An unacceptable fit is deemed by [CONTACT_288794]: 
xlimbal exposure at primary gaze or 
with extreme eye movement;
xedge lift;
xexcessive movement in primary and 
up gaze; or 
xinsufficient movement in all three of 
the following conditions: primary 
gaze, up gaze, and Josephson push up.
NOTE : If lens fit is unacceptable subject 
will be discontinued from the study. Remove 
the lenses, and complete the Final 
Evaluation forms.
5.[ADDRESS_352179] letter OD, OS and 
OU. 
NOTE: The distance visu al acuity must be at 
least 20/[ADDRESS_352180] will be 
discontinued.
xDistance Snellen acuity equal to or 
better than 20/[ADDRESS_352181] the following:
CR-6418, v 2.0  
Page 53 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xThe lenses will be worn on a daily wear 
basis. 
xOnly enough lenses will be dispens ed to 
the subject to wear for the required 
number of days until their follow- up visit. 
No additional lenses will be dispensed.
xA new lens will be opened and worn each 
day.
xInstruct the subject to bring back all 
unworn study lenses.
xInstruct the subject no cleaning or 
disinfecting solutions will be used for this 
lens type. 
xIf determined necessary by [CONTACT_93851]-preserved 
rewetting drops may be dispensed to be 
used as needed for dryness.
xSubjects will be instructed to wear lenses 
for a minim um of 6 hours a day, every 
day during the study.
xSubjects will be instructed to wear their 
glasses when not wearing the study 
lenses .
xA patient instruction booklet will be 
provided.
xSubjects will be instructed to bring their 
habitual contacts or glasses to the next 
visit.
NOTE: In the event a lens is lost or damaged, 
the subject will return to  the clinical site for 
replacement.  As much as reasonably 
possible, a damaged lens and packaging 
should be returned to th e clinical site (wet, if 
possible) and then return ed to the Sponsor.  
If lens damage is present, complete the 
Product Quality Complaint Form.  The lens will be stored in labeled vial with saline, and clearly differentiated from the other worn lenses that will be shipped back to the 
Sponsor.
CR-6418, v 2.0  
Page 54 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
5.[ADDRESS_352182] will be scheduled to return for 
their follow -up appointment in 7±1 days.
NOTE :To count the follow- up visit as a day 
of wear the Subject must have worn the 
study lenses for [ADDRESS_352183] six (6) hours prior to the visit.
Visit 6: Treatment [ADDRESS_352184]’s concomitant 
medications and record any changes from the previous study visit.Record any adverse events or medical history changes from the previous study visit.
6.[ADDRESS_352185]’s compliance with 
wearing the study lenses.  
NOTE : Subje cts must have worn lenses for 
at least [ADDRESS_352186] worn the study lenses for 6 hours prior to the visit .
6.4 PRO (CLUE and 
MRD) and CLDEQ-[ADDRESS_352187] will evaluate the vision 
characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO (CLUE and MRD) questionnaires.  
6.[ADDRESS_352188]’s distance and 
near vision with the lenses is acceptable.
6.[ADDRESS_352189]. 
For near measures use the ETDRS
2000
Series Chart 1 or 2. The acuity will be 
CR-6418, v 2.0  
Page 55 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
recorded to the nearest letter OD, OS and 
OU. 
6.8 Visual Performance
Distance (4M) 
Intermediate (64 cm)
Near (40 cm)Binocular Visual performance will be
recorded for the following:
Distance, Bright Illuminance
High and Low Contrast ET DRS Charts         
4M- HC#3 and LC#3
Near, Bright Illuminance
Reduced Guillon-Poling Charts Intermediate
(64 cm) High Contrast and Low Contrast
Near (40 cm) High Contrast and Low
Contrast
Distance, Dim Illuminance (with Distan ce
goggles)
High Contrast ET DRS Charts 4 M- HC#6
Near, Dim Illuminance (with Near goggles)
Reduced Guillon-Poling charts
High Contrast Intermediate (64 cm) and N ear 
(40 cm).
Note:
xThe room illuminance must be
between 7.3 and 7.9 EV (394- 597 
lux).
xDistance, HC-1 Chart luminanc e
Acceptable Range 10.5-10. 7 EV 
(181-208 cd/m2).
xGuillon-Poling, Near Chart
Luminance Acceptable Range 1 0.8-
11.1 EV (223-274 cd/m2).
xDo not use the Mesopic filter for 
Dim luminance (Dim luminance will 
be simulated by [CONTACT_19561])
6.[ADDRESS_352190] the OD and OS results and distance visual acuity.  
Note: No lens changes are allowed based on 
the over-refraction.
6.10 Lens Fit Assessment Evaluate and grade lens centration, primary gaze movement
, upgaze movement and 
tightness (push -up test).
The subject should not proceed to wear the 
lenses if any of the following is observed:
CR-6418, v 2.0  
Page 56 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xpresence of limbal exposure (appearance 
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement 
(excessive or insufficient) in all three
movement categories (primary gaze, 
upgaze, and push-up).
NOTE : If lens fit is unacceptable subject 
will be disconti nued from the study. Remove 
the lenses, and complete the Final 
Evaluation forms.
6.11 Collection of
unworn lense s (if 
applicable)Collect unworn lenses returned by [CONTACT_19564].
6.[ADDRESS_352191] remove the study lenses and 
store in s aline in a labeled glass vial.
NOTE : Lenses do not need to be stored in a 
refrigerator.
6.[ADDRESS_352192]
-corrected distance visual acuity (OD and
OS)to the nearest letter. 
Note :This step is not necessary if the subject 
was exited due to screen failure.
CR-6418, v 2.0  
Page 57 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Final Evaluation
Step Procedure Details
F.3 Exit Slit Lamp 
Biomicroscopy (for subjects that are discontinued early)FDA Slit Lamp Classification Scale will be 
used to grade the findings.
If the clearance of the fluorescein needs to be 
expedited, preservative -free rewett ing drops 
or saline may be instilled. This step is not 
necessary if the subject was exited due to screen failure.
Note
: This step is not necessary if t he subject 
was exited due to screen failure, o ri f
biomicroscopy was performed as part of the 
final foll ow-up visit procedures (i.e., 
immediately prior to the final evaluation).
7.3. Unscheduled Visits 
If, during the investigation, a subject requires an unscheduled visit to the clinical site, the 
following information will be collected, as appropriate:
xChief complaint prompting the visit. If the re ason is an adverse event, the applicable 
eCRF for the adverse event must be co mpleted and subject record completed as 
appropriate.
xDate and time of the visit and all procedures completed at the unscheduled visit.
xReview of adverse event and concomitant medications.
xDocumentation of any test article dispensed or collected from the subject, if applicable.
xSlit lamp findings (using the Slit Lamp Classification Scale).
If the Investigator withdraws a subject from th e study, the final study visit case report forms 
must be completed indicating the reason(s) w hy the subject was withdrawn. The subject record 
must be completed documenti ng the date and primary reason for  withdrawal and the study 
CRA notified.
Any ocular and non-ocular Adverse Events that ar e ongoing at the time of the study visit will 
be followed by [CONTACT_737], within licensure , until they have resolved, returned to pre-
treatment status, stabilized, or been satisfactor ily explained. If further treatment i.e., beyond 
licensure is required, the subject will be refe rred to the appropriate health care provider. 
The following information will be co llected during an unscheduled visit.
CR-6418, v 2.0  
Page 58 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Unscheduled Visit
Step Procedure Details
U.[ADDRESS_352193] articles. If 
the reason is other than resupply of 
previously dispensed lenses , specify the 
reason for the visit.
U.2 Chief Complaints (if 
applicable)Record the subject’s chief complaints for 
reasons for the unscheduled visit.
U.3 Adverse Events and 
Concomitant Medications Review(if applicable)Review any changes to the subject’s medical 
history or concomitant medications from the previous study visit. Record any changes, and any adverse events.
U.4 Entrance VA (if 
applicable)Record the entrance distance visual acuity 
(OD, OS) to the nearest letter. 
U.5 Subjective Sphero-
cylindrical Refraction
(if 
applicable)Perform bare-eye subjective spherocylindrical 
refraction with a phoropter (adopt the maximum plus to maximum visual acuity (MPMVA) approach and use the duo
-chrome 
test for binocular balancing) and record the 
best corrected distance visual acuity to the 
nearest letter (OD, OS). 
U.6 Slit Lamp 
Biomicroscopy (if applicable)FDA Slit Lamp Classification Scale will be 
used to grade the findings.  If the clearance of the fluorescein needs to be expedited, preservative
-free rewetting drops may be 
instilled.
U.7 Dispensing (if 
applicable)If the subject requires additional lenses to 
complete the wear period and is eligible to do so, provide additional lenses per 
the
dispensing instructions given in the detailed 
study procedures.
U.8 Exit Visual Acuity 
(if applicable)Record the subject’s exit distance visual 
acuity (OD, OS) to the nearest letter. 
Note : If the only reason for the unscheduled visit is that the subject requires additional test 
articles, only the dispensing information needs to be recorded.
7.4. Laboratory Procedures  
Not Applicable
8. SUBJECTS COMPLETION/WITHDRAWAL  
8.1. Completion Criteria 
Subjects are considered to have completed the study if they: 
CR-6418, v 2.0  
Page 59 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xprovided informed consent.
xthey are eligible.
xcompleted all study visits
8.2. Withdrawal/Discontinuation from the Study 
A subject will be withdrawn from the study for any of the following reasons:
xSubject withdrawal of consent.
xSubject not compliant to protocol.
xSubject lost to follow-up.
xSubject no longer meets eligibility criteria (e.g. the subject becomes pregnant).
xSubject develops significant or serious adverse events necessitating discontinuation of 
study lens wear
xSubjects who have experienced a Corneal Infiltrative Event (CIE).
xInvestigator’s clinical judgment regarding the s ubject safety reasons (that it is in the 
best interest of the subject to stop treatment).
xSubject missed any study visits
xSubject not compliant with study lens wear schedule 
xSubject not successfully dispensed due to lack of efficacy and safety including poorvision, poor comfort or unacceptable fit.
For discontinued subjects, the Investigator will:
xComplete the current visit (scheduled or unscheduled).
xComplete the Final Evaluation, indicating the reason that the subject was discontinued from the study.
xRecord the spherocylindrical refraction with best corrected distance visual acuity.
xCollect used test article(s) (worn or brought to  the visit) from the subject and discard 
them, unless otherwise stated in section 7.2.
xCollect all unused test article(s) from the subject.
xMake arrangements for subject care, if needed, due to their study participation
Additional subjects may be enrolled be enrolled if a subject discontinues from the study 
prematurely. 
In cases where a subject is lost to follow-up, eve ry possible effort must be made to contact [CONTACT_35508]/withdrawal. The measures taken to follow 
up must be documented including two written attemp ts and a certified letter (or equivalent) as 
the final attempt. 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION 
Concomitant medications will be documente d during screening and updated during the study.
Disallowed medications and therapi[INVESTIGATOR_288764].
CR-6418, v 2.0  
Page 60 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
9.1. Systemic Medications 
Certain systemic medications are known to have  a higher likelihood to interfere with contact 
[CONTACT_13279], chiefly by [CONTACT_35509]. A summary of disallowed medications is shown 
in Table 4.
NOTE: Subjects who previously used these medications on a temporary basis must have 
ceased that medication at least 1 week pr ior to signing the informed consent.
Table 4: Disallowed systemic medications
Class of Drug Common Indication(s) Common Examples
Anticholinergics Irritable bowel syndrome, 
Parkinson’s disease, peptic 
ulcer, cystitis, nasal 
congestion, cold symptoms, 
overactive bladder, COPDBentyl, Spi[INVESTIGATOR_35444], Atrovent, 
Hyosyne, Levsin, Symax 
Fastab, Symax SL, Homax 
SL, Cogentin, Transderm 
Scop, etc.
Oral Phenothiazines Antipsychotic disorders 
(schizophrenia, mania)Compazine, Mellarill, 
Thorazine, Phenagran, etc. 
Oral/Inhaled Corticosteroids Arthritis, colitis, asthma, 
bronchitis, allergic or 
inflammatory conditions Cortisone, Prednisone, 
Hydrocortisone, Med rol, 
Kenalog, Flonase etc. 
Oral Retinoids Seborrhea, acne Isotretinoin, Acitretin, 
Alitretinoin, etc. 
Oral Tetracycline Urinary Tract Infection, acne, 
chlamydia, gonorrhea Sumcyin, Acitsite, 
Achromycin V, etc. 
10. DEVIATIONS FROM THE PROTOCOL 
Investigator will notify study sponsor upon iden tification of a protocol deviation. Protocol 
deviations must be reported to the sponsor within 24 hours after discovery of the protocol 
deviation. The Investigator will report deviations  per IRB/IEC requirements. All deviations 
will be tracked, and corrective act ions implemented as appropriate. 
If it becomes necessary for the Investigator to implement a deviation in order to eliminate an immediate hazard to the trial subject, th e Investigator may implement the deviation 
immediately without notification to the spons or. Within [ADDRESS_352194] notify and provi de the rationale to the Sponsor and, as 
required, the IEC/IRB. 
If the deviation potentially impacts the safety of patient or changes the technical integrity of 
the study, then it must be reported to IEC/IRB. This is a "Major Deviation". Deviations
CR-6418, v 2.0  
Page 61 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
that contradict the information contained in the Informed Consent/Assent forms will be
considered Major Deviations.
Minor deviations have no substantive effect on patient safety or technical integrity of the 
study. They are often logistical in nature. Protocol waivers are prohibited.Table 5 lists examples of deviations that will  constitute major and minor protocol deviations
for this study. 
Table 5: Examples of major and minor protocol deviations
Deviation category Major deviation Minor deviation
Out-of-window visit Visit attended more than 2
days out of vi sit window 
defined in study proceduresVisit attended 2o rf e w e r
days out of visit window 
defined in study procedures
Unanswered PRO questions For questionnaires where 
data is related to a primary orsecondary 
endpoint, more 
than 2PRO questions are 
unanswered (i.e., left blank)
in a single domain (i.e. vision)
.For questionnaires where 
data is related to a primary orsecondary 
endpoint, 2or
fewer PRO questions are
unanswered (i.e., left blank).
For questionnaires where 
data where data is not related 
to a primary or secondary endpoint
, any PRO questions 
are unanswered (i.e., left 
blank).
In the case of a major protocol deviation, the decision of whether or not the subject will be 
excluded from the Per-Protocol analysis population will be made at the time of cohort review.
11. STUDY TERMINATION 
The occurrence of one or more Unanticipate d Serious Adverse Device Effect ([LOCATION_003]DE), or 
any SAE where the relationship to study agent cannot be ruled out, may result in stoppi[INVESTIGATOR_35446]. In the event of a [LOCATION_003]DE or SAE, the Sponsor may unmask the treatment regimen for the subject(s) and w ill discuss this with the Investigator before any 
further subjects are enrolled.
CR-6418, v 2.0  
Page 62 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
The Sponsor will determine when a study will be stopped. The Principal Investigator [INVESTIGATOR_126095]’s results are compromised.
JJVC reserves the right to terminate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the study  if an unreasonable risk is determined. The 
study can be terminated by [CONTACT_126117], if in their opi[INVESTIGATOR_21677], after a discussion with  JJVC, it is determined 
that it would be unwise to continue at the clinical site.JJVC (and the IEC/IRB and DMC, if applicable) w ill evaluate all adverse events. If it is 
determined that an adverse event presents an unreasonable risk, the investigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible.
Should the study be terminated (either prematu rely or as scheduled), the Investigator will 
notify the IEC/IRB and Regulatory Authority as required by [CONTACT_35512].
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS 
A Product Quality Complaint (PQC) refers to an y written, electronic, or oral communication 
that alleges deficiencies relate d to the identity, quality, dura bility, reliability, safety, 
effectiveness or performance of test articles after th ey have been released for clinical trial use.  
Potential complaints may come from a variety of sources including but not limited to subjects, 
clinical research associates (CRA), clinical operations managers (COM), medical monitors, 
and site personnel, etc. The following are not considered product quality complaints:
xSubject satisfaction inquiries repor ted via “Subjective Ques tionnaires” and “Patient 
Reported Outcomes (PRO). ”
xClinical test articles that are stored improperly or damaged after receipt at the 
investigational site.
xLens replacements that occur due to drops/fall-outs.
xDamage deemed by [CONTACT_288795] f to be caused by [CONTACT_288796], 
and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where 
there is no deficiency alleged by [CONTACT_423].
Within [ADDRESS_352195] be recorded in the EDC system, which will tr igger an automatic email notification to the 
appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use 
is not configured to send automatic notificati ons or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.  
Upon receipt of the EDC notification, the COM/CR A will contact [CONTACT_19568]: 
xDate the complaint was received/recorded in the EDC System (Date of Sponsor 
Awareness).
xWho received the complaint.
CR-6418, v 2.0  
Page 63 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xStudy number.
xClinical site information (contact [CONTACT_2300], site ID, telephone number).
xLot number(s).
xUnique Subject Identifier(s).
xIndication of who first observed complaint (site personnel or subject).
xOD/OS indication, along with whether the lens was inserted.
xAny related AE number if applicable.
xDetailed complaint description (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms, etc.).
xEye Care Provider objective (sli t lamp) findings if applicable.
xConfirmation of pro duct availability for return (and tracking information, if available), 
or rationale if product is not available for return 
Once a complaint is received, it will be asse ssed by [CONTACT_19569], CRA, or trained site personnel 
to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or traine d site personnel will follow section 13 of this 
protocol. If the AE/SAE was potentially the result  of a product quality related deficiency, these 
procedures also applies and will be executed in parallel.  
In some cases, a PQC form may be generated in EDC by [CONTACT_35514]. In this event, the 
PQC forms will be marked “Intentionally Left Bla nk” or “ILB”.  Justification for ILB must be 
documented.
13. ADVERSE EVENTS 
13.1. Definitions and Classifications 
Adverse Event (AE) – An AE is “any un toward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to  the investigational medical device. ”
Note : This definition includes events related to the investigational medical device or the 
comparator, and to the procedures involved. For users or other persons, this definition is 
restricted to events related to investigational medical devices.1
An AE includes any condition (including a pre-existing condition) that:
1. Was not present prior to the study, but a ppeared or reappeared following initiation of 
the study.
2. Was present prior to the study but worsen ed during the study. This would include any 
condition resulting from concomitant illnesse s, reactions to concomitant medications, 
or progression of disease states.
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immediately upon learning of the event.
Serious Adverse Event (SAE) –An SAE is any adverse event that led to any of the following:
xDeath
CR-6418, v 2.0  
Page 64 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xSerious deterioration in the health of the s ubject that resulted in any of the following:
xLife-threatening illness or injury
xPermanent or persistent impairment of a body structure or a body function
xHospi[INVESTIGATOR_35448]-threatening illness or injury or 
permanent impairment to a body structure or a body function.
xChronic disease
xFetal distress, fetal death or a congenital physical or mental impairment of birth defect.
Diagnoses and conditions that are considered Oc ular Serious Adverse Events include, but not 
limited to:
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber)
xPermanent decrease in best sp ectacle corrected visual acuity equivalent to 2 acuity lines 
or greater
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis
xHypopyon
xHyphemia
xPenetration of Bowman’s Membrane
xPersistent Epi[INVESTIGATOR_35449] –are defined as events that are symptomatic and warrant 
discontinuation (temporary or permanent) of the contact [CONTACT_126118], but 
not limited to the following:
xContact [CONTACT_35516] (CLPU)
xSignificant Infiltrative Events (SIE)
xSuperior Epi[INVESTIGATOR_32955] (SEALs)
xAny Temporary Loss of >[ADDRESS_352196] lens related corneal events - e.g. Epi[INVESTIGATOR_71155] (EKC)
xAsymptomatic Corneal Scar
xAny corneal event which necessitates temporary lens discontinuation > 2 weeks
Non-Significant Adverse Events –are defined as those events that are usually asymptomatic 
and usually do not warrant discontinuation of con tact lens wear but may cause a reduction in 
wear time.  However, the Investigator may choos e to prescribe treatment as a precautionary 
measure.
CR-6418, v 2.0  
Page 65 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Diagnoses and conditions that are considered Oc ular Non-Significant Adverse Events include, 
but not limited to the following:
xNon-significant Infiltrative Event (NSIE)
xContact [CONTACT_19573][INVESTIGATOR_19534] (CLPC)
xSuperficial Punctate Keratitis (SPK)
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact [CONTACT_35518], which 
necessitates temporary lens discontinuation < [ADDRESS_352197] (ADE) – An ADE is an “adverse event related to the use of an 
investigational medical device. ”
Note 1: This definition includes adverse events re sulting from insufficient or inadequate 
instructions for use, deployment, implanta tion, installation, or operation, or any malfunction 
of the investigational medical device.
Note 2: This definition includes any event resulting from use error or from intentional misuse 
of the investigational medical device.[ADDRESS_352198] (UADE) –A UADE is any serious adverse effect on 
health or safety or any life-threatening problem or death caused by, or associated with, the test article, if that effect, problem, or death was not  previously identified in nature, severity, or 
degree of incidence in the investigational pla n, Investigator’s Brochure or protocol, or any 
other unanticipated serious problem  associated with the test artic le that relates to the rights, 
safety and welfare of subjects.
13.2. Assessing Adverse Events 
In conjunction with the medical monitor, the Invest igator will evaluate adverse events to ensure 
the events are categorized correctly. Elements of categorization will include:
xSeriousness/Classifications (see  definition in section 13.1).
xCausality or Relatedness –i.e. the relationship between the test article, study treatment 
or study procedures and the adverse event (not related, unlikely related, possiblyrelated, or related - see definition in section 13.2.1).
xAdverse Event Severity –Adverse event severity is used to assess the degree of 
intensity of the adverse event (mild, moderate , or severe - see definition in section 0).
xOutcome –not recovered or not resolved, rec overing or resolving, recovered or 
resolved with sequelae, recovered or reso lved, death related to adverse event, or
unknown.
xActions Taken –none, temporarily discontinued, permanently discontinued, or other.
CR-6418, v 2.0  
Page 66 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
13.2.1. Causality Assessment 
Causality Assessment –A determination of the relationship be tween an adverse event and the 
test article. The test article relationship for each  adverse event should be determined by [CONTACT_19575]:
xNot Related- An adverse event that is not re lated to the use of the test article, study 
treatment or study procedures.
xUnlikely Related –An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatment, concom itant disease(s), or the relationship of time
suggests that a causal relationship is not likely.
xPossibly Related –An adverse event that might be due  to the use of the test article, or 
to the study treatment or study procedures. An  alternative explanation, e.g. concomitant 
treatment, concomitant disease(s), is in conclusive. The relationship in time is 
reasonable. Therefore, the causal relationship cannot be excluded.
xRelated –An adverse event that is listed as a po ssible adverse effect (device) or adverse 
reaction (drug) and cannot be reasonably exp lained by [CONTACT_4867], e.g. 
concomitant treatment of c oncomitant disease(s). The relationship in time is very 
suggestive, e.g. it is confirmed by [INVESTIGATOR_5328]-challenge and re-challenge.
13.2.2. Severity Assessment 
Severity Assessment –A qualitative assessment of the degree of  intensity of an adverse event 
as determined by [CONTACT_126121]/her by [CONTACT_423]. The assessment of 
severity is made irrespective of test article, st udy treatment or study procedure relationship or 
seriousness of the event and should be evaluated according to the following scale:
xMild –Event is noticeable to the subject but is  easily tolerated and does not interfere 
with the subject’s daily activities .
xModerate –Event is bothersome, possible requiring additional therapy, and may 
interfere with the subject’s daily activities .
xSevere –Event is intolerable, necessitates additi onal therapy or alteration of therapy 
and interferes with the subject’s daily activities .
13.3. Documentation and Follow-Up of Adverse Events 
The recording and documenting of adverse events  (ocular and non-ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure.  Adverse events 
reported before the use of test article, start of study treatment, or study procedures will be 
recorded as medical history. However, if the c ondition deteriorates at any time during the study 
it will be recorded and reported as an AE. Unto ward medical events reported after the subject’s 
exit from the study will be recorded as adve rse events at the discretion of the Investigator.
Upon finding an adverse event, the Principal In vestigator will document the condition in the 
subject record and in the eCRFs and complete the Adverse Event eCRF.  
Complete descriptions of all adverse events must be available in the subject record. All 
Adverse Events including local and systemic re actions not meeting the criteria for “serious 
adverse events” shall be captured on the appropriate case report form or electronic d ata system. 
CR-6418, v 2.0  
Page 67 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
All adverse events occurring while the subject is enrolled in the study  must be documented 
appropriately regardless of relationship.  
It is the Investigator’s responsibility to maintain  documentation of each reported adverse event. 
All adverse events will be followed in accordan ce with applicable licensing requirements. Such 
documentation will include the following:
xAdverse event (diagnosis not symptom).
xDrawings or photographs (where appropriate) that detail the finding (e.g., size, 
location, and depth, etc.).
xDate the clinical site was notified.
xDate and time of onset.
xDate and time of resolution.
xAdverse event classification, severity, and relationship to test articles, as applicable.
xTreatment regimen instituted (where appropr iate), including concomitant medications 
prescribed, in accordance with applicable licensin g requirements.
xAny referral to another health care provider if needed.
xOutcome, ocular damage (if any).
xLikely etiology.
xBest corrected visual acuity at the disc overy of the event and upon conclusion of the 
event, if the AE is related to the visual system.
Upon discovery of an AE that is deemed ‘possibly related ’or ‘related ’to the test article or 
study procedures (whether related to the visual system or not), a nAE review form 
must be completed .Additional dated and initialed entries should be made atfollow -up 
evaluations .Separate forms must be completed for each eye if the AE is bilateral. 
In addition, if an infiltrate(s) is present, he /she will complete the Corneal Infiltrate Assessment 
eCRF. Where necessary, a culture of the corneal les ion will be collected to determine if the 
infection is microbial in nature. If cultures are collected, the date of  culture collection and 
laboratory utilized will be recorded. 
Changes in the severity of an AE shall be documented to allow an assessment of the duration 
of the event at each level of in tensity to be performed. Adve rse events characterized as 
intermittent require doc umentation of the onset and duration of each epi[INVESTIGATOR_1865]. Changes in the 
assessment of relationship to the Test Article shall also be clearly documented.Subjects who present with an adverse event shall be followed by [CONTACT_737], within 
licensure, until all signs and symptoms have returned to pre-treatment status, stabilized, or 
been satisfactorily resolved. If further treatm ent beyond licensure is required, the patient will 
be referred to the appropriate health care provider. The Investigator will use his/her clinical 
judgment as to whether a subject reporting with an adverse event will continue in the study. If a subject is discontinued from the study, it w ill be the responsibility of the Investigator to 
record the reason for discontinuation. The Invest igator will also document the adverse event 
appropriately and complete the Adverse Even t eCRF. Any subjects with ongoing adverse 
events related to the test article, study treatment or study procedures, as of the final study visit 
date, should be followed to resolution of the adve rse event or until referral to an appropriate 
CR-6418, v 2.0  
Page 68 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
health care provider, as recommended by [CONTACT_737]. Non-ocular adverse events that are 
not related to the test article, study treatmen t, or study procedures may be recorded as 
“ongoing” without further follow -up.
13.4. Reporting Adverse Events  
The Investigator will notify the Sponsor of an adverse event by e-mail , facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery for any serious /significant 
adverse events, and 2 days from discovery for any non-significant adverse event. In addition, 
a written report will be submitted by [CONTACT_288797]/IRB according to 
their requirements (section 13.4.2). The report will comment whether the adverse event was considered to be related to the test article, study treatment or study procedures.
13.4.1. Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events
The Investigator will inform the sponsor of all serious/significant adverse events occurring 
during the study period as soon as possib le by e-mail or telephone, but no later than [ADDRESS_352199] igator is obligated to pursue and obtain 
information requested by [CONTACT_35519]. All subjects experiencing a serious/si gnificant adverse event must be  followed up and all outcomes 
must be reported.
When medically necessary, the Investigator may break the randomization code to determine 
the identity of the treatment that the subject received. The Sponsor and study monitor should 
be notified prior to unmas king the test articles.
In the event of a serious/significant adverse event, the Investigator must:
xNotify the Sponsor immediately.
xObtain and maintain in the subject’s reco rds all pertinent medical information and 
medical judgment for colleague s who assisted in the treatment and follow-up of the 
subject.
xProvide the Sponsor with a complete case history which includes a statement as to 
whether the event was or was not related to the use of the test article.
xNotify the IEC/IRB as required by [CONTACT_6179]/IRB reporting procedure according to national regulations.
Unanticipated (Serious) Adverse Device Effect (UADE)In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later 
than [ADDRESS_352200] report the results of the
evaluation to FDA, the IEC/IRB and participati ng Investigators within [ADDRESS_352201].
CR-6418, v 2.0  
Page 69 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Non-Serious Adverse Events
All non-serious adverse events, including non-seri ous adverse device effects, will be reported 
to the sponsor by [CONTACT_35521] 2 days from discovery.
13.4.2. Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities 
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB’s written guidelines. Each clinical site wi ll refer to and follow any guidelines set forth 
by [CONTACT_19581]/IRB. Each clinical site will  refer to and follow any guidelines set forth 
by [CONTACT_19582].
The Sponsor will report applicable Adverse Events  to the local health authorities according the 
written guidelines, incl uding reporting timelines. 
13.5. Event of Special Interest 
None
13.6. Reporting of Pregnancy 
Subjects reporting pregnancy (by [CONTACT_6270]-report) durin g the study will be discontinued after the 
event is recorded as an Adverse Event. Once  discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact [CONTACT_126124] d studies for safety concerns, but due to 
general concerns relating to pregna ncy and contact [CONTACT_19584]. Spec ifically, pregnant women are 
discontinued due to fluctuations in refractive error and/or visual acuity that occur secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus.
14. STATISTICAL METHODS 
14.1. General Considerations 
Statistical Analysis will be undertaken by [CONTACT_35522]. A 
general description of the statistical methods to be implemented in this clinical trial is outlined 
below.
All data summaries and statistical analyses will be performed using the SAS software Version 
9.4 or higher (SAS Institute, Cary, NC).9Throughout the analysis of data, the results for each 
subject/eye will be used when available for summarization and statistical analysis. 
Unscheduled visits will be su mmarized separately and will be  excluded from the statistical 
analysis.Summary tables (descriptive statistics and/or freque ncy tables) will be provided for all baseline 
variables, efficacy variables and safety variable s as appropriate. Continuous variables will be 
summarized with descriptive statistics (n, mea n, standard deviation [SD], median, minimum 
and maximum). Frequency count an d percentage of subjects or eyes within each category will 
be provided for categorical data.
 
CR-6418, v 2.0  
Page 70 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Summaries will be presented by [CONTACT_288798] t ype (Test and Control) and will be performed 
separately by [CONTACT_19587] (Safety Populatio n, Per-Protocol Population or Intent-to-Treat 
Population). 
14.2. Sample Size Justification 
This study was designed and powered to demonstrate that the binocular high luminance high
contrast, visual performance (logMAR) of the Te st lens at distance (4 meters), intermediate 
(64 cm) and near (40 cm) after1-week of lens wear is  non-inferior to the Control lens. Historical 
data for the Test lens with respect to visu al acuity is presented in the Table below.
Table 6: Binocular High Luminance High C ontrast Visual Performance –1-Week 
Follow -up
Position Lens Mean SD*Minimum Maximum
Distance (4 M) Test -0.[ZIP_CODE] 0.[ZIP_CODE] -0.2400 0.2400
Control -0.[ZIP_CODE] 0.[ZIP_CODE] -0.2200 0.1600
Intermediate (64 cm) Test -0.[ZIP_CODE] 0.[ZIP_CODE] -0.2600 0.2600
Control -0.[ZIP_CODE] 0.[ZIP_CODE] -0.2400 0.2200
Near (40 cm) Test 0.0667 0.[ZIP_CODE] -0.1000 0.4400
Control 0.0790 0.[ZIP_CODE] -0.1600 0.3000
*SD: Standard Deviation 
Visual Performance (logMAR)
Sample size calculation for Visual performance (logMAR) was carried out using Monte Carlo simulation methods using PROC IML. One-thousa nd boot strap samples we re simulated based 
on the historical data in Table [ADDRESS_352202] not be evaluated together in 
the same clinical study. For each replicated sa mple a linear mixed model was used; lens was 
included as the only fixed effect.  A variance component (VC) covariance structure was used 
to model measurements from the same subject  across study periods. Seventy subjects to
complete provides >99% power to meet all pr imary hypotheses (Distance, Intermediate and 
Near) associated with visual performance.
The plan is to enroll [ADDRESS_352203] drop-out rate with be closely monitored, if an unexpectedly high 
dropout rate is observed, then the targeted to tal enrollment number maybe be increased 
accordingly to ensure that a minimum of 70 subjects complete the study.
14.3. Analysis Populations 
Safety Population:
All subjects who were administered any test article excluding subjects who drop out prior to 
administering any test article. At lea st one observation should be recorded.
CR-6418, v 2.0  
Page 71 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Per-Protocol Population:
All subjects who have successfully  completed all visits and did not substantially deviate from 
the protocol as determined by [CONTACT_35524] 
(Per-Protocol Population). Justific ation of excluding subjects with protocol deviations in the 
Per-Protocol Population set will be documented in a memo to file.
Intent-to-Treat (ITT) Population:
All subjects regardless of actual treatment and subsequent withdrawal from study or deviation 
from protocol. At least one observation should be recorded.
14.4. Level of Statistical Significance 
All planned analysis for this study will be conduc ted with an overall type I error rate of 5%. 
14.5. Primary Analysis  
All primary analysis will be conducted on the In tent-to-Treat Population. A sensitivity analysis 
will be conducted on the Per-Protocol population. 
Visual Performance (logMAR)
Binocular, high luminance, high contrast visual performance (logMAR) will be analyzed using 
a linear mixed model. Sequence of lens wear, study period, lens type, distance (4 M, 64 cm 
and 40 cm), first order carryover effect and the lens by [CONTACT_288799]. Other character istics including, age, gender and race and ADD power may be 
included when appropriate. Site will be include d as a random effect (G-side). The covariance
between residual errors from the same subject  and distance across study periods will be 
modeled using either homogenous compound sy mmetry (CS) or unstructured (UN) covariance 
structure. The structure that returns th e lowest finite-sample corrected Akaike ’s Information 
criterion7will be selected as the structure that best  fits the model. The Kenward and Roger 
method8will be used for the denominator degrees of freedom.
Comparisons between the Test and Control lenses w ill be carried out at each distance (4 M, 64 
cm and 40 cm) using 2-sided 95% confidence in tervals constructed of least square means 
(LSM) differences (Test minus Control) at the 1-week follow-up evaluation.
Primary hypothesis 1: 
The null and alternative hypothesis for binocular  distance HLHC visual performance to test 
for non-inferiority of the Test lens relative to the Control lens is as follows: 
ܪ௢:ߤ்௘௦௧−ߤ஼௢௡௧௥௢௟≥0.05 logMAR
ܪ஺:ߤ்௘௦௧−ߤ஼௢௡௧௥௢௟ <0.05 logMAR
Non-inferiority will be declared if the upper  limit of the 95% confide nce interval of the LSM 
difference between the Test and Control is below 0.05 logMAR. i.e. P( ߤ்௘௦௧−ߤ஼௢௡௧௥௢௟ <0 .05)
≥ 0.975. 
CR-6418, v 2.0  
Page 72 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Primary hypothesis 2: 
The null and alternative hypothesis for binocular Intermediate HLHC visual performance to 
test for non-inferiority of the Test lens relative to the Control lens is as follows: 
ܪ௢:ߤ்௘௦௧−ߤ஼௢௡௧௥௢௟≥0.05 logMAR
ܪ஺:ߤ்௘௦௧−ߤ஼௢௡௧௥௢௟ <0.05 logMAR
Non-inferiority will be declared if the upper  limit of the 95% confide nce interval of the LSM 
difference between the Test and Control is below 0.05 logMAR. i.e. P( ߤ்௘௦௧−ߤ஼௢௡௧௥௢௟ <0 .05) 
≥ 0.975. 
Primary hypothesis 3: 
The null and alternative hypothesis for binocular near HLHC visual performance to test for 
non-inferiority of the Test lens relative to the Control lens is as follows: 
ܪ௢:ߤ்௘௦௧−ߤ஼௢௡௧௥௢௟≥0.05 logMAR
ܪ஺:ߤ்௘௦௧−ߤ஼௢௡௧௥௢௟ <0.05 logMAR
Non-inferiority will be declared if the upper  limit of the 95% confide nce interval of the LSM 
difference between the Test and Control is below 0.05 logMAR. i.e. P(ߤ ்௘௦௧−ߤ஼௢௡௧௥௢௟ <0 .05) 
≥ 0.975. 
14.6. Secondary Analysis  
CLUE Vision
CLUE vision scores at the 1-week follow-up will  be analyzed using a linear mixed model 
adjusting for baseline values as a covariate. Sequence of lens wear, study period, lens type will 
be included as fixed effects. Ot her factors such as, race, gend er or ADD power may be included 
in the model as covariates when appropriate. Site  will be included as a random effect (G-side). 
The covariance between residual errors from th e same subject across study periods will be 
modeled using either homogenous compound symmetry (CS) or unstructured (UN). The structure that returns the lowest finite- sample corrected Akaike’s Information criterion
7will 
be selected as the structure that best fits the model. The Kenward and Roger method, (Kenward 
and Roger, 1997)8will be used for the denominator degrees of freedom. 
Comparisons between the Test and Control lense s at the 1-week follow-up evaluation will be 
carried out using two-sided 95% confidence intervals constructed for the least-square mean difference (Test minus Control).     
Secondary Hypothesis 1:
The null and alternative hypothesis for CLUE visi on to test for non-inferiority of the Test lens 
relative the Control lens is as follows: 
ܪ
௢:ߤ்௘௦௧− ߤ஼௢௡௧௥௢௟≤-5
ܪ஺:ߤ்௘௦௧−ߤ஼௢௡௧௥௢௟ >-5
Non-inferiority will be declared if the lower limit of the 95% confiden ce interval for the least-
square mean difference is greater than -5. i.e. P( ߤ்௘௦௧− ߤ஼௢௡௧௥௢௟ >-5) ≥ 0.975
CR-6418, v 2.0  
Page 73 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
14.7. Other Exploratory Analysis 
CLUETMcomfort and handling scores will  be descriptively summarized for each timepoint and 
lens type.
Further exploratory analysis may be undertaken  at the discretion of the study responsible 
clinician.
14.8. Interim Analysis 
An interim analysis will be conducted after at  least [ADDRESS_352204] completed the study. The 
interim read will include descriptive summaries on all primary and secondary endpoints. 
Additionally, descriptive summaries on other objectives will also be provided including: 
CLUE™ Comfort, Handling, Lens Optimization Summary, Me chanical Lens Fit and Slit 
Lamp Findings. Listings on any adverse events, corneal infiltrates of other slit lamp findings may also be provided if necessary. 
14.9. Procedure for Handling Missing Data and Drop-Outs 
Missing or spurious values will not be imputed. The count of missing values will be included 
in the summary tables and listings. 
Subject dropout is expected to be one of the main reasons of missing data in this clinical trial. 
Past clinical trials don’t provide the evidenc e that subject dropout is systematic or not-at-
random. To evaluate the impact of missing data, sensitivity analysis will be conducted using 
multiple imputation methods if the proportion of s ubject dropout is greater than the 15%. The 
SAS/STAT procedures PROC MI and PROC MIANAL YZE will be utilized with a parametric 
regression method used to make at least [ADDRESS_352205] KEEPI[INVESTIGATOR_1645]/ARCHIVING 
15.1. Electronic Case Report Form/Data Collection 
The data for this study will be captured on electronic case report forms (eCRFs) using the 
BioClinica EDC system. An authorized data origi nator will enter study data into the eCRFs 
using the EDC system. Data collected on equip ment that is not captured in EDC will be 
formatted to the specification of the JJVC database manager and sent to JJVC for analysis. 
External data sources for this study include: Not Applicable
CR-6418, v 2.0  
Page 74 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
The clinical data will be recorded on dedicated eCRFs specifically designed to match the study 
procedures for each visit. Only specifically  delegated staff can enter data on a CRF.  Once
completed, the eCRFs will be reviewed for accuracy and completeness and signed by [CONTACT_3786]. The sponsor or sponsor’s representatives will be authori zed to gain access to the 
subject recordation for the purposes of monitoring and auditing the study.
Edit checks, electronic queries, and audit trails ar e built into the system to ensure accurate and 
complete data collection. Data will be transmitte d from the clinical site to a secure central 
database as forms are completed or updated, en suring information accuracy, security, and 
confidentiality. After the final database lock, the Investigator will be provided with Individual 
Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all of 
the study data. The IPP must be retained in the study files as a certified copy of the source data 
for the study. 
The content and structure of the eCRFs are compliant with ISO14155:2011.[ADDRESS_352206] should be available for the following: 
xsubject identification
xeligibility
xstudy identification
xstudy discussion
xprovision of and date of informed consent
xvisit dates
xresults of safety and efficacy pa rameters as required by [CONTACT_35526]-up of adverse events
xmedical history and concomitant medication
xtest article receipt/dispensing/return records
xdate of study completion
xreason for early discontinuation of test ar ticle or withdrawal from the study, if 
applicable
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of entry is considered to be the source record.
Adverse event notes must be reviewed and initialed by [CONTACT_737].
15.3. Trial Registration on ClinicalTrials.gov 
This study will be registered on ClincalTrials.gov.
CR-6418, v 2.0  
Page 75 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
16. DATA MANAGEMENT 
16.1. Access to Source Data/Document 
The Investigator/Institution will permit trial-related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by [CONTACT_20618]/documents. Should the clinical site be contact[CONTACT_129816]/IRB or regulatory authority, JJVC must be 
contact[CONTACT_19592] [ADDRESS_352207]  and therefore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands that he/she has an 
obligation to provide complete test results and all data developed during this study to the Sponsor.
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy a nd reliability of data, include the selection of 
qualified investigators and appropriate clinica l sites and review of protocol procedures with 
the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical site personnel are fami liar with the protocol and all study-specific 
procedures and have appropriate knowledge of the study article.
Training on case report form completion will be provided to clinical site personnel before the 
start of the study. The Sponsor will review case report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmission to data management. Any data discrepancies will be  resolved with the Investigator or designee, 
as appropriate.
Quality Assurance representatives from JJVC may visit clinical sites to review data produced 
during the study and to access compliance with applicable regulations pertaining to the conduct 
of clinical trials. The clinical sites will provi de direct access to study-related source 
data/documents and reports for the purpose of monitoring and auditing by [CONTACT_71182].
16.4. Data Monitoring Committee (DMC) 
An independent Data Monitoring Committee (DMC ) will be established to oversee the study. 
Members of DMC must be free of si gnificant conflicts of interest (i.e., financial, intellectual, 
professional, or regulatory), and are experts in all scientific disciplines needed to interpret the 
data and ensure study participant safety.
During the conduct of the trial, responsibilities of the DMC will be to periodically review and 
monitor the incidence of adverse events, determine whether the basic study assumptions 
CR-6418, v 2.0  
Page 76 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
remain valid, evaluate whether the overall inte grity, scientific merit and conduct of the study 
remain acceptable, and make recommendations to  the Sponsor. DMC meetings will be held 
quarterly until all subjects have completed th e study. The DMC may also meet for an ad hoc 
review of data in the event that a UADE or othe r event is reported that may affect the outcome 
and/or continuation of the study.
The DMC will receive a data review package prior to the scheduled meeting. Data packages 
will include the following information/listings:
xSubjects enrollment and disposition information, such as
oNumber and Reason for Subject Early Withdrawal
oNumber of subjects screened, randomized, early withdrawal, and complete
oNumber and Reason for Screen Failure
xMedical History
xConcomitant Medications
xAdverse Events
xProtocol Deviations
xProduct Quality Complaints
Additional descriptive su mmary statistics of study endpoints may be provided per the DMC’s 
requests. Unless otherwise specified, the mas king of the treatment information will be 
maintained in the data prepared for the DMC.Detailed information regarding the roles and responsibilities of the DMC for this study is provided in the Data Monitoring Committee Charter.
17. CLINICAL MONITORING 
The study monitors will maintain close contact [CONTACT_35530] [INVESTIGATOR_35453]’s designated clinical site personnel. The monitor’s responsibilities will incl ude:
xEnsuring that the investigation is bei ng conducted according to the protocol, any 
subsequent versions, and regulatory requirements are maintained.
xEnsuring the rights and wellbeing of subjects are protected.
xEnsuring adequate resources, including facilities, laboratories, equipment, and 
qualified clinical site personnel.
xEnsuring that protocol deviations are documen ted with corrective action plans, as 
applicable.
xEnsuring that the clinical site has sufficient test article and supplies.
xClarifying questions regarding the study.
xResolving study issues or problems that may arise.
xReviewing of study records a nd source documentation verif ication in accordance with 
the monitoring plan.
18. ETHICAL AND REGULATORY ASPECTS 
18.1. Study-Specific Design Considerations 
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new informati on that may affect their decision to continue 
CR-6418, v 2.0  
Page 77 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
participation. Subjects will be to ld that their consent to particip ate in the study is voluntary and 
may be withdrawn at any time with no reason give n and without penalty or loss of benefits to 
which they would otherwise be entitled. Only  subjects who are fully able to understand the 
risks, benefits, and potential adverse events of the study, and provide their consent voluntarily 
will be enrolled.
18.2. Investigator Responsibility 
The Principal Investigator [INVESTIGATOR_71157], the i nvestigational plan, section 4 of the ICH E6(R2)
guidelines on Good Clinical Practice (GCP),2and applicable regulatory requirements. GCP is 
an international ethical and sc ientific quality standard for designing, conducting, recording, 
and reporting studies that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of study subjects are 
protected, consistent with the principles of the Declaration of Helsinki [ADDRESS_352208] maintain 
clinical study files in accordance with section 8 of the ICH E6(R2) guidelines on Good Clinical 
Practice (GCP),2and applicable regulatory requirements.
18.3. Independent Ethics Committee or In stitutional Review Board (IEC/IRB) 
Before the start of the study, the Investigator (o r Sponsor when applicable) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (where applicable):
xFinal protocol.
xSponsor-approved informed consent form (a nd any other written materials to be 
provided to the subjects)
xInvestigator’s Brochure (or equivalent information) .
xSponsor-approved subject recruitment materials.
xInformation on compensation for study-related injuries or payment to subjects for participation in the study.
xInvestigator’s curriculum vitae, clinical licenses, or equivalent information (unless not 
required, as documented by [CONTACT_8134]/IRB).
xInformation regarding funding, name [CONTACT_17008] S ponsor, institutional affiliations, other 
potential conflicts of interest, and incentives for subjects.
xAny other documents that the IEC/IRB requests to fulfill its obligation.
This study will be undertaken only after IEC/ IRB has given full approval  of the final protocol,
the informed consent form, applicable rec ruiting materials, and subject compensation 
programs, and the Sponsor has received a copy of this approval. This approval letter must be 
dated and must clearly identi fy the documents being approved.
During the study, the Investigator (or Sponsor when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate:
xProtocol revisions
xRevision(s) to informed consent form and any other written materials to be provided to 
subjects
xIf applicable, new or revised subject re cruitment materials approved by [CONTACT_288800]-6418, v 2.0  
Page 78 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xRevisions to compensation for study-re lated injuries or payment to subjects for 
participation in the study
xInvestigator’s Brochure revisions
xSummaries of the status of the study (at least  annually or at intervals stipulated in 
guidelines of the IEC/IRB)
xReports of adverse events that are serious, una nticipated, and associated with the test 
articles, according to the IRB’s requirements
xNew information that may adversely affect th e safety of the subj ects or the conduct of 
the study
xMajor protocol deviations as required by [CONTACT_6179]/IRB
xReport of deaths of subjects under the Investigator's care
xNotification if a new Investigator is responsible for the study at the clinical site
xAny other requirements of the IEC/IRB
For protocol revisions that increase subject ris k, the revisions and applicable informed consent 
form revisions must be submitted promptly to  the IEC/IRB for review and approval before 
implementation of the change(s).
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in writing.
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about the study completion. Documentation of this not ification must be retained at the clinical 
site and a copy provided to the CRO or Sponsor as applicable.
18.4. Informed Consent 
Each subject or their representative, must give  written consent according to local requirements 
after the nature of the study has been fully e xplained. The consent form must be signed before 
performance of any study-related activity. The consent form that is used must be approved by 
[CONTACT_19597]/IRB. The informed consent is in accordance with principles that originated in the Declaration of Helsinki,
3current ICH GCP2and ISO [ADDRESS_352209] 's dated signature. After having obtained the 
consent, a copy of the informed consent form must be given to the subject.
CR-6418, v 2.0  
Page 79 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
18.5. Privacy of Personal Data 
The collection, processing and disclosure of pe rsonal data and medical information related to 
the Study Subject, and personal data related to  Principal Investigator [INVESTIGATOR_93794] (e.g., name, clinic address and phone number, curriculum vitae) is subject to 
compliance with the Health Information Portab ility and Accountability Act (HIPAA) in the 
[LOCATION_002]5and other applicable personal data protecti on and security laws and regulations. 
Appropriate measures will be employed to safe guard these data, to maintain the confidentiality 
of the person’s related health and medical information, to pr operly inform the concerned 
persons about the collection and processing of their personal data, to grant them reasonable 
access to their personal data and to prevent access by [CONTACT_35532].
All information obtained during the course of the invest igation will be regarded as confidential. 
All personal data gathered in this trial will be treated in strictest confidence by [CONTACT_4718], 
monitors, Sponsor’s personnel and IEC/IRB. No data will be disclosed to any third party 
without the express permission of the subject  concerned, with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulato ry organizations in the context of their 
investigation related activities that, as part of the investigation will have access to the CRFs 
and subject records.
The collection and processing of pe rsonal data from subjects enrolled in this study will be 
limited to those data that are necessary to invest igate the efficacy, safety, quality, and utility of 
the investigational product(s) used in this study.These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations.
The Sponsor ensures that the personal data will be:
xprocessed fairly and lawfully.
xcollected for specified, explicit, and legiti mate purposes and not further processed in a 
way incompatible with these purposes.
xadequate, relevant, and not excessive in relation to said purposes.
xaccurate and, where necessary, kept current.
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data. Such consent should also addre ss the transfer of the data to 
other entities and to other countries.
The subject has the right to request through the Investigator access to his personal data and the 
right to request rectificati on of any data that are not correc t or complete. Reasonable steps 
should be taken to respond to such a request, taking into consideration the nature of the request, 
the conditions of the study, and the applicable laws and regulations.
Appropriate technical and organizational meas ures to protect the personal data against 
unauthorized disclosures or access, accidental or  unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor pers onnel whose responsibilities require access to 
personal data agree to keep the identity of study subjects confidential.
CR-6418, v 2.0  
Page 80 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
19. STUDY RECORD RETENTION 
In compliance with the ICH GCP guidelines,2the Investigator/Institution will maintain all 
CRFs and all subject records that support the data co llected from each subject, as well as all 
study documents as specified in ICH GCP2and all study documents as specified by [CONTACT_12926](s). The Investigator/Institution will take measures to prevent 
accidental or premature destruction of these documents.
Essential documents must be retained until at  least two (2) years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical devel opment of the investigational product. These 
documents will be retained for a longer period if required by [CONTACT_35533]. It is the responsibility of the Sponsor to inform the 
Investigator/Institution as to when these documents no longer need to be retained.
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], custo dy must be transferred to a person who will 
accept the responsibility. The Sponsor must be notified in writing of th e name [CONTACT_19619]. Under no circumstance shall the Investigator relocate or dispose of any study documents before having obtained written approval from the Sponsor.
If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the Investigator must permit access to such reports.
If the Investigator has a question regarding re tention of study records, he/she should contact 
[CONTACT_19599].
20. FINANCIAL CONSIDERATIONS 
Remuneration for study services and expenses will be set forth in detail in the Clinical Research 
Agreement. The Research Agree ment will be signed by [CONTACT_079] [INVESTIGATOR_1238] a JJVC 
management representative prior to study initiation.
JJVC reserves the right to withhold remuneration for costs associated with protocol violations 
such as:
xContinuing an ineligible subject in the study.
xScheduling a study visit outside the subject’s acceptable visit range .
JJVC reserves the right to withhold final remune ration until all study related activities have 
been completed, such as:
xQuery resolution.
xCase Report Form signature.
xCompletion of any follow-up action items.
CR-6418, v 2.0  
Page 81 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
21. PUBLICATION 
This study will be registered on ClinicalTrials.gov by [CONTACT_1034].
22. REFERENCES 
1. ISO [ZIP_CODE]:2011: Clinical Investigation of Medical Devices for Human Subjects —
Good Clinical Practice. Available at: https://www.iso.org/standard/[ZIP_CODE].html
2. International Conference on Harmonization Good Clinical Practice E6 (ICH-GCP). 
Available at: http://www.ich.org/products /guidelines/efficacy/article/efficacy-
guidelines.html
3. Declaration of Helsinki - Ethical princip les for Medical Research Involving Human 
Subjects. Available at: https://www.wma .net/policies-post/wma-declaration-of-
helsinki-ethical-principles-for-medical-research-involving-human-subjects/
4. [LOCATION_002] (US) Code of Federal Regulations (CFR). Available at: 
https://www.gpo.gov/fdsys/browse/collecti onCfr.action?collectionCode=CFR
5. Health Information Portability and Accountability Act (HIPAA). Available at: 
https://www.hhs.gov/hipaa/for-professionals/privacy/index.html
6. Wirth RJ, et al. Development of the Cont act Lens User Experience: CLUE Scales. 
Optom Vis Sci. 2016;93(8):801-808.
7. Keselman HJ, Algina J, Kowalchuk RK, Wolfinger RD. A Comparison of Two 
Approaches for Selecting Covariance Structures in the Analysis of Repeated 
Measures. Communications in Statistics —Simulation and Computation.
1998;27:591-604.
8. Kenward MG, Roger JH. Small Sample Infere nce for Fixed Effects from Restricted 
Maximum Likelihood. Biometrics . 1997;53:983 –997.
9. SAS Institute Inc: SAS® 9.4 Statements: Reference, Third Edition. Cary, NC: SAS 
Institute Inc; 2014.
 
CR-6418, v 2.0  
Page 82 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTC OMES (STUDY QUESTIONNAIRES) 
 
 
CR-6418, v 2.0  
Page 83 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1
CR-6418, v 2.0  
Page 84 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 2
CR-6418, v 2.0  
Page 85 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3
CR-6418, v 2.0  
Page 86 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4
CR-6418, v 2.0  
Page 87 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 5
CR-6418, v 2.0  
Page 88 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 6
CR-6418, v 2.0  
Page 89 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 7
CR-6418, v 2.0  
Page 90 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 8
CR-6418, v 2.0  
Page 91 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 9
CR-6418, v 2.0  
Page 92 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 10
CR-6418, v 2.0  
Page 93 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 11
CR-6418, v 2.0  
Page 94 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 12
CR-6418, v 2.0  
Page 95 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 13
CR-6418, v 2.0  
Page 96 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 14
CR-6418, v 2.0  
Page 97 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 15
CR-6418, v 2.0  
Page 98 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 16
CR-6418, v 2.0  
Page 99 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 17
CR-6418, v 2.0  
Page 100 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 18
CR-6418, v 2.0  
Page 101 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 19
CR-6418, v 2.0  
Page 102 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 20
CR-6418, v 2.0  
Page 103 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 21
CR-6418, v 2.0  
Page 104 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 22
CR-6418, v 2.0  
Page 105 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 23
CR-6418, v 2.0  
Page 106 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 24
CR-6418, v 2.0  
Page 107 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 25
CR-6418, v 2.0  
Page 108 of 243JJVC CONFIDENTIAL 
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 26
CR-6418, v 2.0  
Page 109 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX B: PATIENT INSTRUCTION GUIDE (TO BE PROVIDED 
SEPERATLEY) 
CR-6418, v 2.0  
Page 110 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) 
Dailies Total 1® Multifocal Contact [CONTACT_288801]-6418, v 2.0  
Page 111 of 243JJVC CONFIDENTIAL 
W900236420DAILIES TOTAL1® and DAILIES TOTAL1® Multifocal (delefilcon A) soft 
contact [CONTACT_288802]: This package insert is effective as of December [ADDRESS_352210]. The eye care professional should provide the patient with appropriate instructions that pertain to the patient’s prescribed lenses. Copi[INVESTIGATOR_288765] [PHONE_5997] or download from our website at www.alcon.com. In addition, a Patient Instruction Booklet is available which is recommended to be given to patients.
CAUTION: Federal law ([LOCATION_002]) restricts this device to 
sale by [CONTACT_35537] a licensed eye care professional.
PRODUCT DESCRIPTION
DAILIES TOTAL1® and DAILIES TOTAL1® Multifocal (delefilcon 
A) soft contact [CONTACT_169760] a lens material that is 33% water and 67% (delefilcon A) polymer, a silicone containing hydrogel with added phosphatidylcholine. The core lens material 
containing 33% water transitions through a water gradient to a 
hydrogel surface layer that exceeds 80% water. Lenses contain the color additive copper phthalocyanine, a light blue tint, which makes them easier to see when handling.
Lens Properties
• Refractive Index hydrated: 1.42• Light Transmittance: 93% (@ 610 nm, -1.00 D)• Oxygen Permeability (Dk): 140  x 10
-11 (cm2/sec)(ml O 2 /ml 
x mm Hg), measured at 35° C 
(intrinsic Dk-Coulometric 
method)
• Water Content: 33% by [CONTACT_288803]
• Surface Water Content: ≥ 80%
Lens Parameters• 
Diameter Range  13.0 to 15.0 mm
• Spherical Power Range  -20.00 to [PHONE_565] D
• Base Curve Range  8.0 to 9.2 mm
Lens Parameters Available1
DAILIES TOTAL1® (delefilcon A) spherical contact [CONTACT_13276]
• Chord Diameter: 14.1 mm• Center Thickness: 0.09 mm @ -3.00 D (varies with  
     power)
• Base Curve: 8.5 mm
• Powers: -0.50 to -6.00 D (0.25 D steps)
-6.50 to -12.00 D (0.50 D steps)
+0.50 to +6.00 D (0.25 D steps)
DAILIES TOTAL1
® Multifocal (delefilcon A) contact [CONTACT_13276]
• Chord Diameter: 14.1 mm
• Center Thickness: 0.09 mm @ -3.00 D (varies with  
      power)• Base Curve: 8.5 mm• Powers: +6.00 D to -10.00 D (0.25 D steps) 
ADD: LO, MED, HI
NOTE: Hereafter, DAILIES TOTAL1
® spherical contact [CONTACT_288804]1® Multifocal contact [CONTACT_288805] A contact [CONTACT_288806].
ACTIONS
When hydrated and placed on the cornea, delefilcon A contact 
[CONTACT_288807] a refracting medium to focus light rays on the retina. 
INDICATIONS (Uses)
DAILIES TOTAL1
® (delefilcon A) spherical soft contact [CONTACT_288808] 
(myopia and hyperopia) in phakic or aphakic persons with 
non-diseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.
DAILIES TOTAL1
® Multifocal (delefilcon A) soft contact [CONTACT_288808] 
(myopia and hyperopia) and/or presby[CONTACT_288809]-diseased eyes who may require a reading 
addition of +3.00 (D) or less and who may have up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.
The lenses are to be prescribed for single use, daily disposable 
wear. The lenses are not intended to be cleaned or disinfected and should be discarded after a single use. 
CONTRAINDICATIONS (Reasons Not To Use)
DO NOT use delefilcon A contact [CONTACT_288810]:
• Inflammation or infection of the anterior chamber of the eye
• Active disease, injury or abnormality affecting the cornea, 
conjunctiva, or eyelids • Microbial infection of the eye• Insufficiency of lacrimal secretion (dry eye) that interferes with 
contact [CONTACT_13279]
• Corneal hypoesthesia (reduced corneal sensitivity)• Use of any medication that is contraindicated or interferes 
with contact [CONTACT_13279], including eye medications
• Any systemic disease which may be exacerbated by [CONTACT_288811]
• Allergic reactions or ocular irritation of the ocular surfaces or 
adnexa that may be caused by [CONTACT_288812]
• Patient history of recurring eye or eyelid infections, adverse 
effects associated with contact [CONTACT_13279], intolerance or 
abnormal ocular response to contact [CONTACT_13279]
• If eyes become red or irritated
WARNINGS
Advise patients of the following warnings pertaining to 
contact [CONTACT_13279]:
• Problems with contact [CONTACT_288813]. It is essential that patients follow their eye care professional’s directions and all labeling instructions for proper use of lenses and lens care products. 
Serious eye problems, including corneal ulcers, can 
develop rapi[INVESTIGATOR_145908].
• Daily wear lenses are not indicated for overnight wear, and 
patients should be instructed not to wear lenses while sleepi[INVESTIGATOR_007]. Clinical study results have shown that the risk of serious adverse reactions is increased when contact [CONTACT_288814]
2.
• Studies2 have shown that contact [CONTACT_288815] a higher incidence of adverse reactions than 
nonsmokers.
• If a patient experiences eye discomfort, foreign body 
sensation, excessive tearing, vision changes, or redness of the 
eye, the patient should be instructed to immediately remove 
lenses and promptly contact [CONTACT_288816]. It is recommended that contact [CONTACT_288817].
PRECAUTIONS
To prevent damage to the eyes or to the contact [CONTACT_13276], the 
following precautions should be taken:
Special Precautions for the Eye Care Professional
Due to the small number of patients enrolled in the clinical investigation of lenses, all refractive powers, design 
configurations, or lens parameters available in the lens material 
are not evaluated in significant numbers. Consequently when 
selecting an appropriate lens design and parameters, the eye care professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, central and peripheral thickness and optic 
zone diameter.
The potential impact of these factors on the patient’s ocular 
health should be carefully weighed against the patient’s need for 
refractive correction; therefore the continuing ocular health of the patient and lens performance on the eye should be carefully evaluated on initial dispensing and monitored on an ongoing basis by [CONTACT_288818].
• Fluorescein, a yellow dye, should not be used while the lenses 
are on the patient’s eyes. The lenses absorb this dye and 
become discolored. Whenever fluorescein is used, the eyes should be flushed thoroughly with sterile saline solution that is recommended for in eye use prior to inserting lenses. Avoid dispensing saline from an aerosol can directly into the eye.
• Patients who wear contact [CONTACT_288819]. Visual requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient.
• Before leaving the eye care professional’s office, the patient 
should be able to promptly remove their lenses or should have someone else available who can remove their lenses for them.
• Eye care professionals should instruct the patient to remove 
the lenses immediately if the eye becomes red or irritated.
• Routine eye examinations are necessary to help assure the 
continued health of the patient’s eyes. Eye care professionals 
should make arrangements with the patient for appropriate 
follow-up visits. Alcon recommends that patients see their eye 
care professional once each year, or more often, as recommended by [CONTACT_288820].• Diabetics may have reduced corneal sensitivity and thus are 
more prone to corneal injury and do not heal as quickly or completely as non-diabetics.
• Visual changes or changes in lens tolerance may occur during 
pregnancy or use of oral contraceptives. Caution patients accordingly.
Eye Care Professionals should carefully instruct patients 
about the following safety precautions:
Handling Precautions
• Be sure that before leaving the eye care professional’s office 
the patient is able to promptly remove lenses or have someone else available to remove them.
• Good hygiene habits help promote safe and comfortable lens 
wear. Always wash, rinse and thoroughly dry hands with a lint-free towel before handling lenses.
• REMOVE A LENS IMMEDIATELY if an eye becomes red or 
irritated.
• Always handle lenses carefully. Never use tweezers or other 
sharp objects such as fingernails to remove lenses from the lens container unless specifically indicated for that use.
• Do not use if blister package is damaged or not sealed 
completely. This may result in product contamination which 
can lead to a serious eye infection.
• Ensure that the correct lens for each eye is available. Shake 
the blister pack gently prior to opening. Remove the lens from 
the blister pack by [CONTACT_288821]. Ensure the lens is right side out. Inspect 
lenses prior to insertion. Do not insert damaged lenses.
• To insert lenses:
- Wash and rinse hands thoroughly and dry completely with a 
clean, lint free towel before handling lenses.
- Place a lens on the tip of your clean and dry right or left 
index finger, place the middle finger of the same hand close 
to lower eyelashes and pull down the lower eyelid.
- Use the fingers of the other hand to lift the upper eyelid.
- Place the lens directly on the eye (cornea) and gently roll 
finger away from the lens.
- Look down and slowly remove the hand, releasing the 
lower lid.
- Look straight ahead and slowly remove the other hand, 
releasing the upper lid.
- Blink gently.
• To remove lenses:
- Wash and rinse hands thoroughly and dry completely with a 
clean, lint free towel before handling lenses. Make sure 
hands are clean and completely dry.
- Blink fully several times.
- While looking up, slide the lens down onto the white part of 
the eye.
- Remove the lens by [CONTACT_21173][INVESTIGATOR_288766]. Do not pi[INVESTIGATOR_288767].
- If the lens is difficult to grasp, dry fingers once more and try 
again. Do not use rewetting drops in this instance.
• 
If a lens decenters on the eye, it may be possible to recenter it by:
- Closing the eye and massaging the lens into place, or- Looking in the direction of the lens and blinking gently, or- Gently pushing the off-centered lens onto the cornea with 
light finger pressure on the edge of the upper or lower 
eyelid.
• If a lens tears in the eye it will feel uncomfortable. Advise 
wearers it is impossible to lose a contact [CONTACT_288822] a 
contact [CONTACT_288823]. Lens pi[INVESTIGATOR_288768], 
carefully avoiding pi[INVESTIGATOR_288769]. If the lens pi[INVESTIGATOR_288770], rinsing with saline is 
recommended. If this does not help, the wearer should contact [CONTACT_288824].
Lens Wearing Precautions:
• Patients should never exceed the prescribed wearing schedule 
regardless of how comfortable the lenses feel. Doing so may 
increase the risk of adverse effects.
• The lens should move freely on the eye at all times. If the lens 
sticks (stops moving) on the eye, follow the recommended directions in the Care for a Sticking Lens section. If 
non-movement of the lens continues, the patient should be 
instructed to consult their eye care professional immediately.
• The eye care professional should be consulted about wearing 
lenses during water sports and water related activities. 
Exposure to water or other non-sterile liquids while wearing 
CR-6418, v 2.[ADDRESS_352211] lenses in activities such as swimming, water skiing, and 
hot tubs may increase the risk of ocular infection, including 
but not limited to Acanthamoeba keratitis. 
• Never allow contact [CONTACT_288825]-sterile liquids (including tap water and saliva) as microbial contamination can occur, which may lead to permanent eye damage.
• Eye irritation, infection, or lens damage may result if 
cosmetics, lotion, soap, cream, hair spray, deodorant, aerosol products or foreign particles come in contact [CONTACT_288826]. 
• Environmental fumes, smoke, and vapors should be avoided in 
order to reduce the chance of lens contamination or physical trauma to the cornea.
• Lenses should be disposed of each day upon removal from the 
eye.
• Discard any lens which has become dehydrated or damaged. 
Replace with a sterile, fresh, new lens.
• Note the correct lens power for each eye to prevent getting 
them mixed up.
• Always carry spare lenses with you or have back-up 
spectacles available.
• Do not share lenses with anyone as this may spread 
micro-organisms which could result in serious eye health problems.
• Do not use lenses beyond their expi[INVESTIGATOR_320].
Other Topi[INVESTIGATOR_35460]:
• Periodic eye examinations are extremely important for contact 
[CONTACT_19554]. Schedule and conduct appropriate follow-up examinations to determine ocular response. Alcon 
recommends that patients see their eye care professional 
once each year or as recommended by [CONTACT_288820].
• Certain medications may cause dryness of the eye, increased 
lens awareness, lens intolerance, and blurred vision or visual 
changes. These include, but are not limited to, antihistamines, 
decongestants, diuretics, muscle relaxants, tranquilizers, and those for motion sickness. Caution patients using such medications accordingly and prescribe proper remedial measures.
• Visual changes or changes in lens tolerance may occur during 
pregnancy or use of oral contraceptives. Caution patients accordingly.
Who Should Know that the Patient is Wearing Contact [CONTACT_32993]:• Patients should inform their health care practitioners that they 
are wearing contact [CONTACT_13276].
• Patients should inform their employers that they are wearing 
contact [CONTACT_13276]. Some jobs may require the use of eye protection equipment or may require that contact [CONTACT_288827].
It is strongly recommended that patients be provided with a copy 
of the DAILIES TOTAL1
® and DAILIES TOTAL1® Multifocal 
(delefilcon A) Contact [CONTACT_288828].
WATER ACTIVITIES
Do not expose contact [CONTACT_35551].
Warning:Water can harbor microorganisms that can lead to severe 
infection, vision loss or blindness. If lenses have been submersed 
in water when showering or swimming, discard them and replace with a new pair. Ask the Eye Care Professional for 
recommendations about wearing lenses during any activity 
involving water.
ADVERSE EFFECTS
Patients should be instructed to check eyes regularly to make sure they look well, feel comfortable and vision is 
clear. Potentially serious complications are usually 
accompanied by [CONTACT_288829]:
• Moderate to severe eye pain not relieved by [CONTACT_288830]• Foreign body sensation• Excessive watering or other eye secretions including 
mucopurulent discharge
• Redness of the eyes• Photophobia (light sensitivity)• Burning, stinging or itching or other pain associated with the 
eyes
• Comfort is less compared to when the lens was first placed on 
eye
• Poor visual acuity (reduced sharpness of vision)• Blurred vision, rainbows or halos around objects• Feeling of dryness
WHAT TO DO IF A PROBLEM OCCURS
Patients should be instructed that if any of the above signs or symptoms are noticed, he or she should: 
• IMMEDIATELY REMOVE THE LENSES.
• If the discomfort or problem stops, discard the lens and 
replace it with a new one.
• If the discomfort or problem continues after removing 
lens(es) or upon insertion of a new lens, IMMEDIATELY remove the lens(es) and contact [CONTACT_288831].
• The patient should be informed that a serious condition 
such as corneal ulcer, infection, corneal vascularization, or iritis may be present, and may progress rapi[INVESTIGATOR_375]. Less serious reactions such as abrasions, infiltrates, and 
bacterial conjunctivitis must be managed and treated 
carefully to avoid more serious complications.
• Additionally, contact [CONTACT_288832]. These include but are not limited to local or 
generalized corneal edema, epi[INVESTIGATOR_86159], epi[INVESTIGATOR_288771], infiltrates, neovascularization, endothelial polymegathism, tarsal papi[INVESTIGATOR_288772], conjunctival injection or iritis.
ADVERSE EFFECT REPORTINGIf a patient experiences any serious adverse effects associated with the use of DAILIES TOTAL1
® brand (delefilcon A) contact 
[CONTACT_13276], please notify: Alcon Medical Safety in the [LOCATION_003] at [PHONE_5998].
FITTING GUIDE AND PATIENT BOOKLET
Conventional methods of fitting contact [CONTACT_288833] 
A contact [CONTACT_13276]. For a detailed description of the fitting 
techniques, refer to the DAILIES TOTAL1
® and DAILIES TOTAL1® 
Multifocal (delefilcon A) Contact [CONTACT_288834]. Both the professional fitting guide and a patient instruction booklet are available free of charge from:Alcon Laboratories, Inc.
[ADDRESS_352212]
Fort Worth, TX, [LOCATION_003] [ZIP_CODE]-[ZIP_CODE]-[PHONE_5999]
LENS WEAR & REPLACEMENT SCHEDULES
DAILY WEAR (less than 24 hours, while awake):
• To avoid tendency of the daily wear patient to over-wear the 
lenses initially, stress the importance of adhering to a proper, 
initial wearing schedule. Normal daily wear of lenses assumes a minimum of 6 hours of non lens wear per 24 hour period. 
• It may be advisable for patients who have never worn contact 
[CONTACT_288835] a wearing schedule that 
gradually increases wearing time over a few days. This allows 
more gradual adaptation of the ocular tissues to contact [CONTACT_94638].
• The maximum daily wearing time should be determined by [CONTACT_288836]’s physiological 
eye condition because individual responses to contact [CONTACT_288837]. There may be a tendency for patients to over-wear the 
lenses initially. The eye care professional should stress the 
importance of adhering to the initial maximum wearing 
schedule. Studies have not been conducted to show that delefilcon A contact [CONTACT_288838], therefore patients should be advised to remove their lenses while sleepi[INVESTIGATOR_007]. Normal daily wear of lenses assumes a 
minimum of 6 hours of non-lens wear per 24 hour period. 
Optimum individual wearing schedule will vary.
• Delefilcon A contact [CONTACT_288839] (daily 
disposable wear) and then discarded at the end of each 
wearing period. The patient should be instructed to start the next wearing period with a fresh new lens.
EMERGENCY LENS CARECleaning and disinfection of daily disposable lenses is not recommended. The patient should be reminded to have replacement lenses or back-up spectacles available at all times.
CARE FOR A STICKING LENS
If the lens sticks (stops moving) or begins to dry on the eye, 
instruct the patient to apply several drops of a recommended lubricating solution (used in accordance with package labeling). The patient should wait until the lens begins to move freely on 
the eye before attempting to remove it. It is important that the 
patient wash and dry their hands thoroughly before removing the 
lens. If the lens continues to stick, the patient should 
IMMEDIATELY consult the eye care professional.
IN OFFICE USE OF TRIAL LENSES
Eye care professionals should educate contact [CONTACT_288840].
Each contact [CONTACT_288841] a blister pack containing 
phosphate buffered saline solution.  Hands should be thoroughly washed and rinsed and dried with a lint-free towel prior to 
handling a lens. In order to ensure sterility, the blister pack should not be opened until immediately prior to use. For fitting 
and diagnostic purposes lenses should be disposed of after a single use and not be re-used from patient to patient.
EMERGENCIES
The patient should be informed that if chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes, the patient should: 
flush eyes immediately with tap water or fresh saline solution and immediately contact [CONTACT_288842] a hospi[INVESTIGATOR_288773].
DISPOSAL AND RECYCLINGDispose of contact [CONTACT_288843], not down the sink or toilet. The carton packaging and 
the polypropylene (PP) plastic shell of the blister pack should be 
placed in the waste bin or recycled according to local waste management guidance.
HOW SUPPLIED
Each lens is packaged in a foil-sealed plastic container 
containing phosphate buffered saline solution with approximately 0.3% of polymeric wetting agents consisting of copolymers of polyamidoamine and poly(acrylamide-acrylic) acid and is steam sterilized. The package is marked with the base curve, diameter, 
dioptric power (and ADD power for multifocal lenses), 
manufacturing lot number, date of manufacture, and expi[INVESTIGATOR_320].
The following may appear on the labels or cartons:
Manufacturer:
Alcon Laboratories, Inc.[ADDRESS_352213]
Fort Worth, TX, [LOCATION_003] [ZIP_CODE]
1-800-241-5999www.alcon.comU.S. Pat.: www.alconpatents.com
© [ADDRESS_352214] lenses. N Eng J Med. 1989; 321 (12):773-783.DIA
BC
PWR
L
R
D
ADD
MAX ADD
LO
MED
HIenEXPCAUTION: Federal law ([LOCATION_002]) restricts this device to sale by [CONTACT_288844] a licensed eye care professional.
Single sterile barrier system
Sterilized using steam
Use-by [CONTACT_568] (Expi[INVESTIGATOR_5695])
Batch codeTwo letter code for the language (Example shown: English)Do not re-use Do not use if blister package is damaged
Diameter
Base curvePowerLeft
RightDiopter (lens power)Addition powerMaximum effective addition power
LowMediumHighEuropean conformity markCautionConsult instructions for use
Authorized representative in the European Community
ManufacturerDate of manufactureMedical device
Packaging waste license signSymbol/Abbreviation Description
CR-6418, v 2.0  
Page 113 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 
APPENDIX D: BINOCULAR OVER REFRACTION 
 
 
CR-6418, v 2.0  
Page 114 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX E: PRESBY[CONTACT_288845]-6418, v 2.0  
Page 115 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX F:  OCULAR DOMINANCE 
CR-6418, v 2.0  
Page 116 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX G: LENS FITTING GUIDE 
 
CR-6418, v 2.0  
Page 117 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
       
 
CR-6418, v 2.0  
Page 118 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX H: CONTROL LENS FITTING GUIDE  
 
  
  
CR-6418, v 2.0  
Page 119 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 120 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 121 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 122 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 123 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 124 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 125 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 126 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 127 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 128 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 129 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 130 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 131 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 132 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 133 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 134 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 135 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 136 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 137 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 138 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 139 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 140 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 141 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 142 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 143 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 144 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 145 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 146 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 147 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 148 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 149 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 150 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 151 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX I:  C-QUANT STRAYLIGHT MEASUREMENT 
 
 
  
CR-6418, v 2.0  
Page 152 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 153 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 154 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 155 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 156 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 157 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 158 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX J:  VISIONIX CORNEAL TOPOGRAPHY AND WAVEFRONT 
 
 
  
CR-6418, v 2.0  
Page 159 of 243JJVC CONFIDENTIAL 
  
CR-6418, v 2.0  
Page 160 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 161 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 162 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 163 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 164 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 165 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 166 of 243JJVC CONFIDENTIAL 
CR-6418, v 2.0  
Page 167 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX K:   
x  LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS
x EXPANDED SODIUM FLUORESCE IN CORNEAL STAINING
x DETERMINATION OF NEAR ADD ITION
x  NEAR logMAR VISUAL ACUITY MEASUREMENT PROCEDURE
x  LENS FITTING CHARACTERISTICS
x  SUBJECT REPORTED OCULAR SYMPTOMS /PROBLEMS
x DETERMINATION OF DISTANCE SPHEROCYLINDRIC AL 
REFRACTI VE ERROR
x BIOMICROSCOPY SCALE
x  DISTANCE AND NEAR SNELLEN VISUAL ACUITY EVALUATION
x DISTANCE LOGMAR VISUAL ACUITY MEASURMENT PROCEDURE
x  PATIENT REPORTED OUTCOMES
x  VISUAL ACUITY CHART LUMINANCE AND ROOM ILLU MINATION 
TESTING
CR-6418, v 2.0  
Page 168 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS  
 
CR-6418, v 2.0  
Page 169 of 243JJVC CONFIDENTIAL 
7LWOH/LPEDO	&RQMXQFWLYDO%XOEDU 5HGQHVV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI








 


 

 
 











 

 

 

 

CR-6418, v 2.0  
Page 170 of 243JJVC CONFIDENTIAL 
7LWOH/LPEDO	&RQMXQFWLYDO%XOEDU 5HGQHVV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI 
 

 

 































CR-6418, v 2.0  
Page 171 of 243JJVC CONFIDENTIAL 
7LWOH/LPEDO	&RQMXQFWLYDO%XOEDU 5HGQHVV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI












CR-6418, v 2.0  
Page 172 of 243JJVC CONFIDENTIAL 
7LWOH/LPEDO	&RQMXQFWLYDO%XOEDU 5HGQHVV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI

















CR-6418, v 2.0  
Page 173 of 243JJVC CONFIDENTIAL 
7LWOH/LPEDO	&RQMXQFWLYDO%XOEDU 5HGQHVV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI

CR-6418, v 2.0  
Page 174 of 243JJVC CONFIDENTIAL 
7LWOH/LPEDO	&RQMXQFWLYDO%XOEDU 5HGQHVV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI



CR-6418, v 2.0  
Page 175 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 EXPANDED SODIUM FLUORESCEIN CORNEAL STAINING  
CR-6418, v 2.0  
Page 176 of 243JJVC CONFIDENTIAL 
7LWOH([SDQGHG6RGLXP)OXRUHVFHLQ&RU QHDO6WDLQLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI




 

 
 
 
 








 





CR-6418, v 2.0  
Page 177 of 243JJVC CONFIDENTIAL 
7LWOH([SDQGHG6RGLXP)OXRUHVFHLQ&RU QHDO6WDLQLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI






CR-6418, v 2.0  
Page 178 of 243JJVC CONFIDENTIAL 
7LWOH([SDQGHG6RGLXP)OXRUHVFHLQ&RU QHDO6WDLQLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI
















CR-6418, v 2.0  
Page 179 of 243JJVC CONFIDENTIAL 
7LWOH([SDQGHG6RGLXP)OXRUHVFHLQ&RU QHDO6WDLQLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI
CR-6418, v 2.0  
Page 180 of 243JJVC CONFIDENTIAL 
7LWOH([SDQGHG6RGLXP)OXRUHVFHLQ&RU QHDO6WDLQLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI








 

   
 



 























CR-6418, v 2.0  
Page 181 of 243JJVC CONFIDENTIAL 
7LWOH([SDQGHG6RGLXP)OXRUHVFHLQ&RU QHDO6WDLQLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI







CR-6418, v 2.0  
Page 182 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
DETERMINATION OF NEAR ADDITION  
 
 
CR-6418, v 2.0  
Page 183 of 243JJVC CONFIDENTIAL 
7LWOH'HWHUPLQDWLRQRI1HDU$GGLWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI







 
 
 
 
 
 
 



























 


CR-6418, v 2.0  
Page 184 of 243JJVC CONFIDENTIAL 
7LWOH'HWHUPLQDWLRQRI1HDU$GGLWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI
CR-6418, v 2.0  
Page 185 of 243JJVC CONFIDENTIAL 
7LWOH'HWHUPLQDWLRQRI1HDU$GGLWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI






CR-6418, v 2.0  
Page 186 of 243JJVC CONFIDENTIAL 
7LWOH'HWHUPLQDWLRQRI1HDU$GGLWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI


 
 




CR-6418, v 2.0  
Page 187 of 243JJVC CONFIDENTIAL 
7LWOH'HWHUPLQDWLRQRI1HDU$GGLWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI

 
 
 
 



 


CR-6418, v 2.0  
Page 188 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 
 NEAR LOGMAR VISUAL  ACUITY MEASUREMENT PROCEDURE  
 
 
CR-6418, v 2.0  
Page 189 of 243JJVC CONFIDENTIAL 
7LWOH1HDU/RJ0$59LVXDO$FXLW\0HDVXUHPHQW3URFHGXUH
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI

 



 
 
 
 

 
 
 









CR-6418, v 2.0  
Page 190 of 243JJVC CONFIDENTIAL 
7LWOH1HDU/RJ0$59LVXDO$FXLW\0HDVXUHPHQW3URFHGXUH
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI


 


 




 

CR-6418, v 2.0  
Page 191 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
LENS FITTING CHARACTERISTICS  
 
 
CR-6418, v 2.0  
Page 192 of 243JJVC CONFIDENTIAL 
7LWOH/HQV)LWWLQJ&KDUDFWHULVWLFV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI










 


















 
CR-6418, v 2.0  
Page 193 of 243JJVC CONFIDENTIAL 
7LWOH/HQV)LWWLQJ&KDUDFWHULVWLFV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI
 




















 




CR-6418, v 2.0  
Page 194 of 243JJVC CONFIDENTIAL 
7LWOH/HQV)LWWLQJ&KDUDFWHULVWLFV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI




 


 
























CR-6418, v 2.0  
Page 195 of 243JJVC CONFIDENTIAL 
7LWOH/HQV)LWWLQJ&KDUDFWHULVWLFV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI








CR-6418, v 2.0  
Page 196 of 243JJVC CONFIDENTIAL 
7LWOH/HQV)LWWLQJ&KDUDFWHULVWLFV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI







CR-6418, v 2.0  
Page 197 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS  
 
CR-6418, v 2.0  
Page 198 of 243JJVC CONFIDENTIAL 
7LWOH6XEMHFW5HSRUWHG2FXODU6\PSWRP V3UREOHPV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI









 



 







 





CR-6418, v 2.0  
Page 199 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTI VE ERROR  
 
CR-6418, v 2.0  
Page 200 of 243JJVC CONFIDENTIAL 
7LWOH'HWHUPLQDWLRQRI'LVWDQFH6SKHURF\OLQGULFDO5HIUDFWLYH(UURU
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI



 

 

 

 
 

 



 


 
 


















CR-6418, v 2.0  
Page 201 of 243JJVC CONFIDENTIAL 
7LWOH'HWHUPLQDWLRQRI'LVWDQFH6SKHURF\OLQGULFDO5HIUDFWLYH(UURU
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI



CR-6418, v 2.0  
Page 202 of 243JJVC CONFIDENTIAL 
7LWOH'HWHUPLQDWLRQRI'LVWDQFH6SKHURF\OLQGULFDO5HIUDFWLYH(UURU
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI






CR-6418, v 2.0  
Page 203 of 243JJVC CONFIDENTIAL 
7LWOH'HWHUPLQDWLRQRI'LVWDQFH6SKHURF\OLQGULFDO5HIUDFWLYH(UURU
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI











 


 
 




CR-6418, v 2.0  
Page 204 of 243JJVC CONFIDENTIAL 
7LWOH'HWHUPLQDWLRQRI'LVWDQFH6SKHURF\OLQGULFDO5HIUDFWLYH(UURU
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI


 





 




 


CR-6418, v 2.0  
Page 205 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
BIOM ICROSCOPY SCALE  
  
CR-6418, v 2.0  
Page 206 of 243JJVC CONFIDENTIAL 
7LWOH  %LRPLFURVFRS\6FDOH
'RFXPHQW7\SH 
' R F X P H Q W  1 X P E H U    5 H Y L V L R Q  1 X P E H U     

3DJHRI


 




 

 
 


 
 
 
 
 
 
 


  


CR-6418, v 2.0  
Page 207 of 243JJVC CONFIDENTIAL 
7LWOH  %LRPLFURVFRS\6FDOH
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
' R F X P H Q W  1 X P E H U    5 H Y L V L R Q  1 X P E H U     

3DJHRI


 




  

  



CR-6418, v 2.0  
Page 208 of 243JJVC CONFIDENTIAL 
7LWOH  %LRPLFURVFRS\6FDOH
'RFXPHQW7\SH 
' R F X P H Q W  1 X P E H U    5 H Y L V L R Q  1 X P E H U     

3DJHRI







 
 

CR-6418, v 2.0  
Page 209 of 243JJVC CONFIDENTIAL 
7LWOH  %LRPLFURVFRS\6FDOH
'RFXPHQW7\SH 
' R F X P H Q W  1 X P E H U    5 H Y L V L R Q  1 X P E H U     

3DJHRI

  




 

CR-6418, v 2.0  
Page 210 of 243JJVC CONFIDENTIAL 
7LWOH  %LRPLFURVFRS\6FDOH
'RFXPHQW7\SH 
' R F X P H Q W  1 X P E H U    5 H Y L V L R Q  1 X P E H U     

3DJHRI

 
 
 
  



 


 

 


CR-6418, v 2.0  
Page 211 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
DISTANCE AND NEAR  SNELLEN  VISUAL ACUITY EVALUATION  
 
 
CR-6418, v 2.0  
Page 212 of 243JJVC CONFIDENTIAL 
7LWOH'LVWDQFHDQG1HDU6QHOOHQ9LVXDO$FXLW\(YDOXDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI



 

 
 



 

 



 
 
 

 
 

CR-6418, v 2.0  
Page 213 of 243JJVC CONFIDENTIAL 
7LWOH'LVWDQFHDQG1HDU6QHOOHQ9LVXDO$FXLW\(YDOXDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI
CR-6418, v 2.0  
Page 214 of 243JJVC CONFIDENTIAL 
7LWOH'LVWDQFHDQG1HDU6QHOOHQ9LVXDO$FXLW\(YDOXDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI


 


 
 

 


 

 

 

 


 


 

 


















CR-6418, v 2.0  
Page 215 of 243JJVC CONFIDENTIAL 
7LWOH'LVWDQFHDQG1HDU6QHOOHQ9LVXDO$FXLW\(YDOXDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI

























CR-6418, v 2.0  
Page 216 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 DISTANCE LOGMAR VISUAL ACUITY MEASUREMENT 
PROCEDURE  
 
 
CR-6418, v 2.0  
Page 217 of 243JJVC CONFIDENTIAL 
dŝƚůĞ͗ ŝƐƚĂŶĐĞ>ŽŐDZsŝƐƵĂůĐƵŝƚǇDĞĂƐƵƌĞŵĞŶƚWƌŽĐĞĚƵƌĞ
ŽĐƵŵĞŶƚdǇƉĞ͗ 
ŽĐƵŵĞŶƚEƵŵďĞƌ͗  ZĞǀŝƐŝŽŶEƵŵďĞƌ͗ϰ

3DJHRI
 



  
 
 
 
 
 
 
 
 

 



CR-6418, v 2.0  
Page 218 of 243JJVC CONFIDENTIAL 
dŝƚůĞ͗ ŝƐƚĂŶĐĞ>ŽŐDZsŝƐƵĂůĐƵŝƚǇDĞĂƐƵƌĞŵĞŶƚWƌŽĐĞĚƵƌĞ
ŽĐƵŵĞŶƚdǇƉĞ͗ 
ŽĐƵŵĞŶƚEƵŵďĞƌ͗  ZĞǀŝƐŝŽŶEƵŵďĞƌ͗ϰ

3DJHRI




CR-6418, v 2.0  
Page 219 of 243JJVC CONFIDENTIAL 
dŝƚůĞ͗ ŝƐƚĂŶĐĞ>ŽŐDZsŝƐƵĂůĐƵŝƚǇDĞĂƐƵƌĞŵĞŶƚWƌŽĐĞĚƵƌĞ
ŽĐƵŵĞŶƚdǇƉĞ͗ 
ŽĐƵŵĞŶƚEƵŵďĞƌ͗  ZĞǀŝƐŝŽŶEƵŵďĞƌ͗ϰ

3DJHRI

 
  

 


 
 


 

CR-6418, v 2.0  
Page 220 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
PATIENT REPORTED OUTCOMES  
 
CR-6418, v 2.0  
Page 221 of 243JJVC CONFIDENTIAL 
7LWOH 3DWLHQW5HSRUWHG2XWFRPHV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU 

3DJHRI































CR-6418, v 2.0  
Page 222 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 VISUAL ACUITY CHART L UMINANCE AND ROOM ILLUMINATION 
TESTING  
  
CR-6418, v 2.0  
Page 223 of 243JJVC CONFIDENTIAL 
7LWOH9LVXDO$FXLW\&KDUW/XPLQDQFHD QG5RRP,OOXPLQDWLRQ7HVWLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI




 
 
 
 
CR-6418, v 2.0  
Page 224 of 243JJVC CONFIDENTIAL 
7LWOH9LVXDO$FXLW\&KDUW/XPLQDQFHD QG5RRP,OOXPLQDWLRQ7HVWLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI





















CR-6418, v 2.0  
Page 225 of 243JJVC CONFIDENTIAL 
7LWOH9LVXDO$FXLW\&KDUW/XPLQDQFHD QG5RRP,OOXPLQDWLRQ7HVWLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI 

CR-6418, v 2.0  
Page 226 of 243JJVC CONFIDENTIAL 
7LWOH9LVXDO$FXLW\&KDUW/XPLQDQFHD QG5RRP,OOXPLQDWLRQ7HVWLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI
CR-6418, v 2.0  
Page 227 of 243JJVC CONFIDENTIAL 
7LWOH9LVXDO$FXLW\&KDUW/XPLQDQFHD QG5RRP,OOXPLQDWLRQ7HVWLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI
CR-6418, v 2.0  
Page 228 of 243JJVC CONFIDENTIAL 
7LWOH9LVXDO$FXLW\&KDUW/XPLQDQFHD QG5RRP,OOXPLQDWLRQ7HVWLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI

 





















CR-6418, v 2.0  
Page 229 of 243JJVC CONFIDENTIAL 
7LWOH9LVXDO$FXLW\&KDUW/XPLQDQFHD QG5RRP,OOXPLQDWLRQ7HVWLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI
CR-6418, v 2.0  
Page 230 of 243JJVC CONFIDENTIAL 
7LWOH9LVXDO$FXLW\&KDUW/XPLQDQFHD QG5RRP,OOXPLQDWLRQ7HVWLQJ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI


CR-6418, v 2.0  
Page 231 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX L:  GUIDELINES FOR COVID -19 RISK MITIGATION  
  
CR-6418, v 2.0  
Page 232 of 243JJVC CONFIDENTIAL 
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

3DJHRI 385326(
7KHSXUSRVHRIWKLVGRFXPHQWLVWRSURYLGHJXLGHOLQHVIRUWKHU HRSHQLQJRULQLWLDWLRQRIFOLQLFDOVWXG\VLWHV
SDUWLFLSDWLQJLQ-RKQVRQ	-RKQVR Q9LVLRQ&DUH,QF--9&,FO LQLFDOVWXGLHVGXULQJWKH&29,'
SDQGHPLF
6&23(
7KLVGRFXPHQWSURYLGHVJXLGHOLQHVIRU-RKQVRQ	-RKQVRQ9LVLRQ &DUH--9&,WRDGGUHVVWKHSRWHQWLDOULVNV
IURP&29,'WRVWXG\VXEMHFWV LQYHVWLJDWRUVVWXG\VLWHVWDI IDQGPRQLWRUVDWVWXG\VLWHV7KHJXLGDQFH
SURYLGHGLQWKLVGRFXPHQWLVLQHIIHFWIURPWKHGDWHRIDSSURYD OWKURXJKWKHGDWHRIUHWLUHPHQWRIWKLV:RUN
,QVWUXFWLRQ$WDPLQLPXPWKLV :RUN,QVWUXFWLRQZLOOEHUHYLHZ HGDQGXSGDWHGRQDTXDUWHUO\EDVLVDV
DSSURSULDWH
127(5HRSHQLQJRIVLWHVRXWVLGHRIWKH86ZLOOEHHYDOXDWHG RQDFRXQWU\E\FRXQWU\EDVLVVXEMHFW
WRORFDOKHDOWKDXWKRULW\JXLGDQFH
'(),1,7,216

$PHULFDQ$FDGHP\RI2SWRPHWU\$$2 7KH$PHULFDQ$FDGHP\RI2SWRPHWU\LVDQRUJDQL]DWLRQRI
RSWRPHWULVWVEDVHGLQ2UODQGR )ORULGD,WVJRDOLVWRPDLQWDLQ DQGHQKDQFHH[FHOOHQFHLQRSWRPHWULF
SUDFWLFHE\ERWKSURPRWLQJUHV HDUFKDQGWKHGLVVHPLQDWLRQRIN QRZOHGJH7KH$$2 KROGVDQDQQXDO
PHHWLQJSXEOLVKHVDPRQWKO\VFLH QWLILFMRXUQDOJLYHVFUHGHQWL DOVWRRSWRPHWULVWV WKURXJKWKHIHOORZVKLS
SURFHVVDQGSXEOLVKHVSRVLWLRQVWDWHPHQWV

$PHULFDQ2SWRPHWULF$VVRFLDWLRQ$2$ 7KH$PHULFDQ2SWRPHWULF $VVRFLDWLRQIRXQGHGLQLV
WKHOHDGLQJDXWKRULW\RQTXD OLW\FDUHDQGDQDGYRFDWHIRURXUQ DWLRQ
VKHDOWKUHSUHV HQWLQJPRUHWKDQ
'RFWRUVRI2SWRPHWU\2'RSWR PHWULFSURIHVVLRQDOVDQGRSWRPHWU\VWXGHQWV'RFWR URI2SWRPHWU\WDNH
DOHDGLQJUROHLQSDWLHQWFDUHZLWKUHVSHFWWRH\HDQGYLVLRQF DUHDVZHOODVJHQHUDOKHDOWKDQGZHOOEHLQJ
$VSULPDU\KHDOWKFDUHSURYLGHUV 'RFWRURI2SWRPHWU\KDYHH[WH QVLYHRQJRLQJWUDLQLQJWRH[DPLQH
GLDJQRVHWUHDWDQGPDQDJHRFXODUGLVRUGHUVGLVHDVHVDQGLQMXU LHVDQGV\VWHPLFGLVHDVHVWKDWPDQLIHVWLQWKH
H\H7KH$PHULFDQ2SWRPHWULF$VVRFLDWLRQLVDIHGHUDWLRQRIVWD WHVWXGHQWDQGDUPHGIRUFHVRSWRPHWULF
DVVRFLDWLRQV7KURXJKWKHVHD IILOLDWLRQVWKH$2$VHUYHVPHPEHU VFRQVLVWLQJRIRSWRPHWULVWVVWXGHQWVRI
RSWRPHWU\SDUDRSWRPHWULFDVVLVWDQWVDQGWHFKQLFLDQV7KH$2$D QGLWVDIILOLDWHVZRUNWRSURYLGHWKHSXEOLF
ZLWKTXDOLW\YLVLRQDQGH\HFDUH
&HQWHUVIRU'LVHDVH&RQWURODQG3UHYHQWLRQ&'& 7KH&HQWHUVIRU'LVHDVH&RQWURODQG3UHYHQWLRQLVD
QDWLRQDOSXEOLFKHDOWKLQVWLWXWHL QWKH8QLWHG6WDWHV,WLVD 8QLWHG6WDWHVIHGHUDODJHQF\XQGHUWKH
'HSDUWPHQWRI+HDOWK DQG+XPDQ6HUYLFHVDQGLVKHDGTXDUWHUHGL Q$WODQWD*HRUJLD 
&29,' &XUUHQWRXWEUHDNRIUHVSLUDWRU\GLVHDVHFDXVHGE\DQRYHOFRURQ DYLUXV7KHYLUXVKDVEHHQ
QDPHG³6$56&R9´DQGWKHGLVHDVHLWFDXVHVKDVEHHQQDPHG³&R URQDYLUXV'LVHDVH´&29,'

&OLQLFDO6WXG\ 9ROXQWDU\UHVHDUFKVWXGLHVFRQGXFWHGLQSHRSOHDQGGHVLJQHGWR DQVZHUVSHFLILFTXHVWLRQV
DERXWWKHVDIHW\RUHIIHFWLYHQHVVRIGUXJVYDFFLQHVRWKHUWKH UDSLHVRUQHZZD\VRIXVLQJH[LVWLQJ
WUHDWPHQWV0D\DOVREHFDOOHGFOLQLFDOWULDOVVWXGLHVUHVHDU FKWULDOVRUSURWRFROV 
&OLQLFDO6WXG\6LWH /RFDWLRQZKHUHDFOLQLFDOVWXG\LVF RQGXFWHGVXFKDVDGRFWRU¶ VRIILFHXQLYHUVLW\RU
ODERUDWRU\&OLQLFDOVWXGLHVDUH FRQGXFWHGE\,QYHVWLJDWRUVZKR DUHLQGLYLGXDOVUHVSRQVLEOHIRUWKH
FRQGXFWRIWKHFOLQLFDOVWXG\DWDVWXG\VLWH,IDVWXG\LVFR QGXFWHGE\DWHDPRILQGLYLGXDOVWKH
,QYHVWLJDWRULVWKHUHVSRQVLEOHOHDGHURIWKHWHDPDQGPD\EHF DOOHGWKH3ULQFLSDO,QYHVWLJDWRU 
&OLQLFDO2SHUDWLRQV0DQDJHU&20 7KH-RKQVRQ	-RKQVRQ9LVLRQ&DUH--9&,LQGLYLGXDO
UHVSRQVLEOHIRUWKHRYHUD OOPDQDJHPHQWRIDFOLQLFDOWULDO 
CR-6418, v 2.0  
Page 233 of 243JJVC CONFIDENTIAL 
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

3DJHRI 0RQLWRU$QLQGLYLGXDOGHVLJQDWHGWRRYHUVHH WKHSURJUHVVRIDFOLQLFDOVWX G\DQGHQVXUHWKDWLWLV
FRQGXFWHGUHFRUGHGDQGUHSRUWHGLQDFFRUGDQFHZLWKWKHSURWRF RO6WDQGDUG2SHUDWLQJ3URFHGXUHV623V
*RRG&OLQLFDO3UDFWLFH*&3DQGDSSOLFDEOHUHJXODWRU\UHTXLUH PHQWV

0HGLFDO6DIHW\2IILFHU062 3K\VLFLDQZKRKDVSULPDU\DFFRXQWDELOLW\LQWKHLUSURGXFWSRUW IROLRIRU
SURGXFWKHDOWKDQGVDIHW\DQGZKRVHUYHVDVDQLQGHSHQGHQWPHG LFDOYRLFHIRUSDWLHQWVDIHW\

6DIHW\0DQDJHPHQW7HDP607 $FURVVIXQFWLRQDOFROODERUDWLY HWHDPUHVSRQVLEOHIRUUHYLHZ
DVVHVVPHQWDQGHYDOXDWLRQRIPHGLFDOVDIHW\GDWDDULVLQJIURPD Q\VRXUFHWKURXJKRXWWKHSURGXFWOLIHF\FOH
*8,'$1&()25678'<'2&80(176
,QDOLJQPHQWZLWKUHFHQWKHDOWKDXW KRULW\JXLGDQFH--9&,LVSU RYLGLQJUHFRPPHQGDWLRQVIRUVWXG\UHODWHG
PDQDJHPHQWLQWKHHYHQWRIGLVUXSWLRQWRWKHFRQGXFWRIWKHFOL QLFDOVWXG\7KLVJXLGDQFHGRHVQRWVXSHUVHGH
DQ\ORFDORUJRYHUQPHQWUHTXLUHPHQWVRUWKHFOLQLFDOMXGJHPHQW RIWKHLQYHVWLJDWRUWRSUR WHFWWKHKHDOWKVDIHW\
DQGZHOOEHLQJRISDUWLFLSDQWV DQGVLWHVWDII,IDWDQ\WLPH DSDUWLFLSDQW¶VVDIHW\LVFRQVLGHUHGWREHDWULVN
VWXG\LQWHUYHQWLRQZLOOEHGLVF RQWLQXHGDQGV WXG\IROORZXSZL OOEHFRQGXFWHGDVRXWOLQ HGLQWKHSURWRFRO
'XULQJWKH&29,'SDQGHPLFW KHDGGLWLRQDOULVNVOLVWHGEHORZ QHHGWREHFRQVLGHUHGIRUVWXG\SDUWLFLSDQWV
DQGVWXG\SHUVRQQHO
$GGLWLRQDO5LVNV5HODWHGWRWKH&29,'3DQGHPLF
x7KHSRVVLEOHWUDQVPLVVLRQRIWKH&RURQDYLUXVLQIHFWLRQDQGFRQV HTXHQWFRPSOLFDWLRQVEH\RQGWKH
ULVNRIDGYHUVHHYHQWVGXHWRWKH LQYHVWLJDWLRQDOGHYLFHDQGRU SURFHGXUHV
x7KHULVNPD\EHKLJKHULQDQRSWRPHWULFFOLQLFDOVWXG\EHFDXVH RIWKHFORVHFRQWDFWWKHVXEMHFWZLOO
KDYHZLWKKHDOWKFDUHSURIHVVLRQDOVGXULQJWKHSURFHGXUHVDQGD VVHVVPHQWVVLQFHWKHLQYHVWLJDWRU
PXVWPDNHWKHPHDVXUHPHQWVFORVHWRWKHVXEMHFW¶VIDFHDQGLQ DGGLWLRQWKHQHHGIRUPXOWLSOH
IROORZXS YLVLWVH[DPV ZKLFK PD\ H [SRVH WKH VXEMHFW WR RWKHU SD WLHQWV DQGRU KHDOWKFDUH
SURIHVVLRQDOVZKRPLJKWEHWUDQ VPLWWLQJWKHYLUXVHYHQLIWKH\ GRQRWKDYHV\PSWRPV
x3RWHQWLDOGLVUXSWLRQVWRWKHVWXG\PD\EHQHFHVVDU\GXHWRFXUU HQWRUIXWXUHSDQGHPLFUHODWHG
HPHUJHQF\UHVWULFWLRQVZKLFKPD\OHDGWRGHOD\VLQVFKHGXOHGI ROORZXSYLVLWV
x6XEMHFWVH[SHULHQFLQJDQDGYHUVHHYHQWUHODWHGWRFRQWDFWOHQV ZHDUPD\UHFHLYHGHOD\HGWUHDWPHQW
GXHWR&29,'UHVWULFWLRQV,QWKLVHYHQWDOODVVHVVPHQWVWK DWFDQEHFRQGXFWHGYLUWXDOO\ZLOOEH
FRPSOHWHGE\WKHLQYHVWLJDWRUWR GHWHUPLQHWKHEHVWFRXUVHRIW UHDWPHQWIRUWKHVXEMHFWLQFOXGLQJ
DQXQVFKHGXOHGYLVLWXSWRGL VFRQWLQXDWLRQIURPWKHVWXG\DV DSSURSULDWH
,IDVWXG\VXEMHFWLVIRXQGWRKDYHFRQWUDFWHG&29,'GXULQJ SDUWLFLSDWLRQLQDVWXG\KHVKHZLOOEH
GLVFRQWLQXHGIURPWKHVWXG\DQGIROORZHGXQWLO&29,'$GYHUVH (YHQW$(UHVROXWLRQ
7RKHOSPLQLPL]HWKHDERYHSRWHQWLDOULVNV--9&,UHFRPPHQGUHY LHZLQJFRPSO\LQJZLWKORFDOVWDWH
DQGJRYHUQPHQWDOJXLGDQFHIRU&29,'ULVNV
--9&,ZLOOSURYLGHWKHIROORZLQJVWXG\VSHFLILFGRFXPHQWVZLWK ODQJXDJHSHUWDLQLQJWR&29,'ULVNV
,QIRUPHG&RQVHQW 
:LOOLQFOXGHLQIRUPDWLRQFRQFHUQLQJ WKHVWXG\DVVRFLDWHGULVNV UHODWHGWRWKH&29,'SDQGHPLF
LQEROGIRQWDQGRUER [HGRQWKHILUVWSDJHRIWKH,QIRUPHG&RQ VHQWGRFXPHQW

CR-6418, v 2.0  
Page 234 of 243JJVC CONFIDENTIAL 
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

3DJHRI 678'<$662&,$7('5,6.65(/$7('72 &29,'&2521$9,5863$1'(0 ,&

,WLVLPSRUWDQWWRQRWHWKDWWKL VVWXG\ZLOOEHFRQGXFWHGDWOHDVWLQSDUWGXULQJWKH&29,'SDQGHPLF$VVXFK
DGGLWLRQDOULVNVDVVRFLDWHGZLWK WKHLQIHFWLRQZLWK&29,'H[ LVWIRU\RX7KLVLVSDUWLFXODUO\LPSRUWDQWIRUWKLV
VWXG\GXHLQSDUWWRWKHFORVHQ HVVRIWKHGRFWRUGXULQJWKHV WXG\H[DPLQDWLRQV

7KHSRWHQWLDOHIIHFWVRIWKHGL VHDVHDUHQRWIXOO\NQRZQDWWK LVWLPHDQGPD\LQFOXGHORQJWHUPVHULRXVKHDOWK
FRQVHTXHQFHV,QVHYHUHFDVHVWKLVPD\UHVXOWLQKRVSLWDOL]DWL RQDQGRUGHDWK%DVHGRQFXUUHQWNQRZOHGJHIURPWKH
&HQWHUVIRU'LVHDVH&RQWURODQG3UHYHQWLRQ&'&WKRVHDWKLJK ULVNIRUVHYHUHLOOQHVVIURP&29,'LQFOXGH
ROGHUDGXOWVDQGSHRSOHZLWKXQG HUO\LQJPHGLFDOFRQGLWLRQV
'XULQJWKLVVWXG\DOODSSURSULDWHPHDVXUHVZLOOEHWDNHQWRPL QLPL]HULVNVLQFOXGLQJWKHX VHRISHUVRQDOSURWHFWLYH
HTXLSPHQWVXFKDVPDVNVDQGJORYHVDVZHOODVSURSHUVDQLWL]DW LRQ7KLVLVLQFRQIRUPDQFHWRJXLGDQFHIURPWKH
&'&ORFDOKHDOWKGHSDUWPHQWVDQGWKHVWDWHDQGFRXQW\LQZKLFKWKHVWXG\GRFWRU¶VRIIL FHLVORFDWHG+RZHYHU
WKHVHPHDVXUHVPD\QRWFRPSOHWHO\HOLPLQDWHWKHULVNVDVVRFLDWH GZLWKFRQWUDFWLQJ&29,'

,I\RXDUHIRXQGWRKDYHFRQWU DFWHG&29,'RUIHHOLOOZLWKI OXOLNHV\PSWRPVGXULQJSDUWLFLSDWLRQLQWKHVWXG\
\RXZLOOQRWEHSHUPLWWHGWRFRQWLQXHLQRIILFHVWXG\IROORZXS YLVLWVEXW\RXZLOOUHFHLYHLQVWUXFWLRQVDQG\RXU
FRQGLWLRQZLOOEHPRQLWR UHGE\WKHGRFWRUDQGRUVWXG\VWDII 
&29,'5LVN&RQWURO&KHFNOLVW
:LOOLQFOXGH&29,'ULVNFRQWUR OPHWKRGVWKDWDUHUHTXLUHGE\ DVLWHWRFRQGXFW--9&,FOLQLFDOVWXGLHV
7KHULVNFRQWUROVDUHFRQVLVWHQWZLWK&'&$2$$$2*XLGDQFH7 KH3ULQFLSOH,QYHVWLJDWRUZLOOUHYLHZVLJQ
WKHVWXG\VSHFLILFFKHFNOLVWSULRUWRWKH6LWH,QLWLDWLRQ0HHWL QJ

6WXG
\1XPEHU
6LWH1XPEH U
3ULQFLSDO,QYHVWL JDWRU3,1DPH 

7KHIROORZLQJ&29,'ULVNFRQWUROPHWKRGVDUHUHTXLUHGWRFRQ GXFW-RKQVRQ	-RKQVRQ9LVRQ&DUHFOLQLFDO
VWXGLHV3OHDVHUHYLHZWKHIROORZLQJUHTXLUHPHQWVDQG,QLWLDOHDFKUHTXLUHPHQW
3,,QLWLDOV *HQHUDO6LWH6DIHW \3ODQQLQJ0HDVXUHV
6 LJQDJHZLWKLQVLWHGHVFULELQ J5LVN&RQWUROPHWKRGV
 6RFLDO'LVWDQFLQ JSUDFWLFHVWKURX JKRXWVLWHZDLWLQ JURRPVOREE \H[DPURRPVHWF
 1RQFRQWDFWWKHUPRPHWHUDYDLODEOHWRDVVHVVWHPSHUDWXUHVRIVWDI IDQGSDWLHQWV
 7UDLQLQJRQSDWLHQWIORZDQGSK \VLFDOGLVWDQFLQ JLQZDLWLQJURRP
 (VWDEOLVKORQ JHUWLPHIUDPHEHWZHHQSDWLHQWDSSRLQWPHQWVWRUHGXFHSHUVRQVLQ WKHVLWH
 6WDIIVKRXOGUHFHLYHMREVSHFLILFWUDLQLQJRQ33(DQGGHPRQVWU DWHFRPSHWHQF\ZLWKVHOHFWLRQDQG
SURSHUXVHRI33(D QGZHDUDWDOOWLPHVGXULQJLQWHUDFWLRQVZLW KVXEMHFWVHJSXWWLQJRQDQG
UHPRYLQJZLWKRXWVHOIFRQWDPLQDWLRQ

3,,QLWLDOV 6LWH6WDII'DLO \6DIHW\0HDVXUHV
 $VSDUWRIURXWLQHSUDFWLFHVLWHVWDIIVKRXOGUHJXODUO\PRQLW RUWKHPVHOYHVIRUIHYHUDQGV\PSWRPV
RI&29,'LQFOXGLQ JWHPSHUDWXUHFKHFNV
 $Q\VWDIIPHPEHULQFOXGLQJ,QY HVWLJDWRUVVKRZLQJVLJQVRIEH LQJVLFNRUWHVWLQJSRVLWLYHIRU
&29,'VKRXOGQRWEHSHUPLWWHGW RZRUNDQGWKH6SRQVRUVKDOO EHLQIRUPHG
127(,QIRUP--9&LQKRXUVRID Q\VLJQLILFDQWLPSDFWWRWKH VWXG\
 (QVXUHWKDWDOOVWDIIZHDUDPDVN
*ORYHVVKRXOGEHUHTXLUHGZKHQZRUNLQ JGLUHFWO\ZLWKSDWLHQWVDQGFKDQ JHGEHWZHHQHDFKSDWLHQ W
CR-6418, v 2.0  
Page 235 of 243JJVC CONFIDENTIAL 
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

3DJHRI  +DYHVWDIIWKRURXJKO\ZDVKKDQG VIRUDWOHDVWVHFRQGVRUXV HDQDOFRKROEDVHGKDQGVDQLWL]HU
ZKHQWKH\DUULYHEHIRUHDQGDIWHUHDFKSDWLHQWEHIRUHHDWLQ JDQGDIWHUXVLQ JWKHEDWKURRP
 &OHDQLQJDQGGLVLQIHFWLRQSUR FHGXUHVIRUH[DPURRPVDQGLQVWUXPHQWVRUHTXLSPHQWEHWZHHQ
SDWLHQWVZLWK JORYHV
 &OHDQLQJDQGGLVLQI HFWLRQSURFHGXUHVIRUFRPPRQO\WRXFKHGVXUI DFHVGRRUVFKDLUVFRPSXWHUV
SKRQHVHWFZLWK JORYHV

3,,QLWLDOV %HIRUHD3DWLHQWRU6WXG \9LVLW
 3DWLHQWVVKRXOGEHDVNHGSULRUWRHQWHULQJWKHVLWHDERXWIHYH UDQGUHVSLUDWRU\LOOQ HVVDQGZKHWKHU
WKH\RUDIDPLO\PHPEHUKDYHKDGFRQWDFWZLWKDQRWKHUSHUVRQZL WKFRQILUPHG&29,'LQWKH
SDVWGD\V3DWLHQWV H[KLELWLQJVLJQVRIE HLQJVLFNVKRXOGEH UHVFKHGXOHGZKHQWKHLUV\PSWRPV
UHVROYH
 ,QVWUXFWSDWLHQWVWKDWFRPSDQL RQVVKRXOGUHPDLQRXWVLGHRIWKH IDFLOLW\DQGQRWDFFRPSDQ\WKH
SDWLHQWLQWRWKHIDFLOLW\XQOHVVWKH \DUHDSDUHQWJXDUGLDQRIWKHSDWLHQWRULIWKH\DUHDWUXH
FDUHJLYHUDQGQHHGWRDVVLVWWKHSDWLHQ W
 5HTXHVWWKHSDWLHQWWRFDOORUWH[WWKHRIILFHXSRQDUULYDOVR HQWUDQFHWRDQGPRYHPHQWWKURXJK
IDFLOLW\FDQEHFRRUGLQDWHGE \VLWHVWDII

3,,QLWLDOV 3DWLHQWV(QWHULQ JWKHVLWH
 7HPSHUDWXUHFKHFNVXWLOL]LQJDQRQFRQWDFWWKHUPRPHWHUIRUDOO SDWLHQWVDQGFRPSDQLRQVHQWHULQJ
WKHVLWH
 $OOSDWLHQWVDQGFRPSDQLRQVPX VWZHDUFORWKRUGLVSRVDEOHPDVN DWDOOWLPHVLQWKHVLWH
 0DLQWDLQVRFLDOGLVWDQFLQJ:DLWLQJURRPVRUOREELHVVKRXOGEH DVHPSW\DVSRVVLEOH$GYLVH
VHDWHGSDWLHQWVWRUHPDLQDWOHDVWIHHWIURPRQHDQRWKHU
 &RPPXQDORE MHFWVLQHJWR\VUHDGLQJPDWHULDOVHWFVKRXOGEH UHPRYHGR UFOHDQHGUH JXODUO\


,FHUWLI\WKDW,KDYHUHDGDQGDJUHHWRLPSOHPHQWDOOWKHOLVWH G&29,'5LVN&RQWURO0HDVXUHVUHTXLUHGIRUWKH
FRQGXFWRI-RKQVRQ	-RKQVRQ9LVLRQ&DUHVWXGLHV

3ULQFLSDO,QYHVWLJDWR U6LJQDWXUHDQG'DWH



CR-6418, v 2.0  
Page 236 of 243JJVC CONFIDENTIAL 
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

3DJHRI 5(6285&(/,1.6

865HVRXUFH/LQNV

x26+$7UDLQLQJ
KWWSVZZZRVKDJRY6/7&FRYLGFRQWUROSUHYHQWLRQKWPO 

3HUVRQDO3URWHFWLYH(TXLSPHQW33(7UDLQLQJ&'&KWWSVZZZFGFJRYFRURQDYLUXVQFRYKFSXVLQJSSHKWPO

x,	57UDLQLQJ$&898(
/HQV$VVLVW KWWSVZZZDFXYXHFRPOHQVDVVLVW 

x&OLQLF3UHSDUHGQHVV*XLGHV&'&KWWSVZZZFGFJRYF RURQDYLUXVQFRY KFSFOLQLFSUHSDUHGQH VVKWPO
$2$KWWSVDRDXEHUIOLSFRPL DRDJXLGDQFHIRUUHRSHQLQJ SUDFWLFHVFRYLGā"P 
$PHULFDQ2SWRPHWULF$VVRFLDWLRQ KWWSVZZZDRDRUJRSWRPHWU\SUDFWLFHUHDFWLYDWLRQSUHSDUHGQHV V
JXLGH

xOQ2IILFH'LVLQIHFWLRQRI0XOWL3DWLHQW8VH'LDJQRVWLF&RQWDFW /HQVHV
KWWSVZZZJSOLLQIRZSFRQWHQWXSORDGVLQRIILFHGLVLQIHFWLQJRIGLDJQRVWLF
OHQVHVSGI
2865HVRXUFH/LQNV

x8SGDWHVRQORFDOUHJXODWLRQVLQ+RQJ.RQJKWWSVZZZFRURQDYLUXVJRYKNHQJLQGH[KWPO 

x5HVXPSWLRQRIRSWLFDOVHUYLFHVLQ(QJODQG/HWWHUIURP0DWW1HO LJDQDQG3RRQDP6KDUPD
KWWSVZZZHQJODQGQKVXNFRURQDYLUXVZSFRQWHQWXSORDGVVLWHV &UH RSHQLQJRIRSWLFDO
VHUYLFHVOHWWHUMXQHSGI

x1+62SWLFDO/HWWHUKWWSVZZZHQJODQGQKVXNFRURQDYLUXVZSFRQWHQWXSORDGVVLWHV &RSWLFDOOHWWHUDSULO
SGI

x7KH&ROOHJHRI2SWRPHWULVWVSULPDU\H\HFDUH&29,'JXLGDQFH 5HGSKDVH
KWWSVZZZFROOHJHRSWRPHWULVWVRUJWKHFROOHJH PHGLDKXEQHZV OLVWLQJFRURQDYLUXVFRYLGJXLGDQFH
IRURSWRPHWULVWVKWPO 

x7KH&ROOHJHRI2SWRPHWULVWV &29,'&ROOHJHXSGDWHV
KWWSVZZZFROOHJHRSWRPHWULVWVRUJWKHFROOHJH PHGLDKXEQHZV OLVWLQJFRURQDYLUXVDGYLFHIRU
RSWRPHWULVWVKWPO&ROOHJH*XLGHOLQHV

x,QIHFWLRQ&RQWURO*XLGHOLQHVQG 5HWULHYHGIURP&DQDGLDQ$ VVRFLDWLRQ2I2SWRPHWULVWV
KWWSVRSWRFDVLWHVGHIDXOWILOHVUHVRXUFHVGRFXPHQWVLQIHFWL RQBFRQWUROBJXLGHOLQHVBSGI
x,QIHFWLRQSUHYHQWLRQDQGFRQWURO IRU&29,',QWHULPJXLGDQFH IRURXWSDWLHQWDQG DPEXODWRU\FDUH
VHWWLQJV0D\0D\5HWULHYHGIURP*RYH UQPHQWRI&DQD GDKWWSVZZZFDQDGDFDHQSXEOLF
KHDOWKVHUYLFHVGLVHDVHVQRY HOFRURQDYLUXVLQIHFWLRQJXLGD QFHGRFXPHQWVLQWHULPJXLGDQFH
RXWSDWLHQWDPEXODWRU\FDUHVHWWLQJVKWPO
CR-6418, v 2.0  
Page 237 of 243JJVC CONFIDENTIAL 
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

3DJHRI x,QIRUPDWLRQIRU0HPEHUV2Q&RURQDYLUXV&29,'QG5HWU LHYHGIURP&DQDGLDQ$VVRFLDWLRQ2I
2SWRPHWULVWV
KWWSVRSWRFDVLWHVGHIDXOWILOHV UHVRXUFHVGRFXPHQWVLQIRUPD WLRQBIRUBPHPEHUVBRQBFRURQDYLUXVSGI
x&RURQDYLUXV&29,'UHVRXUFHVIRUKHDOWKSURIHVVLRQDOVLQFO XGLQJDJHGFDUHSURYLGHUVSDWKRORJ\
SURYLGHUVDQGKHDOWKFDUHPDQDJH UV6HSWHPEHU5HWUL HYHGIURP$XVWUDOLDQ*RYHUQPHQW
'HSDUWPHQWRI+HDOWK
KWWSVZZZKHDOWKJRYDXUHVRX UFHVFROOHFWLRQVFRURQDYLUXVFR YLGUHVRXUFHVIRUKHDOWKSURIHVVLRQDOV
LQFOXGLQJDJHGFDUHSURYLGHUVSDWKRORJ\SURYLGHUVDQGKHDOWKFD UHPDQDJHUV

x(QYLURQPHQWDO&OHDQLQJDQG'LVLQI HFWLRQ3ULQFLSOHVIRU&29,' QG5HWULHYHGIURP$XVWUDOLDQ
*RYHUQPHQW'HSDUWPHQWRI+HDOWK
KWWSVZZZKHDOWKJRYDXVLWHVGHIDXOWI LOHVGRFXPHQWV HQYLURQPHQWDOFOHDQ LQJDQGGLVLQIHFWLRQ
SULQFLSOHVIRUFRYLGSGI
x,QIHFWLRQFRQWUROJXLGHOLQHVDQGDGYLFHQG5HWULHYHGIURP 2SWRPHWU\$XVWUDOLD
KWWSVZZZRSWRPHWU\RUJDXSUDFWLFHSURIHVVLRQDOVXSSRUWFRUR QDYLUXVFRYLGZKDWRSWRPHWULVWVQHHG
WRNQRZFRYLGFOLQLFDODGYLFHLQIHFWLRQFRQWUROJXLGHOLQHVD QGDGYLFH


3URWRFRO&RPSOLDQFH,QYHVW LJDWRUV6LJQDWXUH3DJH
:LOOLQFOXGHDVWDWHPHQWLQGLFDWLQJWKDWWKH3ULQFLSDO,QYHVWLJ DWRU3,DJUHHVWRFRQGXFWWKHVWXG\
LQFRPSOLDQFHZLWKDOOORFDO VWDWHDQGJRYHUQPHQWDOJXLGDQFH¶ VIRU&29,'ULVNPLWLJDWLRQ
,KDYHUHDGWKHVXJJHVWHGJXLGDQFHSURYLGHGE\--9&,SHUWDLQLQJ WRWKH&29,'ULVNPLWLJDWLRQ
&29,':RUN,QVWUXFWLRQLQWKH$SSHQGL[RIWKLVSURWRFRO, DJUHHWRFRQGXFWWKLVVWXG\LQ
FRPSOLDQFHZLWKORFDOVWDWHJRYH UQPHQWDOJXLGDQFHIRU&29,' ULVNV
6WXG\6LWH,QLWLDWLRQ7UDLQLQJ6OLGHV
:LOOLQFOXGHVXJJHVWLRQVWRKHOS PLWLJDWHSRWHQWLDOWUDQVPLVVLR QRI&29,'6XJJHVWLRQVPD\
LQFOXGHPDLQWDLQLQJVRFLDOGLVWDQFL QJLQWKHFOLQLFDOVLWHE\V WDJJHUHGVFKHGXOLQJRIVWXG\SDWLHQWV
ZHDULQJSURSHU33(VIUHTXHQWGLVLQIHFWLRQDQGLQVWDOOLQJVKLHOGVRQWKHVOLWODPSDQGRWKHU
DSSOLFDEOHHTXLSPHQW
*8,'$1&()255(027(68%-(&79,6,76
3RWHQWLDOGLVUXSWLRQVWRWKHVWXG\PD\EHQHFHVVDU\GXHWRFXUU HQWRUIXWXUHSDQGHPLFUHODWHGHPHUJHQF\
UHVWULFWLRQV3RVVLEOHGLVUXSWL RQRIWKHVWXG\DVDUHVXOWRI &29,'FRQWUROPHDVXUHVPD\OHDGWRGHOD\V
LQVFKHGXOHGIR OORZXSYLVLWV
6XEMHFWVPD\EHGHOD\HGLQEHLQJVHHQIRUVWXG\IROORZXSYLVLW VIRUH[DPSOHGXHWR&29,'FRQWURO
PHDVXUHVRUGXHWRWKHVXEMHFW¶V FRQFHUQVRUIHDUVDERXW&29,'ULVN:KHQDSSURSULDWHWKHUH PRWH
DVVHVVPHQWZLOOEHFRQGXFWHGWRWK HH[WHQWSRVVLEOH'LVFXVVLR QVZLWKWKHVXEMHFWGXULQJUHPRWHDVVHVVPHQWV
PD\LQFOXGH
CR-6418, v 2.0  
Page 238 of 243JJVC CONFIDENTIAL 
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU 9:, 5HYLVLRQ1XPEHU

3DJHRI 
3URFHGXUH 'HWDLOV
6XEMHFW5HSRUWHG2FXODU
6\PSWRPV6XEMHFWVZLOOUHVSRQGWRDYHUEDO RSHQHQGHGV\PSWRPVTXHVWLRQQ DLUH
UHJDUGLQJWKHWHVWDUWLFOHZKHQDSSOLFDEOHDQGIHDVLEOH
&KDQJHRI0HGLFDO+LVWRU\$GYHUVH(YHQWVDQG&RQFRPLWDQW0HGLFDWLRQV
7KHUDSLHV5HYLHZ5HFRUGDQ\DGYHUVHH YHQWVRUPHGLFDOKLVW RU\FKDQJHVIURPWKH
SUHYLRXVVWXG\YLVLWZLWKWKHVXEMHFWSDUHQWV
5HYLHZWKHVXEMHFW ¶VFRQFRPLWDQWPHGLFDWLRQVWKHUDSLHVDQGUHFR UG
DQ\FKDQJHVIURPWKHSUHYLRXVVWXG\YLVLW
:HDULQJ7LPHDQG
&RPSOLDQFH5HFRUGWKHDYHUDJHZHDULQJWLPHLQFOXGLQJQXPEHURIKRXUVSHU GD\
GXULQJZHHNGD\VDQGZHHNHQGVDQGQXPEHURIGD\VSHUZHHN
&RQILUPFRPSOLDQFHZLWKWKHS UHVFULEHGZHDUVFKHGXOH
x5HFRUGDQGGLVFXVVWKHOHQVZHDUFRPSOLDQFHEDVHGRQWKH
VXEMHFW¶VVHOIUHSRUW)RUH[DPSOHWKHVXEMHFWVZLOOEHDVNHG WKH
WLPHRIWKHGD\WKHVXEMHFWW\SLFDOO\SXWVRQWKHVWXG\OHQVHV LQWKH
PRUQLQJDQGWDNHVRIILQWKHHYHQLQJWKHQXPEHURIGD\VSHUZH HN
OHQVHVZHUHZRUQDQGWKHQXPEHURIFRQVHFXWLYHGD\VWKHVXEMHF W
GLGQ¶WZHDUWKHVWXG\OHQVHVHWF
7KHGLVFXVVLRQZLWKWKHVXEMHFWZLOOEHGRFXPHQWHGLQ('&XQGHU 7HOH9LVLWDQGDPLQRUSURWRFROGHYLDWLRQ
ZLOOEHQRWHG,IGXULQJWKHWHOHS KRQHFRQVXOWDWLRQDVXEMHFW VWDWHVKHVKHZLVKHVWRGLVFRQWLQXHSDUWLFLSDWLQJ
LQWKHVWXG\LQVWUXFWWKHVXEMHFWWRVWRSZHDULQJWKHVWXG\OH QVHVDQGVFKHGXOHWKHVXEMHFWWRUHWXUQWRWKH
FOLQLFIRUD)LQDO(YDOXDWLRQDWWKHDWHDUOLHVWSRVVLEOHWLPH 6XEMHFWVVKRXOGUHWXUQDOOXQXVHGOHQVHVWRWKH
FOLQLFDWWKHODVWYLVLW
&KDQJHVLQVWXG\YLVLWVFKHGXOHV PLVVHGYLVLWVRUSDUWLFLSDQWGLVFRQWLQXDWLRQVPD\OHDGWRPLVVLQJGDWD
LQFOXGLQJ GDWD UHODWHG WR SURWRFROVSHFLILHG SURFHGXUHV &DVH UHSRUW IRUPV VKRXOG FDSWXUH VSHFLILF
LQIRUPDWLRQUHJDUGLQJWKHEDVLVRI PLVVLQJGDWDLQFOXGLQJWKH UHODWLRQVKLSWRWKH& 29,'SDQGHPLF
678'<&21'8&7'85,1*3$1'(0,&
,WLVUHFRJQL]HGWKDWWKH&RURQDYLUXV'LVHDVH&29,'S DQGHPLFPD\KDYHDQLPSDFWRQWKHFRQGXFW
RIWKLVFOLQLFDOVWXG\GXHWRIRUH[DPSOHVHOILVRODWLRQTXDU DQWLQHE\SDUWLFLSDQWVDQGVWXG\VLWHSHUVRQQHO
WUDYHOUHVWULFWLRQVOLPLWHGDFFHVVWRSXEOLFSODFHVLQFOXGLQJ 2SWRPHWU\&OLQLFVDQGFKDQJHVLQFOLQLF
SURFHGXUHVUHTXLUHGWRDGGUHV VWKH&29,'FKDOOHQJH
(YHU\HIIRUWVKRXOGEHPDGHWRDGKHUHWRSURWRFROVSHFLILHGDVV HVVPHQWVIRUVWXG\SDUW LFLSDQWVLQFOXGLQJ
IROORZXS+RZHYHULIVFKHGXOHG YLVLWVFDQQRWEHFRQGXFWHGLQ SHUVRQDWWKHVWXG\VLWHLWLVVXJJHVWHGWKDW
DVVHVVPHQWVEHSHUIRUPHGWRWKHH[WHQWSRVVLEOHUHPRWHO\YLUWXD OO\RUGHOD\HGXQWLOVXFKWLPHWKDWRQVLWH
YLVLWVFDQEHUHVXPHGLQRUGHU WRFRQWLQXHSDU WLFLSDQWPRQLWRUL QJLQDFFRUGDQFHZLWKWKHSURWRFROZKHUH
SRVVLEOH$WHDFKFRQWDFWSDUWLFLS DQWVZLOOEHLQWHUYLHZHGWR FROOHFWVDIHW\GDWD.H\HIILFDF\HQGSRLQW
DVVHVVPHQWVVKRXOGEHSHUIRU PHGLIUHTXLUHGDQGDVIHDVLEOH
0RGLILFDWLRQVWRSURWRFROUHTXLUH GDVVHVVPHQWVPD\EHSHUPLWWHG YLD&29,'$SSHQGL[DIWHUFRQVXOWDWLRQ
ZLWKWKHSDUWLFLSDQWLQYHVWLJDWRUDQGWKHVSRQVRU0LVVHGDVV HVVPHQWVYLVLWVZLOOEHFDSWXUHGLQWKHFOLQLFDO
WULDOPDQDJHPHQWV\VWHPIRUSURWRFROGHYLDWLRQV,QWHUUXSWLRQV RIWHVWDUWLFOHZHDURUGLVFRQWLQXDWLRQVRI
VWXG\LQWHUYHQWLRQVDQGZLWKGUDZDOIURPWKHVWXG\VKRXOGEHGRF XPHQWHGZLWKWKHSUHIL[³&29,'
UHODWHG´LQWKHFDVHUHSRUWIRUP&5)
CR-6418, v 2.0  
Page 239 of 243JJVC CONFIDENTIAL 
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

3DJHRI 7KHVSRQVRUZLOOFRQWLQXHWRPRQLWRUWKHFRQGXFWDQGSURJUHVVR IWKHFOLQLFDOVWXG\DQGDQ\FKDQJHVZLOOEH
FRPPXQLFDWHGWRWKHVLWHVDQG WRWKHKHDOWKDXWKRULWLHVDFFRUGL QJWRORFDOJXLGDQFH

,IDSDUWLFLSDQWKDVWHVWHGSRVLWL YHIRU&29,'WKHLQYHVWLJ DWRUVKRXOGFRQWDFWWKHV SRQVRU¶VUHVSRQVLEOH
PHGLFDOPRQLWRUWRGLVFXVVLQLWLDOSODQVIRUVWXG\ LQWHUYHQWLRQ DQGIROORZXS7KH PHGLFDOPRQLWRUZLOO
QRWLI\WKH6DIHW\0DQDJHPHQW7HDPRIDQ\VXEMHFWVWKDWKDYHU HSRUWHG³&29,'´³$V\PSWRPDWLF
&29,'´RU³6XVSHFWHG&29,'´D GYHUVHHYHQWVZLWKLQKRX UVRIWKHQRWLILFDWLRQ
0RGLILFDWLRQVPDGHWRWKHVWXG\FRQGXFWDVDUHVXOWRIWKH&29, 'SDQGHPLFZLOOEHVX[COMPANY_003]UL]HGLQWKH
FOLQLFDOVWXG\UHSRUW
&29,'VFUHHQLQJSURFHGXUHVWKDWPD\EHPDQGDWHGE\ORFDOKHD OWKFDUHV\VWHPVGRQRWQHHGWREH
UHSRUWHGDVDQDPHQGPHQWWRWKHS URWRFROHYHQLIGRQHGXULQJFO LQLFDOVWXG\YLVLWV
0RQLWRULQJ9LVLWV
:KHQRQVLWHPRQLWRULQJE\WKHVSRQVRULVQRWIHDVLEOHWKHVSR QVRU¶VVLWHPRQLWRUZLOOFRQWDFWWKHVWXG\
VLWHWRVFKHGXOHUHPRWHYLVLWV,QVXFKFDVHVRQVLWHPRQLWRUL QJYLVLWVZLOOUHVXPHZKHQIHDVLEOHZLWK
LQFUHDVHGIUHTXHQF\WRDGGUHVVWKHVRXUFHGDWDYHULILFDWLRQEDF NORJ
(YHQZLWKVWDIILQJOLPLWDWLRQVGXULQJ WKLV&29,'SDQGHPLFDOOURXWLQHRSHUDWLRQVUHODWHGWRFOLQLFDO
WULDOVVKRXOGEHZHOOGRFXPHQWHGDQGDUFKLYHGDVSDUWRIVWDQGD UGSURFHVV:KHQFRQGLWLRQVSHUPLWDOO
SDUWLHVLQYROYHGLQWKLVFOLQLF DOWULDOVKRXOGFRPPXQLFDWHUHOH YDQWLQIRUPDWLRQLQDWLPHO\PDQQHUVRWKDW
DOOUHOHYDQWSDUWLHVUHPDL QVXIILFLHQWO\LQIRUPHG
6WXG\6LWH,QLWLDWLRQ'XULQJWKHSHULRGWKDWWKLV:RUN ,QVWUXFWLRQLVLQHIIHFW6LWH ,QLWLDWLRQ0HHWLQJVDQGWUDLQLQJRI
VWXG\VLWHVWDIIZLOOEHFRQGXFWHGUHPRWHO\7KH--9&,VWXG\WH DPZLOOFRQGXFWWUDLQLQJYLD6N\SH
=RRP0LFURVRIW7HDPVRUVLPLODUVRIWZDUHDVZHOODVXWLOL]HRQ OLQHWUDLQLQJPDWHULDOVDVDSSOLFDEOH
6WXG\VLWHWUDLQLQJZLOOEHGRFXPHQWHGXWLOL]LQJ6LWH,QLWLDWLR Q5HSRUW

2QVLWHYLVLWVPD\EHFRQVLGHUHGZ KHQIRUH[DPSOHKDQGVRQWU DLQLQJRUHYDOXDWLRQRIVLWHIDFLOLWLHV
LVUHTXLUHG:KLOHRQVLWHWKH&OLQLFDO5HVHDUFK$VVRFLDWH&5 $ZLOOIROORZDOOORFDOVWDWHDQG
JRYHUQPHQWDOSROLFLHVIRU&29,' 5LVN0LWLJDWLRQLQFOXGLQJV RFLDOGLVWDQFLQJZHDULQJRI33(
HWFDVDSSOLFDEOHIRUWKHORFDWLRQRIWKHVWXG\VLWH
,QWHULP0RQLWRULQJ9 LVLWVLIDSSOLFDEOH
'XULQJWKHSHULRGWKDWWKLV:RUN ,QVWUXFWLRQLVLQHIIHFW,QWH ULP0RQLWRULQJ2QVLWHYLVLWVZLOOEH
NHSWWRDPLQLPXPDQGLQFOXGHRQO\WKRVHWDVNVWKDWWKH&5$FDQ QRWSHUIRUPUHPRWHO\HJVRXUFH
GRFXPHQWYHULILFDWLRQWHV WDUWLFOHUHFRQFLOLDWLRQHWF
7RHQVXUHGDWDLQWHJULW\GXULQJWKHFRQGXFWRIDOO--9&VWXGLHV FOLQLFDOVWXG\WH DPVZLOOIROORZWKH
VWXG\VSHFLILF&OLQLFDO0RQLWRULQJ3ODQ 
:KLOHRQVLWHWKH&5$ZLOOIROORZDOOORFDOVWDWHDQGJRYHUQ PHQWDOSROLFLHVIRU&29,'5LVN
0LWLJDWLRQLQFOXGLQJVRFLDOGLVWDQ FLQJZHDULQJRI33(HWFD VDSSOLFDEOHIRUWKHORFDWLRQRIWKH
VWXG\VLWH
CR-6418, v 2.0  
Page 240 of 243JJVC CONFIDENTIAL 
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

3DJHRI 6WXG\6LWH&ORVXUH
'XULQJWKHSHULRGWKDWWKLV:RUN ,QVWUXFWLRQLVLQHIIHFWWKH GXUDWLRQRIWKH6WXG\6LWH&ORVXUH9LVLW
ZLOOEHOLPLWHGWRWDVNVWKDWWKH&5$FDQQRWSHUIRUPUHPRWHO\ HJVRXUFHGRFXPHQWYHULILFDWLRQ
WHVWDUWLFOHILQDOUHFRQFLOLDWLRQDQGUHWXUQHWF


CR-6418, v 2.0  
Page 241 of 243JJVC CONFIDENTIAL 
7LWOH *XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQ
'RFXPHQW7\SH :RUN,QVWUXFWLRQ
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU

3DJHRI $WWDFKPHQW$6WXG\6LWH&RUUHVSRQGHQFH

;;;;;;


5H&29,'0LWLJDWLRQ3ODQ&5[[[[SURWRFROWLWOH!!

'HDU3ULQFLSDO,QYHVWLJDWRU!!DQG6WXG\7HDP

&RURQDYLUXV&29,'KDVLPSDFWHGVHYHUDOFRPPXQLWLHVDQGEXV LQHVVDFWLYLWLHVRYHUWKHSDVWVHYHUDOPRQWKV
:KLOHZHZRUNWRZDUGWKHVXFFHVVIXOFRQGXFWRIFOLQLFDOVWXGLHV RXUFRPPLWPHQWFRQWLQXHVWREHWKHVDIHW\RI
SDWLHQWVKHDOWKFDUHSURIHVVLRQDOVDQGWRRXUFRPPXQLWLHV7KHUHIRUHZHZRXOGOLNHWRVKDUHWKHIROORZLQJUHYLVLRQVDGGLW LRQVUHODWHGWRWKHDERYHUHIHUHQFHG-RKQVRQ	
-RKQVRQ9LVLRQ&DUHFRPSDQ\V SRQVRUHGFOLQLFDOWULDOV\RXDUHFXUUHQWO\ZRUNLQJRQRUF RQVLGHULQJSDUWLFLSDWLRQ
ZLWKLQ
3URWRFRO
x*XLGHOLQHVIRU&29,'5LVN0LWLJDWLRQSURYLGHGLQWKH$SSHQGL [VHFWLRQ
3URWRFRO6LJQDWXUH3DJH

x:LOOLQFOXGHDVWDWHPHQWLQGLFDWLQJ WKH3ULQFLSOH,QYHVWLJDWRU DJUHHVWRFRQGXFWWKHVWXG\LQFRPSOLDQFH
ZLWKDOOORFDOVWDWHDQGJRYHUQP HQWDOJXLGHOLQHVIRU&29,' ULVNPLWLJDWLRQ

,QIRUPHG&RQVHQW

x:LOOLQFOXGHLQIRUPDWLRQFRQFHUQLQJWKHVWXG\DVVRFLDWHGULVNV UHODWHGWRWKH&29,'SDQGHPLFLQEROG
IRQWDQGRUER[HGRQWKHILUVWSDJH RIWKH,QIRUPHGFRQVHQWGRF XPHQW
&29,'5LVN&RQWURO&K HFNOLVWIRU&OLQLFDO6WXGLHV
x:LOOLQFOXGH&29,'ULVNFRQWUROPHDVXUHVWKDWDUHUHTXLUHGW RHQVXUHWKHVDIHW\DQGKHDOWKRIVXEMHFWV
VLWHVWDIIDQGPRQLWRUVGXULQJWKHSDQGHPLF

:HZDQWWRHQFRXUDJHWKHQHHGIRURSHQOLQHVRIFRPPXQLFDWLRQD ERXWSRWHQWLDOFKDOOHQJHV\RXPD\IRUHVHHDVWKH
UHVXOWRIWKHFXUUHQW&29,'VLWXDWLRQ7KHUHIRUHZHHQFRXUD JH\RXWRUHJXODUO\FRQQHFWZLWK\RXUUHVSHFWLYH
-RKQVRQ	-RKQVRQFOLQLFDOVWX G\WHDP&OLQLFDO5HVHDUFK$VVRFL DWH&5$/HDG&5$RU6W XG\0DQDJ HUV
7KDQN\RXIRU\RXUFRQWLQXHGHQ JDJHPHQWFROODERUDWLRQDQGGHG LFDWLRQWR\RXUVWXG\VXEMHFWVGXULQJWKLV
FKDOOHQJLQJWLPH

3OHDVHILOHWKLVOHWWHULQ\RXUVLWHILOHVWXG\FRUUHVSRQGHQFH 

CR-6418, v 2.0  
Page 242 of 243JJVC CONFIDENTIAL 
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_169778]: CR-[ADDRESS_352215] Lenses Produced with Different Manufacturing Processes
Version and Date: 2.[ADDRESS_352216] this study according to ISO [ZIP_CODE],1GCP and ICH guidelines,2the Declaration of 
Helsinki,3[LOCATION_002] (US) Code of Federal Regulations (CFR),4and the pertinent individual country 
laws/regulations and to comply with its obligations, subject to ethical and safety considerations. The 
Principal Investigator [INVESTIGATOR_19539], including Sub-
Investigators adhere to all ICH2regulations and GCP guidelines regarding clinical trials during and 
after study completion.
I will assure that no deviation from or changes to the protocol will take place without prior agreement 
from the Sponsor and documented approval from the Institutional Review Board (IRB), except where 
necessary to eliminate an immediate hazard(s) to the trial participants.
I am responsible for ensuring that all clinical site personnel including Sub-Investigators adhere to all 
ICH2regulations and GCP guidelines regarding clinical trials during and after study completion.
All clinical site personnel involved in the co nduct of this study have completed Human Subjects 
Protection Training. I agree to ensure that all clinical site personnel in volved in the conduct of this study are informed about 
their obligations in meeting the above commitments.
I shall not disclose the information contained in this  protocol or any results obtained from this study 
without written authorization.
I have read the suggested guidance provided by [CONTACT_288846]-19 risk mitigation, 
(COVID-19 Work Instruction in the Appendix of th is protocol). I agree to conduct this study in 
compliance with local, state, govern mental guidance for COVID-19 risks.
Principal 
Investigator:
[INVESTIGATOR_19540] (Printed)
Institution/Site:
Institution/Site Name
[CONTACT_16277]/Site Address
CR-6418, v 2.0  
Page 243 of 243JJVC CONFIDENTIAL 